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Among women in the United States, breast cancer is the most frequently occurring 
cancer and is the second-leading cause of cancer deaths. Approximately 30% of cancer 
risk is estimated to be attributed to diet. Apple consumption has been correlated with 
reduced breast cancer risk as well as more favorable prognostic factors. The first 
objective was to develop a more efficient methylene blue assay for cell counting 
which could be applied to a broader range of cell densities and various cell culture 
plates. A linear relationship (r2>0.99) was established between cell number and 
absorbance at 570 nm wavelength when the modified methylene blue assay was 
applied to three cell lines plated in a broad range of cell densities in 4 different types 
of culture plates. This modified methylene blue assay is a powerful tool for any 
application requiring a versatile, efficient, and accurate method of cell counting, 
especially in the research of natural products, bioactive compounds, phytochemicals, 
functional foods and nutraceuticals. The second objective was to determine whether 
whole apple extracts and purified compounds from apples interfered with IGF-I-
mediated signal transduction pathways in MCF-7 human breast cancer cells. 
Quercetin-3-Glucoside (Q-3-G) proved to be surprisingly effective, inhibiting IGF-I-
induced MCF-7 cell proliferation more potently than FBS-stimulated proliferation, as 
well as more potently than quercetin inhibited cell growth. Q-3-G blocked cell cycle 
progression and induced apoptosis via down-regulated Akt phosphorylation, Cyclin 
D1 and CDK-4 expression, and increased Caspase-9 and PARP cleavage. The results 
help to explain the mechanisms by which apple consumption may reduce breast cancer 
risk. Additionally, such studies of purified compounds contribute to the understanding 
of cancer cell behavior and may inform future endeavors in chemotherapeutic drug 
design. The third objective was to determine the effects of apple phytochemical 
extracts on cell proliferation and apoptosis in mammary tissues in DMBA-treated 
Sprague-Dawley rats in vivo. The expression of PCNA, BrdU-labeled cells, Cyclin D1 
and Bcl-2 decreased, and Bax expression and apoptosis increased in the apple treated 
groups. These results demonstrate the potent capacity of fresh apples to suppress 
promotion and progression of DMBA-initiated mammary carcinogenesis in rats. 
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CHAPTER 1 
 
DIET AND BREAST CANCER:  THE ROLES OF APPLE PHYTOCHEMICALS 
AND IGF-I RECEPTOR SIGNALING 
 
I. BREAST CANCER 
In the United States, breast cancer is the most frequently occurring cancer 
among women, accounting for an estimated 26% of new diagnoses in 2008, and is the 
second-leading cause of cancer deaths among women, accounting for 15% of cancer 
deaths estimated in 2008 (estimates exclude basal and squamous cell skin cancers and 
in situ carcinoma except bladder) (American Cancer Society, 2008). The American 
Cancer Society predicts ~185,000 new cases and more than 40,000 deaths due to 
breast cancer in 2008. While advances in treatment are being made, cancer is still 
considered a preventable disease since many significant causes are exogenous, such as 
viruses and carcinogenic chemicals. As discussed below, epidemiology studies have 
linked a diet high in fruits and vegetables, including apples, with reduced breast cancer 
risk, and cell and molecular studies are beginning to reveal the many and varied anti-
cancer properties of the dietary phytochemicals. Therefore, research in the area of 
breast cancer prevention is necessary and valuable.  
 
II. DIET AND CANCER 
A. Cancer is a Preventable Disease. Cancer has long been viewed as a 
preventable disease. In 1981, Doll and Peto calculated that ~35% of cancer deaths in 
the U.S. were due to dietary factors (Doll and Peto, 1981). In 1995, Willett concluded 
that although the body of knowledge on the subject had grown immensely since 1981, 
the estimate still had not changed drastically (Willett, 1995), offering a range of 20 to 
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42% of cancer deaths being attributed to diet. Peto (2001) revisited the subject, 
discussing the major, and for the most part avoidable, causes of cancer. The 
observation that immigrants adopt the cancer risk of the native population of their new 
homeland offered insights into the environmental causes of cancer (Dunn, 1977; 
McMichael et al. 1980; Stanford et al. 1995). The association between tobacco use 
and cancer was another critical discovery (Doll and Hill, 1950; Wynder and Graham, 
1950). Up to 60% of cancer deaths among smokers can be attributed to their tobacco 
use (Peto et al. 1994). Reproductive and hormonal factors play a significant role in 
certain cancers, such as the contribution of lifetime estrogen exposure (e.g. ages of 
menarche, first childbirth, and menopause; hormone replacement therapy, etc.) to 
breast cancer risk (Kelsey, Gammon and John, 1993). Many cancers are associated 
with infectious pathogens such as Helicobacter pylori and stomach cancer (IARC, 
1994a), human papillomaviruses (HPVs) and cervical cancer (Walboomers et al., 
1999), hepatitis B virus and hepatocellular carcinoma (HCC), and hepatitis C virus 
and HCC (IARC, 1994b) while occupational exposures have been linked with certain 
cancers such as asbestos and mesothelioma (Peto et al., 1999). Being overweight has 
been shown to increase overall cancer risk (Josefson, 2001). 
 B. Diet Accounts for up to 30% of Cancer Risk. Peto also discussed 3 
important studies that attempted to quantify the contribution of diet to cancer risk 
(COMA, 1998; Glade, 1997; Doll and Peto, 2003). While the 3 studies reported a 
contribution of about one third, “opinions still differ on the strength of the evidence” 
(Peto, 2001). Taken together, Peto (2001) calculates that after eliminating the 
avoidable causes of smoking, known infections, alcohol, sunlight, air pollution, lack of 
exercise and overweight, diet may account for 10 to 30% of cancer deaths.  
 C. Fruits, Vegetables, and Cancer Risk. Fruit and vegetable consumption 
has been consistently linked to reduced risk of cancer, as demonstrated by an analysis 
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of approximately 200 epidemiology studies relating diet and incidence of various 
cancers (Block et al., 1992). Steinmetz and Potter (1996) reviewed 20 cohort and 174 
case-control studies which evaluated associations between fruit and vegetable 
consumption and various cancers. Of the 20 cohort studies, 19 found inverse 
associations between some category of fruit and/or vegetable and some type of 
cancers; 12 of these associations were statistically significant. The most consistent 
protective effect of fruit and vegetable consumption was found to be against lung 
cancer. Of the 174 case-control studies evaluated in the paper, only prostate cancer did 
not show a significant inverse relationship with any category of fruit or vegetable 
consumption, although 5 out of 5 studies showed a non-significant inverse association. 
A significant inverse association was found, however, in more than 80% of the studies 
for cancers of the stomach, esophagus, lung, oral cavity and pharynx, rectum, bladder, 
cervix, endometrium, and larynx (Steinmetz and Potter, 1996).   
 Studies of stomach cancer, lung cancer, and colon cancer were quite 
convincing. Of the 31 studies which looked at stomach cancer, 28 (93%) found a 
significant inverse relationship, 2 (7%) found a non-significant inverse relationship, 
and one study did not report the significance of their results. The break-down of fruit 
and vegetable associations with stomach cancer was as follows: vegetables: 11 out of 
11 studies found an inverse association; 17 fruit studies found 14 inverse and 3 null; 
raw vegetables: 10 out of 10 inverse; legumes: 7 inverse and 2 positive; allium 
vegetables: 9 inverse, 1 null, 1 positive; green vegetables: 8 out of 8 inverse; carrots: 7 
inverse, 1 null, 1 positive; tomatoes: 9 inverse, 1 null, 1 positive; citrus fruits: 11 
inverse and 1 null association. Of the 13 studies which evaluated associations between 
fruit and vegetable intakes and lung cancer, 11 (85%) found significant inverse 
relationships and 1 (15%) found statistically non-significant inverse relationships. 7 
out of 7 studies found an inverse relationship between vegetable intake and lung 
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cancer; 8 out of 8 found an inverse association with fruit, 9 out of 9 found an inverse 
association with green vegetables, and 4 out of 4 studies found an inverse association 
with tomatoes. Out of 7 studies that measured intake of carrots, 6 associations were 
inverse and 1 was found to be null (Steinmetz and Potter, 1996).  
 Out of 21 studies which evaluated fruit and vegetable intake and colon cancer, 
15 (79%) found significant inverse relationships, 4 (21%) found non-significant 
inverse relationships, and 1 study did not report the significance of their results. The 
breakdown by food group was as follows: vegetables: 9 inverse associations and 1 
positive association; fruit: 5 inverse, 2 null and 1 positive; raw vegetables: 3 inverse, 1 
positive; cruciferous vegetables: 8 inverse, 3 null and 1 positive; legumes: 1 inverse, 2 
null, 2 positive; allium vegetables: 4 inverse, 1 null, 1 positive; green vegetables: 4 
inverse, 1 null; carrots: 4 inverse, 1 null, 2 positive; tomatoes: 4 inverse, 2 positive; 
citrus fruits: 2 inverse, 1 null and 3 positive (Steinmetz and Potter, 1996). 
 Out of the 174 case-control and 20 cohort studies evaluated in this paper, 
vegetables, raw vegetables, and fruit are the groups that demonstrated the most 
convincing protective effects against cancer overall: 81% (55 out of 68 studies) 
showed an inverse association between vegetables and cancer, 85% (33 out of 39 
studies) showed an inverse association between raw vegetables and cancer, and 63% 
(29 out of 46 studies) showed an inverse association between fruit and cancer. In many 
of the studies, groups with the lowest intake of fruits and vegetables had as much as 
twice the cancer rate of populations with the highest intake (Steinmetz and Potter, 
1996). 
 While the anti-cancer properties of fruits and vegetables are attributed to the 
phytochemicals, the non-nutrient bioactive components of the plant material, studies 
attempting to show a link between particular phytochemicals and cancer risk have not 
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been as convincing. For example, in their review of dietary flavonoids, Ross and 
Kasum (2002) found sufficient data to support the hypothesis that high fruit and 
vegetable intake can decrease cancer risk. However, they note that epidemiological 
studies attempting to make the same correlation with flavonoids specifically are not 
conclusive (Ross and Kasum, 2002).  
 The Zutphen Elderly Study, for instance, found no association between cancer 
mortality and flavonol or flavones intake based on food frequency questionnaires 
(Hertog et al. 1993a; Hertog et al. 1993b; Arts et al. 2001). Arts et al. (2001) looked at 
the same cohort ten years later, and concluded that catechins from non-tea sources 
slightly reduced lung cancer incidence, yet tea catechins did not (Ross and Kasum, 
2002). A study in the Netherlands followed rather large cohorts (58,279 men and 
62,573 women) for four years and found no association between flavonol or flavones 
intake and incidence of several forms of cancer (stomach, colon, lung) (Goldbohm et 
al., 1995). In a Finnish cohort study of 9,959 men and women, flavonoid intake 
correlated with decreased incidence of total cancers (Knekt et al., 1997). A case-
control study in Uruguay analyzed dietary data from a group of individuals and 
hospitalized controls, reporting reduced cancer incidence associated with carotenoid, 
glutathione, flavonoid, vitamin E, and total fruit and vegetable intake (DeStephani et 
al., 1999). In a case-cohort analysis attempting to relate antioxidant and folate intake 
with male lung cancer risk, it was determined that lutein+zeaxanthin, β-cryptoxanthin, 
folate and vitamin C exerted protective effects against lung cancer incidence, while α-
carotene, β-carotene, lycopene and vitamin E did not (Voorrips et al., 2000). 
 The discrepancies among these epidemiology studies, which show a 
correlation between high fruit and vegetable intake and reduced cancer risk, but 
inconclusive results regarding a particular class of phytochemical with cancer risk, 
may offer important insights. Experimental designs and methods of data collection and 
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analysis differ, making comparisons across studies difficult. But perhaps more 
importantly, this phenomenon may indicate the mechanisms by which the fruits and 
vegetables exert their anti-cancer activities. In other words, it may not be one 
particular class of phytochemicals that is working alone and is responsible for the 
protective effects seen. It is becoming clear that the greatest benefits of the 
phytochemicals are conferred through the additive and synergistic effects of these 
compounds in our diets (Liu, 2003; Liu, 2004; Liu and Felice, 2007).  
 
III. DIET AND BREAST CANCER 
The relationship between diet and breast cancer continues to be extensively 
studied. Many dietary and lifestyle factors have been associated with breast cancer 
risk, some more convincingly than others (Holmes and Willett, 2004). All told, the 
most convincing factors increasing breast cancer risk are alcohol consumption, 
overweight or obesity, and physical activity. The common link among the three is their 
influence on circulating estrogens, androgens, and insulin, elevated levels of which are 
all correlated with increased breast cancer risk. Alcohol consumption increases 
endogenous estrogen and androgen concentrations (Holmes and Willett, 2004; Hanf 
and Gonder, 2005; Berrino et al., 2006). As summarized by Holmes and Willett, 
combined results of 6 large cohort studies demonstrated a 9% increase in breast cancer 
risk for every 10 g alcohol/day (95% CI = 4 to 13%; beer, wine or liquor). Intervention 
studies showed increased estrogen levels in both pre- and post-menopausal women 
with addition of 1 to 2 alcoholic drinks daily. Honf and Gonder discuss alcohol’s 
abilities to interfere with hormone metabolism (30 g of ethanol daily increased 
bioavailable estrogens compared to the control group), increase transport of less 
soluble carcinogens, and damage cell membrane integrity and cell-to-cell 
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communication (Hanf and Gonder, 2005). Finally, the synthesis of both androgens and 
estrogens is increased by alcohol consumption (Berrino et al., 2006).  
 Obesity, a sedentary lifestyle, and a high fat diet lead to metabolic syndrome 
(having at least 3 of the following 5 symptoms: increased plasma glucose, increased 
triglycerides, decreased HDL, increased waist circumference and hypertension) 
(Berrino et al., 2006). Metabolic syndrome may lead to increased androgenic activity 
and insulin resistance. Increased circulating insulin will increase synthesis of 
androgens and growth hormone receptor expression, while blocking synthesis of 
IGFBP1 (Insulin-like Growth Factor Binding Protein 1), IGFBP2 and SHBG (Sex 
Hormone Binding Globulin), thus rendering IGFs and estrogen more bioavailable. 
Physical activity appears to confer protective effects by increasing insulin sensitivity, 
decreasing testosterone, and decreasing IGF-I concentrations. The effect of exercise is 
so strong that 30 minutes daily of brisk walking cuts risk of breast cancer recurrence 
by half (Berrino et al., 2006).  
 A. Dietary Factors and Breast Cancer. Many epidemiology studies have 
investigated the influence of a low-fat, high-fiber diet on estrogen levels and breast 
cancer risk (Forman, 2007). A high-fat diet encourages re-absorption of estrogens in 
the intestine by increasing activity of a deconjugating enzyme. A high-fiber diet 
counters that process and thus more estrogens are excreted rather than reabsorbed into 
the blood stream. Accordingly, vegetarians were shown to have higher fecal estrogen 
levels while omnivores had higher urinary estrogen levels (Dos Santos Silva et al., 
2002). Two meta-analyses, one in 1999 and one in 2007, concluded that low-fat, high-
fiber diets reduced estrogen levels (Wu et al., 1999; Forman, 2007).  
 Wu et al. (1999) analyzed 14 papers that were published between January 1966 
and June 1998 that fit their criteria: they included only intervention studies that 
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reported the level of fat intake, duration of the study, and endogenous estrogen levels 
before and after intervention or the percent change. Only studies on healthy women 
were included and not those that involved patients with breast cancer. Ultimately the 
meta-analysis included 10 studies of premenopausal women and 4 studies of post-
menopausal women. In the studies of premenopausal women, the subjects’ baseline 
diets contained 29 – 46% of calories from fat, and changed to a low fat diet (12 – 25% 
of calories from fat) for 2 to 3 months. The fiber intake changed as well (~30 g/d 
increase in 4 studies and 2-9 g/day increase in 6 studies). The low fat diet significantly 
reduced circulating estradiol levels in 2 studies; in 7 studies the decrease was > 5%, in 
one study decreased < 2%, and in 2 studies estradiol increased but slightly and non-
significantly. In the 4 intervention studies of postmenopausal women, fat intake 
ranged from 10 to 24% of calories for 3 weeks to 5 months. There were large 
differences in fiber intake among these studies, two of which did not report fiber 
intake, one of which increased fiber by 2 g/day, and the last whose subjects consumed 
35-45 g/d (per 1000 kcal). The results showed a statistically significant decrease in 
estradiol in 2 studies, a non-significant decrease in one, and a non-significant increase 
in the last (Wu, Pike and Stram, 1999). The authors’ pooled analysis of the data 
generated the following results: in premenopausal women, estradiol levels changed by 
-7.4% (95% CI = -11.7% to -2.9%); in postmenopausal women, -23.0% (95% CI = -
27.7% to -18.1%); combined, -13.4% (95% CI = -16.6% to -10.0%). Two studies 
which decreased fat intake the most, to 10 and 12% of calories, had the most dramatic 
effects. Removing these studies from the pooled analysis changed the results to -6.7% 
(95% CI = -11.1 to -2.1%) in premenopausal women; -6.2% (95% CI = -13.1 to -
1.3%) in postmenopausal women; and -6.6% (95% CI = -10.3 to -2.7%) combined. 
The authors considered the heterogeneity of the studies, and indeed removing the 2 
lowest-fat studies decreased the heterogeneity across studies. Repeating the pooled 
9 
 
analysis accounting for heterogeneity changed the results somewhat: in pre- and 
postmenopausal women combined, the low-fat diet changed estradiol by -6.8% (95% 
CI = -13.2 to 0.1%). Ultimately this analysis marginally increased the change in 
estradiol level but widened the confidence interval such that the result was no longer 
statistically significant at the α = 0.05 level. Yet from a pragmatic standpoint the 
outcome still demonstrates a correlation between fat intake and estrogen levels. 
However the data were analyzed, the results supported the conclusion that reduced fat 
intake leads to reduced circulating levels of estradiol (Wu et al., 1999).   
 Although there were differences across studies in the type, timing, and duration 
of the dietary intervention, and weight loss and physical activity were not considered 
in many studies, the effect of reduced estrogen levels as a result of a high fiber/low fat 
diet was seen in girls and in pre- and post-menopausal women (Forman, 2007). The 
differences were not always significant, but the trend existed. Forman discusses the 
importance of considering the following in designing future intervention trials 
investigating risk factors for breast cancer: Among ethnic groups, there are differences 
in energy expenditure, endogenous hormone levels, average age of menarche, and 
gene polymorphisms. Estrogen levels are affected by ethnicity, gene polymorphisms, 
life cycle (e.g. age of menarche and menopause, parity, etc.), normal menstrual cycle 
variations, physical activity, weight and diet (Forman, 2007, and sources therein).  
 B. Fruits, vegetables and breast cancer. Out of 13 case-control studies that 
measured associations between fruit and vegetable intakes and breast cancer, 9 (69%) 
found significant inverse relationships and 4 (31%) found non-significant inverse 
relationships (Steinmetz and Potter, 1996). Four of those studies measured fruit intake 
and breast cancer: 3 found inverse associations and one found a positive association. 
Six studies measured intake of green vegetables: 5 inverse and one null; 4 measured 
10 
 
carrots and found 3 inverse and 1 null; 3 measured citrus fruits: one inverse and 2 
positive (Steinmetz and Potter, 1996). 
  Holmes and Willett (2004) reported that case-control studies associated 
increased fruit and vegetable consumption with a decreased breast cancer risk, while 8 
prospective studies demonstrated weak and non-significant relationships. Rock (2003) 
reported that the protective effect of fruit and vegetable consumption, in 8 follow-up 
epidemiology studies, ranged from a 20 to 90% reduction in risk of death from breast 
cancer. The WHEL (Women’s Healthy Eating and Living) Study showed that a diet 
with increased fruits, vegetables, grains and fiber and decreased fat, without weight 
loss, had a protective effect against breast cancer (Rock, 2003).  
 Duncan (2004) concisely summarized the findings of several studies linking 
fruit and vegetable intake and breast cancer: A review of 19 case-control and 3 cohort 
studies by the American Institute for Cancer Research showed a protective effect of 
fruit and vegetable consumption (Glade, 1997). A meta-analysis of 14 case-control 
and 3 cohort studies found a protective effect of vegetables, but not fruit (Gandini et 
al., 2000). The Nurse’s Health Study found a non-significant reduced risk with higher 
fruit and vegetable consumption among premenopausal women (5 or more servings: 
33% reduced risk vs. 2 or fewer servings) (Zhang et al., 1999). A pooled analysis of 8 
prospective studies revealed a non-significant 7% reduction in BC risk among those 
with the highest fruit and vegetable consumption (Smith-Warner et al., 2001). Duncan 
concludes the evidence, although not always statistically significant, supports a 
protective effect of fruits and vegetables against breast cancer risk, citing the proper 
consideration of various micronutrients and phytochemicals as possible reasons for the 
inconsistencies among studies (Duncan, 2004). 
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 In contrast to their 1997 report mentioned above, the World Cancer Research 
Fund and the American Institute for Cancer Research (AICR) were unable to reach 
conclusions regarding the influence of fruit or vegetable intake on either pre- or 
postmenopausal breast cancer risk in their 2007 report. The reasons cited were that the 
data reviewed were inconsistent or of inadequate quality, or too few studies existed 
(World Cancer Research Fund, 2007). 
 The non-significant findings of the Pooling Project mentioned above (Smith-
Warner et al., 2001) may have much to do with study design (Slattery, 2001). Among 
the 8 cohort studies analyzed, there were variations in the questionnaires in number of 
different food categories listed as well as which specific food items were included. For 
example, many studies in the Pooling Project did not include such commonly 
consumed fruits as apples, bananas and oranges. Not only does this create differences 
between studies, but the lists could have been incomplete compared to what the 
subjects were actually consuming. In the case where a subject left a question 
unanswered, the response was recorded as non-consumption of that particular food; 
this can affect energy intake analysis as well as the final associations made. Cohort 
studies recruit volunteers; perhaps there is a form of self-selection occurring such that 
healthier, more active people would choose to participate in such a study. The effects 
of the study may be more dramatic in a different sub-population. Due to these design 
differences, protective effects of specific foods (i.e. apples) or groups of foods (i.e. 
Brassica vegetables) may have been missed in such studies (Slattery, 2001). In fact, 
Brassica vegetables have been shown to reduce breast cancer risk. A case-control 
study of postmenopausal women in Sweden found no relationship between total fruit 
and vegetable consumption and breast cancer (Terry et al., 2001). They did, however, 
find a significant protective effect of Brassica vegetables, with a relative risk of 0.58 
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for the upper decile (who consumed 1.5 servings/day) compared to the lowest decile 
(virtually no consumption).  
 A study in 1992 analyzed the effects of various anthropometric, nutritional and 
hormonal factors on prognostic characteristics of early-detected breast tumors in 91 
women. Fruits and vegetables were the only food groups that were significantly 
associated with a more favorable prognosis, namely more differentiated tumors, less 
vascular invasion, and positive estrogen and progesterone receptor status (Ingram et 
al., 1992). 
 It is unclear whether increased fruit and vegetable intake protects against breast 
cancer indirectly, by lowering fat and increasing fiber in the diet, or directly, through 
the bioactivity of the phytochemicals. Some epidemiology studies have attempted to 
sort out the contribution of different classes of phytochemicals. For example, a cohort 
study in Finland found that total flavonoids non-significantly reduced breast cancer 
(R.R. 0.72 for highest quintile vs. lowest) (Knekt et al., 1997) but a later follow-up 
found quercetin to be significantly associated with reduced risk (R.R. = 0.62) while 
other flavonoids were not (Knekt et al., 2002). A case-control study in Greece found 
an inverse association with flavones (O.R. = 0.87) but not other classes of flavonoids 
(Peterson et al., 2003). A large case-control study in Italy (2,569 cases and 2,588 
controls from 1991-1994) found a significant inverse relationship between breast 
cancer and flavones (O.R. = 0.81) and flavonols (O.R. = 0.80), while 4 other classes of 
flavonoids had non-significant associations (flavanones O.R. = 0.95; flavan-3-ols O.R. 
= 0.86; anthocyanidins O.R. = 1.09; isoflavones O.R. = 1.05) (Bosetti et al., 2005). 
 Slattery (2001) discussed the strengths and limitations that the various types of 
epidemiology studies (clinical, case-control, and cohort) have in determining the 
association between diet and cancer. She underscores the importance of timing and 
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duration of exposure, considering that certain foods such as fruits and vegetables may 
exert protective effects at a specific stage in the disease process. In that light, animal 
and cell studies become extremely valuable in helping to uncover the mechanisms by 
which whole foods or individual phytochemicals can prevent or slow the growth of 
cancer. That information, in turn, is crucial for effective and careful design of dietary 
intervention studies.  
 
IV. APPLES AND BREAST CANCER 
A. Apples. Phytochemicals are classified according to structure, the largest 
sub-class being phenolic compounds which includes further sub-classes such as 
phenolic acids, flavonoids, and tannins (Liu, 2004). Among commonly consumed 
fruits, apples contain the second highest phenolic content and second highest 
antioxidant activity (Sun et al., 2002). However, since they are more popular than 
other fruits, apples are the number one source of phenolics in the American diet 
(Wolfe et al., 2008).  
 1. Phytochemical Composition of Apples. Our lab has improved the analysis 
of total phenolic content of fruits and vegetables by accounting for bound phenolics, in 
addition to the standard free phenolics (Sun et al., 2002). This method was used in our 
lab to determine the total phenolic content of various fruits. The phenolic content was 
measured using a colorimetric Folin-Ciocalteau method with gallic acid as a standard. 
Results were presented as mg of gallic acid equivalents per 100 g of the edible parts of 
the fruit. Out of the 11 commonly consumed fruits tested, apple had the second highest 
total phenolic content, while cranberry had the highest. The total phenolic content of 
the apple in this study was 296.3 ± 6.4 mg/100g, while cranberry contained 527.2 ± 
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21.5 mg/100 g. However, since apples are consumed far more than cranberries, they 
remain a significant source of phenolics in the diet (Sun et al., 2002). 
 Our lab also measured the distribution of phenolics among the flesh and peel of 
the apple (Wolfe et al., 2003). In 4 apple varieties, the phenolic contents of the flesh, 
the peel, and the flesh with the peel (whole apples) were measured. In Idared, Rome 
Beauty, Golden Delicious, and Cortland apples, total phenolic contents of the flesh 
were 75.7 ± 4.0, 93.0 ± 4.1, 97.7 ± 8.9, and 103.2 ± 12.3 mg/100 g fruit, respectively. 
In the same order, total phenolic contents of the flesh with the peel were 120.1 ± 15.0, 
159.0 ± 15.1, 129.7 ± 9.7, and 119.0 ± 14.9 mg/100 g fruit. Total phenolic contents of 
the peel were 588.9 ± 83.2, 500.2 ± 13.7, 309.1 ± 32.1, and 388.5 ± 82.4 mg/100 g 
fruit. The interesting trends here are the similar levels of phenolics in the flesh and the 
flesh with peel among the four varieties, while the amounts in the peel varied widely 
among the varieties. Most notable is the fact that the phenolics are highly concentrated 
in the peel (Wolfe et al., 2003).   
 In a study of 8 apple varieties, five major groups of polyphenolic compounds 
were detected by HPLC: flavan-3-ols, flavonols, dihydrochalcones, anthocyanins, and 
phenolic acids (hydroxybenzoic acid and hydroxycinnamic acids) (Tsao, et al. 2003). 
The major group was the flavan-3-ols, or catechins, which can account for 55.7% of 
polyphenols in the flesh (0 to 583.0 µg/g) and 59.7% of pholyphenols in the peel 
(151.3 to 1,654.8 µg/g). The dominant catechins in apples are catechin and epicatechin 
(stereoisomers), and the dimers procyanidin B1 (epicatechin plus catechin) and 
procyanidin B2 (2 epicatechin molecules) (Tsao et al., 2003).  
 The second major group of polyphenols in apples was the flavonols, such as 
quercetin, kaempferol and myricetin. Quercetin and its glycosides are by far the most 
abundant flavonols, can contribute up to 18% of total phenolics, and occur exclusively 
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in the peel. Concentrations were found to be 220.3 to 349.9 µg/g fresh weight (Tsao et 
al., 2003).  
 The other three minor polyphenolic groups found in these 8 apple varieties 
were dihydrochalcones, anthocyanins, and phenolic acids. The main dihydrochalcones 
were phloretin 2’-glycoside (phlorizdin) and phloretin 2’-xyloglucoside, which 
occurred mostly in the peel in average concentrations of 124 µg/g fresh weight. 
Anthocyanins, which occur as cyanidin glycosides in red apples, ranged from 42.9 to 
208.2 µg/g fresh weight. The two main groups of phenolic acids found were 
hydroxybenzoic acids and hydroxycinnamic acids. Hydroxybenzoic acids can account 
for less than 5% of phenolics in apples, at concentrations so low they may often be 
below detection levels. In the peel, total benzoic acids may be between 40 and 80 µg/g 
fresh weight. The major hydroxycinnamic acid found in the apples was chlorogenic 
acid, in concentrations of 136 µg/g fresh weight in the peel and 177 µg/g fresh weight 
in the flesh. Two other hydroxycinnamic acids, p-coumaric acid and caffeic acid, 
occur in apples in lower concentrations (Tsao et al., 2003).  
 In our lab, 29 compounds were isolated from red delicious apple peels, 
including triterpenoids, flavonoids, organic acids, and plant sterols (He and Liu, 2007 
and 2008). Extracts of apple peel were fractionated by extraction with 80% acetone, 
followed by subsequent extractions with ethyl acetate and water-saturated n-butanol. 
Ethyl acetate fractions were subject to silica gel chromatography while butanol 
franctions were subject to dianion HP-20 column chromatography, followed by silica 
gel chromatography. Individual compounds were collected and further separations 
were achieved by HPLC. Quercetin-3-O-β-D-glucopyranoside comprised 82.6% of the 
total flavonoids in the peel, while quercetin-3-O-β-D-galactopyranoside comprised 
17.1%. Trace amounts of quercetin (0.2%) were detected along with (-)-catechin, (-)-
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epicatechin, and quercetin-3-O-α-L-arabinofuranoside. In this study, two new 
compounds were isolated from apple peel and identified for the first time: 3β-trans-p-
coumaroyloxy-2α,3β,13β-trihydroxy-urs-11-en-28-oic acid, and its cis counterpart, 
3β-cis-p-coumaroyloxy-2α,3β,13β-trihydroxy-urs-11-en-28-oic acid (He and Liu, 
2008).   
 Thirteen triterpenoids were also isolated from the peels of red delicious apples 
(He and Liu, 2007). Four of the triterpenoids were isolated and identified for the first 
time: Compound 3, identified as 3β-trans-cinnamoyloxy-2α-hydroxyurs-12-en-28-oic 
acid; Compound 7, identified as 2α-hydroxy-3β-{[(2E)-3-phenyl-1-oxo-2-
propenyl]oxy}olean-12-en-28-oic acid; Compound 8 (an isomer of compound 7), 2α-
hydroxy-3β-{[(2Z)-3-phenyl-1-oxo-2-propenyl]oxy}olean-12-en-28-oic acid; and 
Compound 12, 2α,3β,13β-trihydroxyurs-11-en-28-oic acid. Compound 1, ursolic acid, 
was the most abundant triterpenoid in the apple peel. Compound 2 was identified as 
2α-hydroxyursolic acid, and Compound 9 as 3β-trans-p-coumaroyloxy-2α-
hydroxyolean-12-en-28-oic acid. Four of these compounds (2α-hydroxyursolic acid, 
3β-trans-cinnamoyloxy-2α-hydroxyurs-12-en-28-oic acid, 2α-hydroxy-3β-{[(2E)-3-
phenyl-1-oxo-2-propenyl]oxy}olean-12-en-28-oic acid and 3β-trans-p-coumaroyloxy-
2α-hydroxyolean-12-en-28-oic acid) potently inhibited MCF-7 cell proliferation. This 
will be discussed further in a later section (He and Liu, 2007). 
 2. Metabolism and Bioavailability. Metabolism and bioavailability are 
critical factors in determining the beneficial health effects of dietary phytochemicals: 
How are the compounds metabolized by the digestive system? Are the compounds 
readily absorbed into circulation and available to tissues? Many cell, animal, and 
human feeding studies have contributed to answering these questions. For the 
purposes of this review, we will focus on quercetin and its glycosides. 
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The metabolism and absorption of flavonoids was summarized nicely by 
Wiliamson et al. (2000). Briefly, quercetin aglycone may passively diffuse from the 
lumen into the epithelial cells of the small intestine due to its hydrophobic nature, and 
enter circulation. Quercetin may be hydroxylated, methylated, sulphated, or 
glucuronidated in the small intestine, liver, or the kidney. Methylation and 
demethylation may occur at the 3’and 4’ positions, resulting in the metabolite 3’-
methylquercetin being detected in human plasma (Manach et al., 1998). Sulphation 
and glucuronidation are the major pathways of quercetin metabolism, with sulphation 
first becoming saturated at lower concentrations (Morand et al., 1998; Piskula and 
Terao, 1998). When fed either quercetin-3-glucoside or quercetin-4’-glucoside, 
quercetin glucuronides were found in human plasma, not quercetin glycosides (Sesink 
et al., 2001). Sulphated or glucuronidated quercetin conjugates may also be 
methylated on their catechol groups, as seen in bile of rats perfused with quercetin 
(Crespy et al., 2003). Sulphates of quercetin will be excreted in the urine, while the 
liver will release the quercetin glucuronides with the bile back into the small intestine 
(Mulder and Jakoby, 1990). Glucuronides continue on to the large intestine where 
microbes hydrolyze them and free the aglycone to be reabsorbed. In this way, 
phytochemicals may be caught up in enterohepatic circulation, increasing the 
elimination half-life in the body (Williamson et al., 2000). Microbes in the colon may 
hydrolyze glycosides, conjugates, and also degrade the phenolics themselves. 
Alternatively, rather than diffusing into the circulation from the small intestine, 
quercetin may pass through the lumen of the small intestine directly into the colon and 
be subject to degradation by microbes (Hackett, 1986).  
 Quercetin glycosides follow a slightly different path. Being hydrophilic, 
glycosides do not freely diffuse across membranes. Glycosides may be hydrolyzed off 
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of the quercetin in the lumen of the small intestine by lactase phlorizin hydrolase 
(LPH), a type of β-glycosidase found in the brush border of the small intestine (Walle 
et al., 2000; Day et al., 2003). Then, quercetin aglycone may passively diffuse and be 
metabolized as described above. Alternatively, quercetin glycosides may be actively 
transported into the small intestinal cells by active glucose transporters such as SGLT1 
(sodium-dependent glucose transporter 1) (Lostao et al., 1994; Gee et al., 1998) or 
facilitative-type glucose transporters such as GLUT2 (Kellett, 2001), and then cleaved 
by intracellular β-glycosidases. Again, the quercetin aglycone is further metabolized 
as described above.     
 Quercetin glycosides are metabolized differently depending on the sugar 
moiety. For example, as summarized by Williamson et al. (2000), cytosolic β-
glucosidase from human small intestine and liver cells had high affinity for quercetin-
4’-glucoside but exhibited no hydrolyzing activity on quercetin-3-rutinoside (Day et 
al., 1998). Rat intestinal β-glucosidase had higher activity on quercetin-4’-glucoside 
than on quercetin-3-rutinoside (Ioku et al., 1998). Cytosolic β-glucosidase from 
human liver hydrolyzed quercetin-4’-glucoside but not quercetin-3-glucoside. The 
human and rat small intestine enzyme, lactase phlorizin hydrolase (LPH, a different 
kind of β-glycosidase) hydrolyzed quercetin-3-glucoside (Leese and Semanza, 1973). 
Walgren et al. (2000) used a Caco-2 cell model to show for the first time that 
quercetin-4’-glucoside was absorbed into the cells via the SGLT1 glucose transporter 
(Walgren et al., 2000).  
 Wolffram et al. (2002) investigated the absorption of Q-3-G from the mucosal 
side of a rat jejunum mounted in Ussing-type chambers. Under control experimental 
conditions, only 14% of the Q-3-G remained on the mucosal side. Upon addition of 
phloridzin (a competitive inhibitor of SGLT1) and sodium-free medium, 54% of the 
Q-3-G remained. To test whether the GLUT5 transporter was involved, D-fructose 
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was added as a competitive inhibitor, which had no effect on disappearance of Q-3-G 
from the mucosal side. The same experiments were repeated with sections of proximal 
colon, which do not express SGLT1; no Q-3-G was taken up by the tissue. The authors 
conclude SGLT1 transport is a major contributing means of Q-3-G uptake by small 
intestinal cells, and summarize the various possible pathways, all of which may play a 
role. Q-3-G may be cleaved by LPH in the brush border (Day et al., 2000) then 
released as an aglycone into the intestinal lumen; or Q-3-G may be taken up into the 
intestinal cell, cleaved by intracellular enzymes, and then the aglycone may diffuse 
back into the lumen or through to the serosal side. Uptake into the cell may be by 
SGLT1 transporters, but not GLUT 5 transporters. GLUT2 transporters may 
contribute as other studies have indicated (Kellett, 2001).  
 Arts et al. (2002) contested Wolffram’s findings, pointing out that both glucose 
and phloridzin, used as inhibitors of SGLT1 by Wolffram, also have been shown to 
inhibit LPH. Arts et al. (2002) also deem the presence of quercetin aglycone on the 
mucosal side and the absence of conjugates as further evidence of the action of LPH. 
Wolffram of course responded to these criticisms, highlighting the absence of sodium 
in their model as a means of inactivating the SGLT1 transporter, while LPH is not 
sodium dependent (Wolffram, 2002). In addition, Wolffram points out that free 
aglycone from LPH hydrolysis should be subject to the same conjugation as any taken 
up by SGLT1 and subsequently hydrolyzed by intracellular glycosidases. They 
therefore maintain that lack of conjugates in their model does not disprove SGLT1 
transport (Wolffram, 2002).  
 Day et al. (2003) found that quercetin-3-glucoside was hydrolyzed solely in 
the small intestinal lumen by LPH and not by cytosolic β-glucosidase, and that Q-3-G 
was not transported by SGLT1, while quercetin-4-glucoside used both LPH and 
SGLT1. This group used rat everted-jejunal sacs as a model, and utilized phloridzin as 
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a SGLT1 inhibitor, and N-(n-butyl)-deoxy-galactonojirimycin (NB-DGJ) as an LPH 
inhibitor.  
 Finally, in a study published in 2003, Sesink et al. (2003) conceded that 
transport by SGLT1, as proposed by Wolffram (2002), may play a role in Q-3-G 
absorption. Sesink et al. (2003) performed an in situ perfusion of rat small intestine 
with Q-3-G in solution. In the control, 29% of the Q-3-G was absorbed out of the 
perfusion fluid. Addition of NB-DGJ in doses of 0.5, 2 and 10 mmol/L inhibited 
hydrolysis of the Q-3-G by 38, 50 and 67%, respectively, confirming the significant 
role of LPH in intraluminal hydrolysis of Q-3-G. Sesink recalls that the absence of 
sodium in Wolffram’s model inhibited Q-3-G disappearance from the mucosal 
medium by 25% (Wolffram et al., 2002), noting the similarity to the extent of Q-3-G 
absorption that was unaffected by LPH inhibition in their own study. Therefore, 
Sesink et al. concluded that transport of Q-3-G by SGLT1 transporter could not be 
completely discounted (Sesink et al., 2003). 
 While each of the mentioned studies contributed important information 
regarding the absorption and metabolism of quercetin and its glycosides, 
inconsistencies occur between studies and many questions remain. Differences in 
experimental design may account for varying results and interpretations. Such 
differences include: the model used (Caco-2 cell culture, rat intestinal tissues, rat or 
human in situ perfusion); duration of exposure (15 or 30 min., 1-2 h); test compound 
(quercetin aglycone or various glycosides); concentrations of test compounds; which 
compounds and metabolites were measured (such as aglycone, glycosides, and 
methylated, sulfated and glucuronidated conjugated; these papers used HPLC); and 
use of proper inhibitors for the enzymes and glucose transporters of interest. 
 According to Boyer and Liu (2004), quercetin glycosides found in apples have 
varied bioavailabilities. Quercetin-3-glucoside is readily hydrolyzed by LPH as 
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mentioned and absorbed in the small intestine, while other glycosides of quercetin 
such as rhamnosides, xylosides, and galactosides are not as easily absorbed. These 
compounds would then likely continue on to the colon and be subject to hydrolysis 
and further degradation by intestinal microflora. Metabolism of other prominent 
phytochemicals found in apples such as phloridzin, chlorogenic acid, catechin and 
epicatechin, is described by Boyer and Liu (2004).    
 Under typical consumption of plant foods, the blood concentrations of many 
polyphenols was estimated to range from 1 to 10 µM (Wang et al., 2003). In the 
Netherlands, flavonol consumption was measured at about 23 mg/d (Aziz et al., 1998). 
A broad range of flavonol and flavone intakes was recorded by the Seven Countries 
Study, which found the Finnish cohort to consume on average 3 mg/d while the 
Japanese cohort consumed 70 mg/d (Hertog et al., 1995).  
 Bioavailability of phytochemicals, rate of absorption, peak plasma 
concentrations and elimination half-lives depend on the type of sugar moiety and the 
food matrix. As summarized by Ross and Kasum (Ross and Kasum, 2002), many 
studies have observed absorption of phytochemicals from various foods. Hollman et 
al. (1995) restricted ileostomy patients from all quercetin for 12 days, then the patients 
consumed a source of quercetin for 12 days. Patients who ate fried onions (which 
contain quercetin glucosides) absorbed 52% of the quercetin, while those who 
consumed pure quercetin aglycone absorbed only 24%. Another study by Hollman et 
al. (1997) demonstrated that in healthy subjects, quercetin from a single dose of apple 
or pure quercetin-3-rutinoside was absorbed only about 30% compared to that 
absorbed from onions. Apple quercetin reached peak plasma levels after 2.5 hours 
with an elimination half-life of 23 hours, while onion quercetin peaked after only 0.7 
hours, with a longer half-life of 28 hours. DeVries et al. (1998) also demonstrated the 
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high bioavailability of quercetin found in onions: in healthy subjects, the amount of 
quercetin absorbed from black tea was only half that absorbed from the onions.  
 Olthof et al. (2000) fed 9 subjects a single dose of 325 µM Q-3-G, equivalent 
to 150.9 mg, and found the resulting plasma concentration of quercetin to peak at 5.0 
± 1.0 µM after only 37 ± 12 minutes. A single dose of 331 µM quercetin-4’-glucoside 
caused a peak plasma concentration of 4.5 ± 0.7 µM quercetin by 27 ± 5 minutes, with 
an elimination half-life of 17.7 ± 0.9 hours. Since the absorption of Q-3-G and Q-4’-G 
are nearly equivalent, the following study on quercetin-4’-glucoside metabolism may 
prove useful in the discussion of Q-3-G as well. 
 Graf et al. (2005) investigated the absorption, metabolism and disposition of 
quercetin-4’-glucoside (Q-4’-G), a major flavonol found in onions. (2-14C)Q-4’-G was 
synthesized and fed to rats (7.6 mg/kg), and plasma and tissues were harvested at 0.5, 
1, 2, and 5 hours post-ingestion. Q-4’-G was detected only in the gastrointestinal (GI) 
tract at 0.5 and 1 h, with a small amount in the liver at 0.5 h, and none at all in the 
kidneys and plasma. Quercetin aglycone accounted for 25% of the radioactivity in the 
GI tract at 0.5 h, which reduced to < 8% at later time points. Very small amounts of 
quercetin were found in the liver and kidney, but none in the plasma. Methylated and 
unmethylated glucuronides of quercetin were present in all organs tested at 0.5, 1 and 
2 h. At 5 h, only a small amount remained in the liver. Methylated and unmethylated 
glucuronides were the major group of metabolites in the liver and kidney at all 
timepoints, in the plasma at 0.5 h, and in the GI tract at 5 h. Sulfates of quercetin may 
also occur methylated and/or glucuronidated. Glucuronidated sulfates increased over 
time in the plasma, accounting for 76% of the metabolites in plasma at 5 h. Quercetin 
sulfate and methyl-quercetin sulfate were found only in the intestine at 0.5, 1 and 2 h 
(Graf et al., 2005). 
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 Graf et al. (2005) conclude only 6% of the dose of Q-4’-G was absorbed into 
the blood and internal organs, citing the consistency with human feeding studies of 
onions or Q-4’-G supplements which resulted in 1.4 to 6.4% of the ingested dose of 
quercetin being detected in the urine (Hollman et al., 1997; Olthof, 2000; Graefe et al., 
2001). The authors estimated the bioavailability of Q-4’-G from the diet or from 
supplements to be between 1 and 7% (Graf et al., 2005).  
 The authors cite other studies which may have dramatically over-estimated the 
absorption of quercetin. For example, studies on ileostomy patients calculated > 50% 
of the dose was absorbed from the GI tract (Hollman et al., 1995; Walle et al., 2000). 
Graf et al. (2005) point out these researchers measured quercetin, quercetin glycosides 
and quercetin conjugates, but not methyl-quercetin. Approximately 44% of quercetin 
becomes methylated and therefore if that methyl-quercetin were undetected, it may 
have been mistakenly assumed that portion of the quercetin sample had been absorbed 
out of the intestine (Graf et al., 2005). 
 Another example is a study by Wall et al., (2001), in which human subjects 
were fed a radio-labeled dose of quercetin aglycone. Based on radioactivity 
measurements of plasma over 72 h, the researchers concluded 36-53% of the dose was 
absorbed. However, based on previous studies showing plasma quercetin returns to 
baseline within 24 h, Graf suspects the radioactivity in plasma over the 72 h study was 
CO2 from microbial degradation of the quercetin, en route to lungs for exhalation. 
Graf considers the urinary excretion of quercetin, 4.2% of the dose, as the more 
reliable indicator of absorption (Graf et al., 2005). 
 Since the entire dose of Q-4’-G in the rat study was metabolized within 2 h, 
and at all time points 86-93% of the dose was in the GI tract (while no more than 2% 
was in liver at any time point), Graf et al. conclude most of the transformation occurs 
in the GI tract. This is consistent with an in situ rat perfusion study of quercetin, where 
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90% of the quercetin conjugates were found in the intestinal eluent, but only 10% in 
the bile. At the first timepoint, 0.5 h, Graf et al. saw more metabolites in the liver, 
kidneys and plasma than the GI tract, concluding the Q-4’-G was metabolized in the 
intestine, absorbed, and further methylated and glucuronidated in the liver and kidneys 
(Graf et al., 2005). 
 In summary, quercetin, whether the aglycone or a glycoside, will be absorbed 
to a certain extent. The quercetin conjugates found in the circulation ultimately are 
excreted in the urine or the bile. Quercetin that reaches the colon either directly from 
the small intestine or from the bile may be degraded further by intestinal microflora. 
Elimination half-lives differ somewhat according to the form of quercetin and the food 
source, and so regular consumption to maintain plasma levels is recommended to 
achieve the maximum health benefits.  
 B. Epidemiology Studies Linking Apple Consumption to Reduced Breast 
Cancer Risk. A recent epidemiologic study including 2,569 breast cancer patients 
showed that apple consumption was linked to a lower risk of breast cancer (Gallus et 
al., 2005). When compared with subjects consuming <1 apple/day, the multivariate 
odds ratios (OR) for  1 apple/day were 0.82 (95% CI 0.73-0.92) for breast cancer. 
After further allowance for consumption of vegetables and other fruits, the association 
with apples became even stronger for breast cancer (OR 0.76, CI 0.67-0.85) (Gallus et 
al., 2005). A case-control study in Brazil investigated associations between breast 
cancer occurrence and various anthropometric, socio-economic, and dietary factors 
(DiPietro et al., 2007). Thirty-three women recently diagnosed with breast cancer 
comprised the case group, while 33 healthy volunteers formed the control group. 
Breast cancer incidence was strongly correlated with age (> 45 y, OR = 4.00), low 
family income (OR = 3.50), low educational level (primary school or less, OR = 16.7), 
and menopause (OR = 9.84). Adjusting for age changed the odds ratios for low family 
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income to 4.51 and for low education level to 11.02. Since income is associated with 
dietary habits, the authors adjusted for family income before analyzing the dietary 
associations. They then found that breast cancer was increased by consumption of pig 
lard (OR = 6.32) and fatty red meat (OR = 3.48), while consumption of apples (OR = 
0.30), watermelons (OR = 0.31) and tomatoes (OR = 0.16) reduced risk (DiPietro et 
al., 2007).  
 C. Animal Studies of Effects of Apples on Mammary Cancer. Our lab has 
shown that apples fed to Sprague-Dawley rats in doses equivalent to human 
consumption of 1, 3, or 6 apples per day significantly reduced DMBA-induced 
mammary tumor development (Liu et al., 2005). Rats were fed whole apple extracts 
beginning 2 weeks prior to DMBA administration, and continuing throughout the 24 
week study. In a clear dose-dependent manner, the apple extracts down-regulated 
PCNA, Cyclin D1 and Bcl-2, and up-regulated Bax and nuclear fragments, reduced 
tumor size and tumor burden, and delayed tumor onset (Liu et al., 2009). The 
experimental design of beginning the apple feeding prior to DMBA administration, as 
well as the effects on early markers such as PCNA and Cyclin D1, indicate the apple 
interfered with the initiation and promotion stages of carcinogenesis. Since the apple 
feeding continued throughout the duration of the experiment, it is unclear whether the 
treatment also affected progression. 
 D. Cell and Molecular Studies. The mechanisms of action by which fruits 
and vegetables exert their health benefits are not completely understood. However, 
cell culture models and molecular techniques are valuable and efficient tools for 
assessing the various anti-cancer functions of individual phytochemicals. The 
mechanism of action of phytochemicals that has gained much attention recently is 
antioxidant activity, which is a measure of how effectively the compounds can quench 
free radicals. In doing so, the phytochemicals reduce oxidative stress (the imbalance 
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between oxidants and antioxidants) which is associated with chronic diseases such as 
cancer since the free radicals can damage DNA, proteins, and lipids (Ames and Gold, 
1991; Ames et al., 1993; Liu and Hotchkiss, 1995). Cells under oxidative stress are 
susceptible to DNA damage, which may lead to mutations that alter expression or 
activity of key regulatory proteins. Such mutations can result in de-regulation of cell 
cycle and subsequent uncontrolled cell proliferation, which can lead to cancer. These 
cells are then unable to properly respond to further oxidative stress and are highly 
susceptible to additional DNA damage. This cycle contributes to increasing genetic 
instability characteristic of tumor cells (Bartek and Lukas, 2001).  
 While phytochemicals can protect DNA from oxidative stress, they can also 
help prevent cancer by modifying cell cycle progression or inducing apoptosis in the 
event DNA damage does occur. Phytochemicals also regulate gene expression (genes 
governing cell proliferation and differentiation, oncogenes and tumor suppressor 
genes), enzyme activity (detoxification, oxidation and reduction enzymes), immune 
system function and hormone metabolism (Liu, 2004).  
 1. Whole Apple Extracts. Whole apple extracts and apple peels have been 
shown to have potent anti-oxidant activity (Eberhardt et al., 2000; Wolfe et al., 2003; 
Wolfe and Liu, 2007). Eberhardt et al. (2000) found that the Vitamin C in an apple 
accounts for only 0.32% of the fruit’s total antioxidant capacity, implicating the other 
phenolic compounds in the remaining 99.68% of the activity. Using the TOSC (total 
oxyradical scavenging capacity) assay, our lab determined the antioxidant activity of 
whole apple extract was 97.6 ± 4.6 µmol of vitamin C equivalents/g of fresh weight of 
the fruit (Sun, et al. 2002). Out of the 11 commonly consumed fruits analyzed in that 
study, the antioxidant activity of apple was second only to cranberry, which was 177.0 
± 4.3 µmol/g. Later, antioxidant activity in the flesh of the apple was compared to that 
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in the peel (Wolfe et al., 2003). In Idared, Rome Beauty, Golden Delicious, and 
Cortland apples, antioxidant activity of the flesh was 46.9 ± 1.6,  68.02 ± 1.47, 43.5 ± 
0.4, and 50.4 ± 2.2 µmol Vit. C eq/g fruit, respectively. In the same order, antioxidant 
activity of the flesh with the peel was 72.2 ± 2.3, 131.6 ± 0.8, 66.9 ± 1.8, and 83.5 ±  
2.3 µmol Vit. C eq/g fruit. Antioxidant activity of the peel was 312.2 ± 9.8, 228.4 ± 
6.7, 111.4 ± 4.7, and 159.0 ± 4.3 µmol Vit. C eq/g fruit. Similar to the total phenolic 
content, antioxidant activity was higher in the peel than the flesh (Wolfe et al.,  2003). 
 Our lab has shown that non-cytotoxic doses of whole apple extract inhibit 
proliferation of MCF-7 cells (Yoon and Liu, 2007; Sun and Liu, 2008; Felice et al., 
2009). Apple extracts effectively inhibited TNF-α-induced NF-κB activation, which is 
a significant finding since NF-κB plays a role in resistance to chemotherapy in cancer 
cells (Yoon and Liu, 2007). It is important to note that the anti-proliferative activity of 
whole apple extracts is not due to phenolic-induced H2O2 formation in the culture 
medium (Liu and Sun, 2003), as was previously suspected.  
 2. Pure Phytochemicals.  
a. Quercetin. Quercetin isolated directly from fresh red delicious apple peels 
in our lab exhibited anti-proliferative activity against MCF-7 cells in vitro with an 
EC50 of 137.5 ±2.6 µM, while the quercetin-3-O-β-D-glucopyranoside was even more 
potent with an EC50 of 23.9 ± 3.9 µM (He and Liu, 2008).  
 MDA-MB468 cells, an estrogen receptor negative human breast cancer cell 
line, express a mutated form of p53 that is required for their survival. Avila et al. 
(1994) found that quercetin effectively reduced proliferation of these cells in a dose-
dependent manner after only 24 hours, with an EC50 of 7.0 µg/mL after a 72 hour 
exposure. Cell cycle analysis first showed a G2/M accumulation; when the cells were 
synchronized first, a G1 accumulation occurred. Together these results indicate the 
target of quercetin is present throughout the cell cycle. Quercetin down-regulated 
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mutant p53 expression in a time- and dose-dependent manner (2 through 8 hours, 10 – 
75 µg/mL). The authors verified the quercetin was not causing an overall inhibition of 
protein synthesis within the cell, and that this effect was specific to the mutant p53. 
mRNA levels remained stable with quercetin treatment, and labeling with 
[35S]methionine with or without quercetin revealed the phytochemical was preventing 
protein synthesis of the p53 (Avila et al., 1994). Interestingly, two quercetin 
glycosides (quercetrin and quercetin-3-rutinoside) did not affect p53 levels. Quercetin 
appeared to have a specificity for the critical mutant p53 protein in the MDA-MB468 
cell line (Avila et al., 1994).  
 In MCF-7 cells, quercetin was shown to induce a G2-phase accumulation with 
an accompanying increase in Cyclin B1 expression and Cdc2 kinase activity after 
more than 24 hours treatment (Choi et al., 2001). Increased p21 expression and 
association with Cdc2/Cyclin B1 was seen after 48 hours of treatment, as was a p21-
dependent apoptosis induction. Quercetin induced a G1 cell cycle arrest and apoptosis 
in MDA-MB-453 mammary carcinoma cells and down-regulated Bcl-2 expression 
while up-regulating Bax expression and cleavage of caspase-3 and PARP (Choi et al., 
2008). 
 Her-2/neu, a receptor tyrosine kinase (RTK) that functions through dimerizing 
with other RTKs, is an important player in breast cancer signaling (Olayioye et al.,  
2000; Hynes and Lane, 2005). Quercetin caused down-regulation of Her-2/neu 
receptor, along with corresponding decreases in phosphorylation of PI3K and Akt, in 
human breast carcinoma SK-Br3 cells which over-express Her-2/neu (Jeong et al., 
2008). The investigators saw a similar down-regulation of the Her-2/neu receptor by 
quercetin in MCF-7 cells, and in a Her-2/neu over-expressing ovarian cancer cell line 
SK-Ov3.  
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 Quercetin has been shown to interfere with signaling pathways involved in 
migration and metastasis. Matrix metalloproteinases are responsible for dissolving the 
extracellular matrix, allowing tumor cells to migrate and invade distant sites (Duffy et 
al., 2000). In MCF-7 cells, 50 ng/mL TPA (12-O-tetradecanoylphorbol-13-acetate) 
induced invasion, colony formation, and migration as determined by an in vitro 
invasion assay, a soft agar assay, and an in vitro monolayer wound-healing assay, 
respectively (Lin et al., 2008). 80 µM Quercetin aglycone (but not quercetin-3-O-
rhamnoside or quercetin-3-O-rutinoside) was able to reverse these effects of TPA. 
Furthermore, quercetin inhibited enzyme activity of MMP-9 by down-regulating 
expression of both the mRNA and the protein. In this cell model, activation of PKCδ 
was necessary for the TPA-induced MMP-9 activation and subsequent cell migration. 
TPA activated ERK and JNK but not p38 MAPK or Akt. Through the use of inhibitors 
the authors determined that AP-1, not NF-κB (both transcriptional regulators of MMP-
9), was involved in the TPA-induced activation of MMP-9. TPA-treated cells showed 
up-regulation of c-Jun but not c-fos. Quercetin was systematically shown to block 
TPA-induced PKCδ activation, ERK and JNK activation, c-Jun expression, and AP-1 
promoter activity. Structure-activity-relationship experiments determined that the 
hydroxyl (OH) groups on C3’ and C4’ confer quercetin’s ability to suppress MMP-9 
expression, while additional OH groups on C3, C5 or C7 would enhance that ability 
(Lin et al., 2008).  
 In a two-day cell proliferation assay, quercetin inhibited proliferation in a 
dose-dependent manner in three mammary cell lines: normal Human Mammary 
Epithelial Cells (HMEC), spontaneously immortalized human breast epithelial cells 
(MCF-10A), and ER+ breast cancer cells (MCF-7). The quercetin was most effective 
against the HMECs, with an IC50 of 5 µg/mL quercetin (14.8 µM). The IC50 against 
MCF-7 cells was 13 µg/mL quercetin (38.4 µM), while the MCF-10A cells were the 
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most resistance with an IC50 of 32µg/mL quercetin (94.6 µM) (Hakimuddin et al., 
2004).  
 The effects of physiologically relevant doses of quercetin (1, 5 and 10 µM) 
were investigated in 3 human breast carcinoma cell lines, SK-BR3, MDA-MB-453, 
and MDA-MB-231, and one normal breast cell line, MCF-10A (Jeong et al.,  2009). 
Over 4 days of treatment, quercetin inhibited proliferation in a dose-dependent manner 
in SK-Br3 and MDA-MB-453 cells, but had no effect on proliferation of MCF-10A 
cells. After 4 days, viability of SK-Br3 cells was >95% and there was no evidence of 
PARP cleavage, which was used as a marker of apoptosis. Rather, the quercetin was 
causing a cell cycle block at the G1 to S transition. The proportion of SK-Br3 cells in 
G0/G1 phase increased from 61.8% in the control to 75.9% in those treated with 10 
µM quercetin; S phase cells decreased from 30.2% in control to 18.2% with 10 µM 
quercetin; and G2/M phase cells did not change significantly. Over 2 and 4 days of 
treatment, quercetin induced hypo-phosphorylation of Rb (Ser780 and Ser807/811) in SK-
Br3 cells. Additionally, quercetin induced DNA damage, and subsequent 
phosphorylation of histone H2A.X, Chk2 activation, and p21 induction. In these cells 
p53 expression was not affected, nor was expression of Cyclin D1, CDK4, CDK6, 
Cyclin E or CDK2. However, Cyclin B and CDK1 were down-regulated. Quercetin 
also induced p21 expression in MDA-MB-453 cells. In the normal MCF-10A cells, 
quercetin did not affect cell proliferation over 4 days. After 2 and 3 days of treatment, 
quercetin had no effect on phosphorylation of Rb, there was no detectable p21 
expression, and there were no changes in Cyclin B and CDK1 expression. In this study 
of physiologically relevant doses, quercetin had clear cell-type specific effects on 
breast cancer cells in vitro which included inhibition of cell proliferation, an 
accumulation of cells in the G1 phase of the cell cycle, and a p53-independent/Chk2-
dependent induction of p21 in SK-Br3 cells, while none of these effects were seen in 
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normal MCF-10A cells (Jeong et al., 2009). Looking at these two studies together 
(Hakimuddin et al., 2004; Jeong et al., 2009), it is clear that quercetin exerts its anti-
cancer effects in both a cell type- and a dose-specific manner. Further in vitro studies 
in normal and cancerous cell lines, as well as in vivo studies, are needed to clarify the 
mechanisms of action by which quercetin protects against breast cancer. 
 b. Flavanols (Catechins). A class of polyphenols called flavanols or catechins 
is found in green tea and chocolate, among other food sources (Goodin et al., 2002). 
Being the major flavanol in green tea, EGCG has been extensively studied. Catechin 
and epicatechin, however, the main flavanols in apple, are less prevalent in the 
literature. 
 Catechins have been found to inhibit breast cancer cells in vivo (Morre et al., 
2000), and epidemiology studies have demonstrated an inverse relationship between 
green tea consumption and breast cancer development and recurrence (Nakachi et al., 
1998). The authors correlated breast cancer diagnosis and prognostic factors with prior 
green tea consumption in 472 patients. In premenopausal women diagnosed with 
Stage I or II breast cancer, increased tea consumption was associated with a decrease 
in axillary lymph node metastases. In postmenopausal women, the tea was associated 
with increased expression of both the progesterone and estrogen receptors. A 7-year 
follow-up study showed that Stage I or II patients who drank < 4 cups of green tea per 
day had a recurrence rate of 24.3%, while those who drank > 5 cups per day had a 
16.7% recurrence rate. The green tea had no effect on recurrence rates in women 
diagnosed with a Stage III tumor. This study demonstrates that while green tea is able 
to affect clinical characteristics of breast cancer, timing of exposure is also important.  
Goodin et al. (2002) investigated the relationship between three common catechins 
(EGC: epigallocatechin; ECG: epicatechin gallate; EGCG: epigallocatechin gallate) 
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and estrogen receptor function. In vitro assays included receptor binding and ER 
reporter gene assays in MCF-7 cells. In vivo, two markers of estrogen function in 
immature 57BL/6 mice were measured: uterine weight and uterine peroxidase activity 
(Goodin et al., 2002). EGC did not have any significant effect in any of the assays, 
which the authors attribute to the absence of the gallate moiety. EGCG and ECG, 
however, competed with estradiol (E2) for ER and ER binding in MCF-7 cells, 
although the affinity of these catechins was nearly 100 to 17,000 times weaker than 
that of “classical phytoestrogens” (genistein, daidzein and coumestrol). EGCG and 
ECG did not affect E2-induced ER-mediated gene expression in vitro. However, low 
concentrations of catechins (0.5 µM EGCG co-administered with 0.1 nM E2) 
increased ER gene expression by 200%, while high doses (1-50 µM EGCG with 1 
nM E2) decreased ER gene expression by 35 – 50% when compared to E2 control. 
Catechins alone did not alter the in vivo markers of uterine weight or uterine 
peroxidase formation. Yet, when co-administered with E2, EGCG or ECG increased 
uterine weight significantly and uterine peroxidase formation was ~2.3 times greater 
than E2 alone (Goodin et al., 2002). The cancer-protective effect of catechins, 
therefore, may not be attributed to antagonism of ER function. Gallate-containing 
catechins (EGCG and ECG) are able to suppress several cytochrome P450s including 
CYP1A1/2 and CYP 3A4, which are responsible for metabolizing E2. The catechins 
also may influence E2 uptake into the cells. Taken together, these two activities may 
contribute to EGCG’s and ECG’s enhancement of E2 function rather than suppression 
(Goodin et al., 2002). 
 In MCF-7 cells, epigallocatechin-3-gallate (EGCG) reduced cell proliferation 
and induced apoptosis via Akt-dependent survivin suppression (Tang et al., 2007). 
EGCG is a desirable anti-cancer compound in that it has antineoplastic activity but is 
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non-cytotoxic to normal cells. Survivin, which suppresses apoptosis by interfering 
with caspase activity, is expressed in fetal tissues and cancers but expressed at very 
low levels or not at all in normal adult tissues. Tang et al. found the connection 
between these two observations. In a dose range between 10 and 50 µM, EGCG 
reduced colony formation and viability (24 hours) and induced apoptosis (Annexin-V 
staining) in MCF-7 cells. Promoter activity, mRNA and protein expression of survivin 
were suppressed, as well as Akt phosphorylation and kinase activity. A PI3K inhibitor 
(LY294002) also reduced survivin promoter activity, implicating the PI3K/Akt 
pathway in survivin function. Upon treatment with 50 µM EGCG, an increase in 
caspase-9 activation was seen in conjunction with a decrease in survivin expression 
over time (Tang et al., 2007).  
 The effects of resveratrol, quercetin and catechin on cell proliferation and cell 
cycle of mammary tumors in nude mice xenografted with MBA-MD-231 cells were 
tested individually and in combination (Schlachterman et al., 2008). Each of the 3 
phytochemicals had no effect on cell proliferation individually at 0.5 µM, but potently 
inhibited proliferation in combination, by 65% with each phytochemical at 0.5 µM, by 
83% with each at 5 µM, and by 98% with each at 20 µM. Individually, quercetin 
inhibited cell proliferation by ~60% and 90% at 5 and 20 µM, respectively, while 
catechin inhibited proliferation by ~30% at 20 µM.  Individual phytochemicals had no 
effect on cell cycle at 0.5 µM, but the combined treatments at 0.5 µM each caused a 
statistically significant increase in S phase and concomitant decrease in G2/M phase 
cells. In doses of 20 µM, resveratrol alone, quercetin alone, or the combination of the 
three caused a G0/G1 arrest, while catechin alone induced an S-phase accumulation.   
 In a study of the antiproliferative activities of tea catechins, (-)-catechin (400 
µmol/mL) induced cell death in 23.4% ± 1.7 of the population of MCF-7 cells 
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(Friedman et al., 2007). (-)-Epicatechin was much more potent, inducing cell death in 
22.3% ± 2.6 of the population at 100 µmol/mL, 64.7% ± 4.0 at 200 µmol/mL, and 
79.9% ± 19.4 at 400 µmol/mL. As mentioned earlier, both (-)-catechin and (-)-
epicatechin were present in apple peels (He and Liu, 2008). After 48 hours of 
treatment, catechin (30 and 60 µg/mL) and procyanidin fractions (30 µg/mL only) of 
grape seed extract reduced MCF-7 proliferation as measured by MTT assay and DNA 
synthesis (Faria et al., 2006). 
 A study of catechins from litchi fruit extract compared cytotoxicites in MCF-7 
breast carcinoma cells and in HELF human embryonic lung fibroblasts as the normal 
cell line (Zhao et al., 2007). As a benchmark, cytotoxicity of paclitaxel was first 
measured. The IC50 of paclitaxel in MCF-7 cells was lower than 25 µg/mL. At a dose 
of 100 µg/mL, paclitaxel inhibited MCF-7 cells by 72.5% and HELF cells by 62.4%, 
not a very large margin. On the other hand, the IC50 of epicatechin was 102 µg/mL in 
MCF-7 cells and 231 µg/mL in HELF cells, and the IC50 of proanthocyanidin B2 was 
99 µg/mL in MCF-7 cells and 254 µg/mL in HELF cells. The authors conclude that 
this large difference indicates these compounds may be effective at reducing 
proliferation of breast cancer cells while having low toxicity to normal tissues. 
 c. Triterpenoids. Among the 13 triterpenoids isolated from red delicious 
apples in our lab, four potently inhibited proliferation of MCF-7 cells with high 
selectivity (He and Liu, 2007). In other words, the EC50 for antiproliferative activity 
was low while the CC50 for cytotoxicity was high. A low selectivity index (SI = 
CC50/EC50) indicates the effective antiproliferative doses begin approach cytotoxic 
doses. A safe, effective compound will have as high a selectivity index as possible. 
These triterpenoids were denoted as Compound 2 (2-α-hydroxyursolic acid), 
Compound 3 (3β-trans-cinnamoyloxy-2α-hydroxyurs-12-en-28-oic acid), Compound 
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7 (2α-hydroxy-3β-{[(2E)-3-phenyl-1-oxo-2-propenyl]oxy}olean-12-en-28-oic acid), 
and Compound 9 (3-β-trans-p-coumaroyloxy-2-α-hydroxyolean-12-en-28-oic acid). 
For Compound 2, the EC50 was 4.7 ± 1.7 µM, the CC50 was 61.2 ± 5.7 µM, and the 
selectivity index (SI) was 13.0; Compound 3: EC50 = 22.4 ± 1.8 µM, CC50 >166.1 µM, 
SI > 7.4; Compound 7: EC50 = 29.2 ± 3.3 µM, CC50 = 118.4 ± 5.3, SI = 4.0; 
Compound 9: EC50 = 20.9 ± 2.3 µM, CC50 = 67.5 ± 1.5, and SI = 3.2. By contrast, 
Compound 1 (ursolic acid) potently inhibited MCF-7 cells with an EC50 of 14.4 ± 1.8 
µM with a CC50 of 18.2 ± 0.6 µM, giving an SI of only 1.3 (He and Liu, 2007).  
 2α-Hydroxyursolic acid, one of the major triterpenoids isolated from apple 
peels, significantly inhibited MCF-7 cell proliferation (Yoon and Liu, 2008). In 
response to 2α-hydroxyursolic acid treatment, the phosphorylation level of NF-κB 
inhibitor (IκB-α) did not change, but proteasome activity in MCF-7 cells was inhibited 
significantly. These results suggest that 2α-hydroxyursolic acid has antiproliferative 
activity against MCF-7 cells and the ability to inhibit NF-κB activation induced by 
TNF-α partially by suppressing proteasome activity. 
 d. Dihydrochalcones. As mentioned earlier, the main dihydrochalcones 
present in apples were phloretin 2’-glycoside (phlorizdin) and phloretin 2’-
xyloglucoside (Tsao et al., 2003). Phloretin and its glycoside, phloridzen, are known 
as effective inhibitors of glucose transport in the cell: phloretin is a general inhibitor of 
facilitated diffusion transporters (Krupka, 1985; Bakker et al., 1999) and phloridzin is 
a competitive inhibitor of SGLT1 (Toggenburger et al., 1982). Cancer cells can 
develop resistance to chemotherapeutics through overexpression of drug efflux 
proteins, such as P-glycoprotein and MRP1 (multidrug-resistance protein 1). Zhang et 
al. (2003) investigated the influence of various phytochemicals on this mechanism 
(biochanin A, morin, phloretin, and silymarin). For the purposes of this review, we 
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will limit the discussion to the results pertaining to phloretin, which is a 
phytochemical present in apples. In this study, 4 cell lines were used: MCF-7 (no 
detectable P-gp present), MDA435/LCC6WT (MDA/WT; wild type, moderate P-gp 
expression), MCF-7/ADR (overespression of P-gp) and MDA435/LCC6MDR1 
(MDA/MDR1; overexpression of P-gp). There was no significant expression of MRP1 
in any of the cell lines. 50 µM phloretin had no effect on [3H]DNM (daunomycin) 
accumulation in MCF-7 cells as expected due to the lack of P-gp, but it significantly 
increase accumulation in MDA-WT and MCF7/ADR cells. In the MDA/MDR1 cells, 
phloretin non-significantly increased accumulation to 277% of control at 50 µM and 
significantly increased accumulation to 431% of control at 100 µM. The extent of 
increased DNM accumulation was associated with the extent of down-regulation of 
the P-gp. In MDA/MDR1 cells, phloretin actually decreased the cytotoxicity of 
doxorubicin, with an IC50 of 56.67 µM, compared to the control, 30.18 µM. In order to 
measure the effect of the phytochemicals on passive diffusion of the DNM into the 
cells, uptake rates were measured in the P-gp-negative MCF-7 cells. Phloretin did not 
increase passive diffusion but in fact slightly decreased the rate to 82.17% of control 
(50 µM). 50 µM phloretin did not significantly alter P-gp expression after a 2 hour 
incubation in MDA/MDR1 cells (110.2% of control), or a 24 hour pre-incubation in 
MCF7/ADR cells (83% of control). Phloretin did not significantly inhibit direct 
binding of substrate ([3H]axidopine) with P-gp. Verapimil inhibits P-gp activity by 
increasing P-gp ATPase activity. Verapimil alone induced an ATPase activity of 32.6 
and 31.7 in separate experiments; Phloretin alone induced activity to only 5.03. 
However, the combination of verapimil and phloretin induced ATPase activity to 
52.74. The authors speculate the phloretin may bind to one of P-gp’s 2 substrate 
binding sites or its allosteric site, altering the manner in which the verapimil interacts 
with the P-gp and thus enhancing its ATPase activity. The authors conclude 
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phytochemicals such as phloretin can interfere with P-gp-mediated drug efflux, which 
has implications for treatments, as well as drug interactions with dietary supplements 
of flavonoids (Zhang and Morris, 2003).  
 Another group also exploited phloretin’s ability to inhibit glucose uptake to 
sensitize chemoresistant cells to daunorubicin (DNR) under hypoxic conditions (Cao 
et al., 2006). Solid tumors often have hypoxic regions and are able to maintain high 
rates of glycolysis by overexpressing glucose transporters and glycolytic enzymes. 
Hypoxia and high expression of glucose transporters are associated with 
chemoresistance in cancer cells. The researchers measured cytotoxicity of DNR with 
and without phloretin, under normoxic and hypoxic conditions. In SW620 colon 
cancer cells, the IC50 under normoxia was 11 nM and under hypoxia was 50 nM. 
Addition of 50 µM phloretin to the DNR resulted in an IC50 of 14 nM under normoxia 
and 25 nM under hypoxia, thus sensitizing the cells to the effects of DNR under 
hypoxic conditions only. A similar trend was seen in K562 drug-sensitive leukemia 
cells. The IC50 of DNR under normoxia was 21 nM and under hypoxia was 44 nM. 
Addition of phloretin changed the IC50 to 35 nM under normoxia and 20 nM under 
hypoxia. Similar effects were seen in K562/Dox cells, a drug-resistant leukemia cell 
line that overexpresses P-gp: Under normoxia, phloretin alone did not kill cells and 
addition of phloretin to DNR did not enhance the drug’s cytotoxicity. However, under 
hypoxia, addition of 50 µM phloretin to 1 µM DNR increased cytotoxicity from 40-
50% to 70%. Apoptosis was also increased under the hypoxic conditions (phloretin 
induced no significant apoptosis; 1 µM DNR induced 32% apoptosis; combination 
induced 63% apoptosis; Annexin-V staining). The authors note such differences in 
effects under normoxic and hypoxic conditions must be kept in mind when designing 
in vitro assays measuring efficacy of chemotherapeutic agents. Also, they point out 
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that the specificity of the effects of phloretin in combination with DNR on hypoxic 
cells versus normoxic cells may confer tumor selectivity in vivo, a desirable 
characteristic of any chemotherapeutic treatment (Cao et al., 2006).   
 In a review of the anti-cancer activity of chalcones (Go et al., 2005), phloretin 
was cited as having antioxidant activity in a DPPH free radical scavenging assay 
measured by electron spin resonance. The antioxidant activity was attributed to the 
hydroxyl groups (Anto et al., 1995). In doses up to 50 µM, phloretin was found to 
have no effect on proliferation of MCF-7 cells (Calliste et al., 2001).  
 Phloridzen, a glycoside of phloretin, was shown to increase absorption of 
genistin by 2.5-fold in a rat small intestine perfusion model (Andlauer et al., 2004). 
Phloretin and phloridzin both inhibited proliferation of Fisher bladder cell carcinoma 
in vitro, as well as in a rat mammary adenocarcinoma model after intraperitoneal 
administration (Nelson and Falk, 1993). 
 
V. IGF SIGNALING 
A. The IGF System. IGF-I (Insulin-like Growth Factor-I) is a peptide 
hormone which acts as a mediator between growth hormone (GH) and growth during 
fetal and early childhood development (Holly et al., 1999). Insulin-like Growth Factor 
I (IGF-I) is produced by the liver for endocrine functions (Yakar et al., 1999) and by 
many other tissues for autocrine and paracrine functions (Adamo et al., 2005). The 
three major factors influencing endocrine IGF-I production in the liver are growth 
hormone (Bichell et al., 1992), insulin (Kaytor et al., 2001; Kaytor et al., 2001b) and 
nutritional status (caloric and protein intakes, Clemmons et al., 1981; Thissen et al., 
1994).  IGF-I acts through binding to the IGF-I Receptor (IGF-IR). The IGF-IR is 
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70% homologous to the insulin receptor, but has independent roles in cell proliferation 
and survival, differentiation, and neoplastic growth (Baserga et al., 2003).  
 1. Components of the IGF System. The IGF system is comprised of 2 growth 
factors (IGF-I and IGF-II), 3 receptors (the IGF-I Receptor, IGF-IR; the mannose-6-
phosphate/IGF-II Receptor, IGF-IIR; and the Insulin Receptor, IR), and 6 IGF binding 
proteins (IGFBP-1 through -6) (Adamo et al., 2005). IGF-I signals primarily through 
the IGF-IR, a tyrosine kinase receptor made of 2 extracellular α subunits and 2 
transmembrane β subunits. The β subunits are 84% homologous to the IR at the amino 
acid level. IGF-I may bind to the insulin receptor, but with 100 to 1,000-fold lower 
affinity than insulin, and with half the affinity it has for the IGF-IR.  IGF-I has much 
lower affinity for the IGF-IIR than does IGF-II. IGF-II can elicit mitogenic effects by 
binding to the IGF-IR or to the IR. Specifically, IGF-II has a high affinity for the IR-A 
splicing variant but none at all for the IR-B variant (Adamo et al., 2005). The role of 
the IGF-IIR in this system is to internalize and degrade IGF-II, thus removing this 
growth factor from circulation. Insulin does not bind to the IGF-IR; however, it may 
bind to an IGF-IR/IR hybrid, but with a lower affinity than IGF-I has for the hybrid 
(Ryan and Goss, 2008). IGFBPs bind the IGFs in the serum, protecting them from 
degradation and extending the half-life. Locally, BPs may either inhibit or enhance 
IGF action. Most of the circulating IGF-I is bound to IGFBP-3 and acid-labile subunit 
(ALS) in a ternary complex (Adamo et al., 2005 and sources therein). 
 2. Normal physiological roles of the IGF system and the influence of 
nutrition. Somatic growth, from fetus to adult, is regulated mainly by the IGF system. 
As the IGF-I system is highly influenced by nutrition, somatic growth of the fetus is 
regulated by both fetal IGF-I levels and maternal nutrition (Blanco and Ferry, 2005). 
Compared to premature newborns, term newborns have higher IGF-I and -II levels, 
which are good indicators of weight and length at birth as well as gestational age 
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(Prosser, 1996). IGF-II levels are higher than IGF-I in the fetus, while IGF-I levels are 
higher than IGF-II after birth. In the fetus, IGFBP-1 and -2 are the main IGF binding 
proteins present in serum, and decrease over the gestational period as IGFBP-3 and 
ALS increase to become the dominant binding proteins in postnatal life (Prosser, 
1996; Blanco and Ferry, 2005). 
 Human breast milk contains IGF-I and –II, and IGFBPs (Smith et al., 1997; 
Blanco and Ferry, 2005), and is believed to promote the maturation of the newborn’s 
incompletely developed intestinal epithelium (Blanco and Ferry, 2005). At birth, there 
is a positive association between the IGFI:IGFBP-3 ratio and weight, length, and head 
circumference (Prosser, 1996; Blanco and Ferry, 2005). IGF production only becomes 
dependent on GH stimulation after 6 months of age (Prosser, 1996; Blanco and Ferry 
2005). In the newborn, feeding stimulates release of insulin which lowers IGFBP-1 
release, thereby increasing circulating levels of available IGF-I to promote growth 
(Bhala et al., 1998; Blanco and Ferry, 2005). Similarly, in adults and children, fasting 
or decreasing calories or protein will lower total serum IGF-I levels (Clemmons et al., 
1981; Isley et al., 1983; Thissen et al., 2005). Protein and caloric intake influence 
IGF-I levels in premature infants (Donovan et al., 1991; Blanco and Ferry, 2005).  
 The IGF system is vital to the reproductive system. Yet, it does not work in 
isolation but rather as part of a network including GH, steroid hormones (estrogen, 
progesterone, and testosterone) and nutrition to support normal reproductive function 
and successful pregnancies. The ovaries have a self-contained, paracrine IGF system 
necessary for proper ovulation, circulating reproductive hormone concentrations and 
early embryo development (Zhou et al., 1997; Simmen et al., 2005). Circulating 
endocrine IGF and nutrition also impact ovary function, the plausible connection 
being that an undernourished female cannot support a pregnancy. Therefore, ovary 
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function may be turned off, in response to under-nutrition and decreased IGF-I, at 
various stages of the process, such as hormone secretion, ovulation, corpus luteum 
development, and survival of the embryo (Simmen et al., 2005). 
 The fallopian tubes and uterus also have local IGF systems critical to their 
normal functions. IGF-I and nutrition may affect these organs although currently the 
evidence is unclear (Simmen et al., 2005). IGF function in the male reproductive 
system has been less extensively studied. Some indications of a role for IGF and 
nutrition in the testis come from animal studies. Increased feeding in rams is 
associated with increased testis size, plasma testosterone and IGF-I, peak pubertal 
reproductive activity and increased body weight (Adam and Findlay, 1997; Simmen et 
al., 2005). Bovine sperm cells express IGF-IR, and IGF-I and –II increase bovine 
sperm motility (Henricks et al., 1998; Lackey et al., 1998; Simmen et al., 2005). In 
summary, while the reproductive system is influenced by endocrine IGF-I and 
nutrition, it is mostly under the control of local paracrine IGF systems.  
 Over the lifespan, IGF-I levels fall with age, and IGFBPs fall to a lesser extent, 
allowing a higher proportion of circulating IGF-I to be bound to the BPs and therefore 
less bioavailable (Lewitt and Hall, 2005). It is not clear whether the main contributing 
factor is reduced GH levels with age, changes in nutrition over time, or both (Lewitt 
and Hall, 2005). Higher than normal range IGF-I is seen in individuals living longer 
than 100 years (Paolisso et al., 1997; Lewitt and Hall, 2005). IGF-I may play a role in 
many diseases of aging. For example, lower levels of IGF-I are associated with 
dementia (Arai et al., 2001; Lewitt and Hall, 2005) and reduced immune function 
(Krishnaraj et al., 1998; Lewitt and Hall, 2005). The IGF system may play important 
roles in osteoporosis, muscle wasting, and cardiovascular disease in aging (Lewitt and 
Hall, 2005). 
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 IGF-I contributes to bone formation and maintenance of bone density 
throughout life by activating osteoblast cells (Thissen et al., 1994; Bonjour et al., 
2005) increasing reabsorption of inorganic phosphate (Pi) by the kidney (Bonjour et 
al.,1991); Bonjour et al., 2005), and producing calcitriol, the hormonal form of 
Vitamin D, (Caverzasio and Bonjour, 1991; Bonjour et al., 2005) which is responsible 
for intestinal absorption of calcium and Pi. These normal functions of IGF-I in relation 
to bone health are blocked in the face of protein deficiency. (Decreased dietary protein 
lowers GH secretion, and consequently IGF-I secretion is reduced.) For example, a 
protein-deficient diet is common among elderly hip fracture patients (Older et al., 
1980; Bonjour et al., 2005). Upon protein supplementation, circulating IGF-I levels 
increased as did bone mass and muscle mass. Consequently, risks of falling, further 
fractures, medical complications, and deaths were reduced (Delmi et al., 1990; 
Bonjour et al., 2005). Decreased protein intake influences bone loss through two GH-
dependent routes: (1.) by decreasing IGF-I production and action, thereby reducing 
bone formation, and (2.) by decreasing sex hormone production and increasing 
osteolytic cytokines thereby increasing bone resorption (Bonjour et al., 2005). 
 IGF-I aids in skeletal and cardiac muscle protein synthesis and maintenance. 
Catabolic conditions such as critical illness, AIDS, alcohol intoxication, burns, sepsis 
and endotoxemia see lowered levels of IGF-I expression and activity. Some of these 
conditions show a favorable response to treatment with IGF-I (Lang and Frost, 2005). 
IGFs play important roles in the generation and protection of neurons, both in normal 
function and in a clinical setting as a treatment for head injury and nerve damage. 
Growth and interaction between neurons and muscle cells is maintained in part by 
IGF-I. The effects of nutrition on IGF-I’s role in the nervous system need to be further 
studied (Meyer et al., 2005). The kidney expresses a local IGF system. IGF-I plays a 
43 
 
role in renal growth, renal blood flow, glomerular filtration rate, and renal transport of 
phosphate and sodium, as well as in compensatory renal growth and renal hypertrophy 
in several diseases of the kidney (Rabkin et al., 2005). 
 The IGF system is essential to normal mammary gland development and 
function. Briefly, pituitary GH stimulates mammary development during puberty. GH 
induces IGF-I production in the stroma of the mammary gland, and subsequently IGF-
I and E2 work together to promote proliferation of terminal end buds (TEBs) which 
extend, filling the mammary fat pad with a network of branching ducts. During 
pregnancy, IGF-I is necessary for progesterone to stimulate lobulo-alveolar 
development (Kleinberg and Ruan, 2008 ). 
 Rowzee et al.  (2008) review this topic in more detail. Evidence suggests that 
in rat mammary glands, ductal branching relies on locally-produced IGF-I rather than 
circulating IGF-I. In humans, IGF-II may also be important in mammary tissue 
development. In response to GH, IGF-I is expressed in the mammary stroma 
throughout post-natal development and regulates expression of S and G2 cyclins.  
IGF-I and IGF-II expression occurs in TEBs during puberty and promotes ductal 
branching. In the post-pubertal and early pregnancy epithelium, IGF-II is expressed 
while IGF-I is not. IGF-I expression returns to the ductal epithelium during mid- 
through late-pregnancy, and to the alveolar epithelium during late pregnancy. IGF-II 
expression (regulated mostly by prolactin) maintains a non-uniform expression pattern 
in the ductal epithelium in post-puberty as well as in the alveoli during pregnancy. 
There are difficulties in discerning distinct roles of IGF-I and II. It is clear local IGF-II 
cannot rescue pubertal mammary epithelial growth in the absence of IGF-I. However, 
IGF-II does have an essential role in prolactin-mediated alveolar development. 
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IGFBPs, expressed in both the epithelium and stroma, work to regulate and partition 
the IGFs in the mammary tissue (Rowzee et al., 2008).  
 The IGF-IR is expressed in the mammary epithelium during all developmental 
stages and at lower levels in the stroma during periods of growth (puberty, post-
puberty, and pregnancy). It appears the IGF-I expressed in the stroma works in a 
paracrine fashion on the epithelial receptors to induce proliferation. It is possible the 
stromal receptors may play a role as well. Over-expression or over-activation of IGF-
IR may lead to hyperplasias and tumor formation in mammary epithelium. IR isoforms 
have been detected in mammary epithelial cells and breast cancer cell lines, and are 
critical in the development of mammary epithelial cells, particularly the differentiation 
of alveoli. Expression patterns of IR during various stages of development are not as 
defined as for the IGF-IR. IGF-II may mediate functions in mammary tissues through 
both the IGF-IR and the IR-A. Hybrid receptors containing one IGF-IR α-β subunit 
and one IR α-β exist in mammary tissues. These hybrid receptors have higher affinity 
for IGF-I than for insulin, however the exact functions and downstream signaling 
pathways are unknown. In humans, the expression of IR isoforms in normal breast 
epithelium, as well as whether IGF ligand expression patterns mirror those seen in 
rodents, are unknown (Rowzee et al., 2008). 
 3. PI3K Pathway (Figure 1.1). The IGF-IR signals through two major 
pathways: the PI3K/Akt pathway, and the Mek/Erk MAPK pathway (Werner and 
LeRoith, 2000). In MCF-7 cells, the IGF-IR exerts its mitogenic effects through the 
PI3K/Akt pathway (Dufourny et al., 1997), which was the focus of this study. Binding 
of IGF-I to the receptor stimulates autophosphorylation of the receptor which then 
phosphorylates Insulin Receptor Substrate-1 (IRS-1) (Izumi et al., 1987; Shemer et al., 
1987). Phosphorylation of IRS-1 creates a docking site suitable for Src-homology-
domain-containing signaling proteins such as the p85 subunit of PI3K. Through 
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phosphorylation of precursor molecules in the lipid membrane, PI3K is responsible for 
the generation of phosphatidylinositol-3, 4, 5-triphosphate (PIP3), which recruits other 
molecules such as PDK-1 and Akt. PDK-1 is then able to phosphorylate and activate 
Akt, which is responsible for activating a myriad of downstream signaling pathways 
(Lawlor and Alessi, 2001; Cantley, 2002). As a result of IGF-IR signaling, Akt drives 
cell cycle progression by promoting transcription of Cyclin D1 as well as preventing 
Cyclin D1 degradation by inhibiting GSK-3 (Lawlor and Alessi, 2001). Akt 
suppresses apoptosis by phosphorylating and thus inhibiting the pro-apoptotic 
mitochondrial protein Bad (Downward, 1999), and phosphorylating and inactivating 
Caspase-9 (Cardone et al., 1998).  In order to be fully activated, Akt must be 
phosphorylated on two key residues: Ser473 and Thr308. Thr308, which occurs in the 
activation loop of the protein, is phosphorylated by PDK-1 (Alessi et al., 1996). 
mTOR phosphorylates Ser473, in the carboxy terminus (Sarbassov et al., 2005). 
Phosphorylation of both of these residues is required for full Akt activation, both are 
stimulated by IGF-I treatment, and phosphorylation of one is not dependent on the 
phosphorylation state of the other (Alessi et al., 1996). 
4. MAPK Pathway (Figure 1.1). Shc proteins (cytoplasmic tyrosine kinases) 
bind to the Tyr950 residue of the IGF-IR and are activated. Shc proteins then bind 
Grb2, an adaptor protein that also binds SOS. In this way, SOS, a guanine nucleotide 
exchange factor (GEF), activates Ras. Activated Ras sets off the MAPK cascade that 
is comprised of Ras (monomeric GTP-ase), raf (Mitogen activated protein kinase 
kinase kinase, MAPKKK), MEK (MAPK/ERK kinase, MAPKK), and ERK 
(Extracellular signal-regulated kinase, MAPK). Activated ERK translocates to the 
nucleus where it activates the transcription factor Elk-1, which drives transcription of 
the AP-1 transcription factor, responsible for Cyclin D1 transcription. Peruzzi et al. 
(1999) found that sustained MAPK activation (at least 1 hour) was required to sustain 
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Bad phosphorylation. In addition, inhibition of the MAPK pathway resulted in a 
decrease in the level of Bad phosphorylation. 
 
Figure 1.1. IGF-I Receptor-Mediated Signaling Pathways. 
 5. Estrogen Receptor Signaling. ERα functions via genomic events in the 
nucleus, and via signal transduction events in the plasma membrane (Mawson et al., 
2005). The ER and IGF-IR pathways collaborate to promote cell cycle progression in 
various ways. In the nucleus, estrogen has been shown to increase the transcription of 
IGF-I, IGF-IR, and IRS-1. IGF-I-treated ER+ MCF-7 cells demonstrated increased ER 
transcriptional activity. Estrogen increases expression of c-myc, which blocks p21, 
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while insulin increases expression of Cyclin E. Estrogen, insulin, and IGF-I also 
promote expression of Cyclin D1. Together these events lead to enhanced progression 
through the G1-S transition. At the plasma membrane, estrogen-bound ER may bind 
and activate the IGF-IR or bind the p85 subunit of PI3K and Src, directly activating 
the PI3K and p21/ras/MAPK pathways (Mawson et al., 2005). 
 Since the ERα lacks a transmembrane domain, Song et al. (2004) investigated 
whether the IGF-IR may play a role in the translocation of ERα to the plasma 
membrane based on the following evidence: ERα and IGF-IR are co-expressed, there 
is crosstalk among their proliferative and anti-apoptotic signaling pathways, and E2 
stimulated IGF-IR activation and binding of ERα to Shc. Using immunoprecipitation 
assays, the authors found that in cells treated with 0.1 nM E2, ERα and Shc associated 
with the IGF-IR in a time-dependent manner. In the absence of E2, Shc associated 
with IGF-IR but ERα did not. IGF-I (1 ng/mL) did not induce association of ERα with 
the IGF-IR. The ternary complex of ERα, Shc and IGF-IR was disrupted by addition 
of the antiestrogen compound ICI 182,780. The use of inhibitors (AG1024 for IGF-IR, 
ICI 182,780 for ERα, PP2 for Scr) demonstrated that ERα and c-Src regulated E2’s 
ability to activate IGF-IR. Demonstrated by immunoprecipitation, knockdown of Shc 
using a specific siRNA caused an 87% decrease in the association between ERα and 
IGF-IR (both basal levels and E2-induced). Then, using confocal analysis, the authors 
showed that Shc was located in the cytoplasm and ERα in the nucleus. Addition of E2 
caused the translocation of both of these proteins to the plasma membrane, which was 
blocked by knockdown of Shc with siRNA. Total expression of ERα did not change, 
and neither did the effects of ERα-mediated changes in cell morphology induced by 
E2, such as ruffles and filopodia. Knockdown of IGF-IR with siRNA inhibited the 
ability of ERα to translocate to the cell membrane, but had no effects on morphologic 
changes induced by E2. Inhibition of each of the three proteins (IGF-IR, ERα, and 
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Sch) by either siRNA or chemical inhibitors blocked E2-induced MAPK 
phosphorylation. Additionally, treatment with the IGF-IR inhibitor blocked E2-
induced cell proliferation. The authors note that ERα has been shown to associate also 
with the p85 domain of PI3K which may also play a role in the translocation of ERα to 
the plasma membrane. Focusing on the results of the current study, Song et al. propose 
the following model: E2-stimulated interaction between ERα and Shc activates Src. 
Src phosphorylates and activates IGF-IR which recruits the Shc. Shc interaction with 
IGF-IR brings the ERα to the plasma membrane and activates the MAPK pathway 
(Song et al., 2004). This model may partly explain the mechanism by which breast 
cancer cells develop resistance to tamoxifen (Fagan and Yee, 2008).  
Fagan and Yee (2008) review recent findings illustrating the interactions 
between ER and IGF-IR signaling. ER can be activated by phosphorylation induced by 
estrogen or other growth factors such as EGF and IGF-I (Kato et al., 1995; Bunone et 
al., 1996; Fagan and Yee, 2008). Activation function domain-1 (AF-1) of the ER is 
regulated by growth factors, while AF-2 is activated by estrogen. IGF-I can induce ER 
activation in two ways: phosphorylation of Ser118 of the AF-1 by MAPK, and 
phosphorylation of Ser167 of AF-1 by Akt (Ignar-Trowbridge et al., 1993; El-Tanani 
and Green, 1997).  
 In both normal and cancerous breast tissue, IGF-I and estrogen both work to 
potentiate one another’s transcriptional activity (Fagan and Yee, 2008). In the absence 
of estrogen, treatment with IGF-I increased transcriptional activity of the ER in MCF-
7L cells (Lee et al., 1997). IGFBP-1 inhibited ER activation by both IGF-I and by 
estrogen (Figueroa et al., 1993a). The implication is that IGF-I is necessary for the ER 
to reach its full activation potential stimulated by estrogen (Fagan and Yee, 2008). 
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 IGF-I can contribute to ER signaling, while estrogen can contribute to IGF-IR 
signaling. Evidence to support this claim includes the following: IGF-I-stimulated 
growth is inhibited by anti-estrogens, and estrogen-stimulated growth is inhibited by 
anti-IGF-I treatments (Wakeling et al., 1989; Freiss et al, 1990). In breast cancer cells 
and/or MCF-7L xenografts, estrogen can increase expression and phosphorylation of 
IGF-IR and IRS-1, increase phosphorylation of MAPK, increase IGF-II expression, 
and decrease expression of IGFBP3 and IGF-IIR (Osborne et al., 1989; Mathieu et al., 
1991; Lee et al., 1994; Huynh et al., 1996; Nickerson et al., 1997; Lee et al., 1999). 
Anti-estrogens increase IGFBP3 expression (Figueroa et al. 1993b; Huynh et al., 
1996), and decrease expression and activation of IGF-IR and IRS-1 (Stewart et al., 
1992; Salerno et al., 1999). Additionally, estrogen and IGF-I have several 
transcriptional targets in common, such as c-myc, c-fos, c-jun, cyclin D1 and p21 
(Dubik and Shiu, 1992; Musgrove and Sutherland, 1994; Morishita et al., 1995).  
 Cascio et al. (2007) investigated the effects of IGF-I and estrogen on 
transcriptional activity of ER. In MCF-7 cells, treatment for 1 or 4 hr with IGF-I alone 
(50 nM) resulted in significantly less nuclear translocation of the Estrogen Receptor 
(ER) than treatment with E2 alone (10 nM) (Cascio et al,. 2007). Combined treatment 
resulted in slightly less nuclear translocation after 1 hr and slightly more after 4 hr 
compared to the E2 alone. Treatment with IGF-I alone stimulated recruitment of p300 
and SRC-1 to the Cyclin D1 AP-1 sequence and expression of Cyclin D1 mRNA 
(expression was highest when treated with IGF-I, compared to E2 or both together). 
IGF-I also stimulated recruitment of ER and co-regulators of ER to the AP-1 site 
(Carm, Mdm2 and E6L). In the face of ER knockdown by RNA interference, IGF-I 
was still able to recruit p300 and SRC-1 and partially express Cyclin D1, but loading 
of ER, E6L, Mdm2, Carm and polII on the AP-1 sequence was reduced. This paper 
provides further evidence of the crosstalk between IGF-I and ER signaling. While 
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IGF-I can stimulate nuclear localization of the ER, it is less efficient than E2. After 1 
and 4 hrs of treatment, IGF-I stimulated transcription of Cyclin D1 mRNA more 
efficiently than E2 or both in combination. IGF-I recruited ER to the AP-1 sequence to 
fully activate transcription of Cyclin D1, although IGF-I alone recruited less ER than 
E2 had recruited. However, even in the absence of the ER, IGF-I was able to stimulate 
some Cyclin D1 transcription (Cascio et al., 2007).  
 B. IGF-I and Breast Cancer. Nutrition, the IGF-I system, and cancer risk are 
all closely intertwined (Houston et al., 2005). Caloric restriction studies in a p53-
deficient mouse bladder cancer model, which reduced cancer incidence, were also 
shown to reduce IGF-I levels (Dunn et al., 1997). Adding IGF-I back to the circulation 
reversed the effect on cancer incidence. Higher levels of GH are associated with 
higher cancer risk (Maison et al., 1998). Circulating levels of IGF-I, controlling for the 
IGFBP3 binding protein, have been shown to correlate more significantly with 
hormone responsive breast cancer than circulating levels of estrogen, controlling for 
SHBG (sex hormone binding globulin) (Holly et al., 1999). In premenopausal women, 
IGF-I/IGFBP3 levels correlate with high mammographic breast density (Byrne et al., 
2000), which in turn is known to correlate with increased breast cancer risk 
(Hankinson et al., 1998). The IGF-IR has been shown to be overexpressed in both 
breast cancer tumors and cell lines (Lann and LeRoith, 2008). 
 Lann and LeRoith (2008) review various in vivo studies that illustrate the 
interdependence among growth hormone (GH), IGF-I, and breast cancer development, 
progression, and aggressiveness. For example, a transgenic mouse that overexpresses a 
form of IGF-I with reduced affinity for IGFBP-3 had higher occurrence of mammary 
intraepithelial neoplasia and tumor development (Hadsell et al., 2000). Another mouse 
model, in which the GHRH (Growth Hormone Releasing Hormone) gene was 
knocked out resulting in circulating levels of GH and IGF-I that were about 10% of 
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normal, had significantly smaller mammary tumors compared to control mice after 
injection of MCF-7 cells into the mammary fat pads (Yang et al., 1996). Spontaneous 
Dwarf Rats, deficient in GH and IGF-I as a result of a gh gene mutation, are immune 
to chemically-induced mammary cancer (Swanson and Unterman, 2002). Replacing 
GH or IGF-I increased the incidence of mammary tumor development in these rats 
(Thordarson et al., 2004). The Liver IGF-I-Deficient (LID) mouse model, which 
reduces circulating endocrine IGF-I to 25% of normal, demonstrates reduced 
mammary cancer incidence (26% of animals) and delayed latency period (74 days) in 
response to DMBA treatment compared to control animals (56% developed tumors, 
latency period of 59.5 days, Wu et al., 2003). 
 C. Phytochemicals and IGF-IR Signaling. Synergistic effects of soy and tea 
phytochemicals were tested in a mouse model in which MCF-7 cells were implanted 
in the mammary fat pads of SCID (severe combined immune deficient) mice with 
estrogen supplementation to support MCF-7 cell growth (Zhou et al., 2004). Dietary 
interventions were initiated 2 weeks prior to implantation and continued throughout 
the experiment (8 weeks post-implantation). Dietary interventions were soy 
phytochemical concentrate (SPC, 51.9% soy isoflavones by weight), genistein-rich 
soy isoflavone mixture (GSI, 100% soy isoflavones by weight), and green tea or black 
tea infusions (1.5%, 1.5g/100 mL water). GSI and SPC reduced tumor size and 
volume in a dose-dependent manner. Green tea (GT) also decreased tumor weight and 
volume, but black tea (BT) or 0.1% SPC did not. Interestingly, a combination of 0.1% 
SPC with either GT or BT reduced tumor weight and volume to a greater extent, 
indicating some synergistic activity. BT treatment reduced ERα expression in the 
MCF-7 cells, as did the 0.1% SPC/GT combination. However, ERα expression was 
unaffected by other individual treatments (SPC, GSI, GT, or 0.1% SPC). At the end of 
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the 8 week experiment, the researchers measured plasma levels of IGF-I. 0.1% SPC, 
BT, and SPC/BT actually increased circulating IGF-I by 11.1, 5.5 and 4.1%, 
respectively. GT treatment decreased IGF-I by 19.0% (p > 0.05), while the SPC/GT 
combination significantly reduced IGF-I even further, by 35.8% (p < 0.05). The 
authors conclude that in this mouse mammary cancer model, phytochemicals from soy 
and green tea work synergistically to inhibit MCF-7 tumor cell growth by down-
regulating ERα expression and reducing circulating levels of IGF-I (Zhou et al., 
2004). 
 Phytochemical soy concentrate (but not treatment with pure genistein) reduced 
lung metastases by 95% in a mouse lung cancer model by reducing circulating IGF-I 
levels and down-regulating NFκB expression (Singh et al., 2006). 
 Phytochemicals have been shown to modulate cell cycle and induce apoptosis 
via IGF-IR-mediated pathways. For example, in the rat prostate cancer cell line 
AT6.3, phytochemicals commonly found in tomato and soy interfered with IGF-IR-
stimulated cell survival (Wang et al., 2003). Genistein, biochanin A, quercetin, 
kaempferol, diadzein and rutin all inhibited IGF-I-stimulated cell proliferation with 
varying potencies. While IGF-I increased the proportion of cells in S-phase, genistein 
and kaempferol caused a G2/M arrest. Quercetin and biochanin A caused a less 
dramatic G2/M arrest. Daidzein and rutin did not appear to affect cell cycle 
distribution. Genistein, biochanin A, quercetin and kaempferol all induced apoptosis in 
IGF-I-treated cells, as was demonstrated by the sub-G0 peak in cell cycle analysis, 
Annexin V staining, DAPI staining, and the TUNEL assay. Compared to IGF-I control 
(50 µg/L), 50 µmol/L quercetin in addition to the IGF-I significantly reduced Akt 
phosphorylation, and insignificantly increased ERK 1/2 phosphorylation. In this study, 
both Akt and ERK 1/2 activation were shown to play a role in proliferation of the 
AT6.3 cell line (Wang et al., 2003). 
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 Doses of 25 through 100 µM quercetin inhibited proliferation of PC-3 cells, an 
androgen-independent prostate carcinoma cell line, after 24, 48 and 72 hours of 
exposure (Vijayababu et al., 2006). After 24 and 48 hours, quercetin increased 
IGFBP3 secretion, and decreased secretion of IGF-I and IGF-II. Quercetin up-
regulated Bax and caspase-3 expression and down-regulated Bcl-2 and Bcl-xL after 24 
hours of treatment. According to sub-G0 fragment analysis, DNA fragmentation assay 
and the TUNEL assay, 50 and 100 µM quercetin induced apoptosis of PC-3 cells. 
 IGF-I can rescue MCF-7 cells from death in the face of protein synthesis 
inhibition (Geier et al., 1995). Treatment of MCF-7 cells with cycloheximide (CHX), 
a protein synthesis inhibitor, caused cell death which began with apoptosis and ended 
with necrosis. In the presence of 30 µg/mL CHX and continued protein synthesis 
inhibition, 10 ng/mL IGF-I rescued the cells. Genistein, a tyrosine kinase inhibitor, 
demonstrated a dose-response (12-96 µg/mL) in blocking the survival effect of IGF-I. 
The authors concluded the IGF-I triggered some survival mechanism that does not rely 
on protein synthesis, but rather through some post-translational modifications such as 
phosphorylation (Geier et al., 1995). 
 Nordihydroguaiaretic acid (NDGA), a phenolic compound found in the 
creosote bush Larrea divaricatta, inhibits activation of the IGF-IR, and subsequent 
phosphorylation of downstream proteins Akt and BAD in MCF-7 cells (Youngren et 
al., 2005). Pretreatment of isolated IGF-IR preparations with NDGA for 20 minutes 
prior to treatment with 10 nM IGF-I reduced tyrosine kinase activity of the IGF-IR in 
a dose-dependent manner (0.3 to 100 µM NDGA). Similarly, pre-treatment of MCF-7 
cells for 1 h with NDGA before addition of 3 nM IGF-I reduced autophosphorylation 
of IGF-IR in a dose-dependent manner (7.5 to 45 µM NDGA). One hour pre-
incubation with varying doses of NDGA (7.5 to 90 µM) prior to 10 minutes treatment 
with 3 nM IGF-I reduced Akt phosphorylation and BAD phosphorylation in a dose-
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dependent manner. After 3 days of incubation, NDGA significantly reduced MCF-7 
cell proliferation in basal medium containing 10% FCS in a dose-dependent manner. 
In medium containing 10 nM IGF-I and no other growth factors, NDGA also reduced 
proliferation in a dose-dependent manner, more potently than FCS-stimulated cells. 
The researchers also tested the effects of NDGA in vivo. MCNueA breast cancer cells 
were injected into female neuTg mice, and were given NDGA either orally or 
intraperitoneally from day 9 after implantation of cells until the end of the experiment 
at day 29. While the NDGA treatment did not alter the cellular expression of the IGF-
IR nor the HER2/neu receptor, treatment reduced autophosphorylation of both 
receptors and reduced tumor growth rate. Interestingly, the results were the same 
whether the NDGA was administered orally or intraperitoneally (Youngren et al., 
2005).     
 When added to IGF-I-treated MCF-7 cells, curcumin reduced cell numbers in a 
time- and dose-dependent manner (24 and 48 h; 10, 20 and 40 µM Curcumin). After 
24 hours in regular medium, curcumin caused a G2/M arrest with a concomitant 
increase in sub-G0 peak and decrease in S phase cells, indicating cell cycle blockage 
followed by apoptosis. Flow cytometry, Annexin V staining, and observation of 
nuclear morphology showed that IGF-I suppressed apoptosis in the MCF-7 cells, 
while the curcumin was able to reverse this protective effect. Curcumin also reduced 
secretion of IGF-I, and increased secretion of IGFBP3. In addition, the curcumin 
reduced IGF-IR tyrosine kinase activity as well as IGF-IR mRNA expression (Xia et 
al., 2007). 
 Kaempferol inhibited proliferation of ER(+) MCF-7 cells (IC50 of 35 µM at 48 
hours) via a down-regulation of ER-α, progesterone receptor, Cyclin D1, and IRS-1, 
and reduced activity of the estrogen-responsive-element-reporter gene. Kaempferol 
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also inhibited proliferation of ER(-) cells but less potently (IC50 of 70 µM at 48 hours) 
(Hung, 2003). 
 MCF-7 cells were treated for 1 to 3 days with doses of lycopene ranging from 
0.75 to 3 µM in medium containing either a standard concentration of FCS (3%), or 
0.5% FCS with 30 nM IGF-I. Both the [3H]thymidine incorporation assay and direct 
cell counting using a Coulter counter showed that lycopene inhibited cell proliferation 
in both types of medium, but inhibited the IGF-I-stimulated cells to a greater extent 
(Karas et al., 2000). The study went on to analyze cell cycle distribution, cell death, 
and IGF-IR signal transduction. Flow cytometric analysis revealed lycopene treatment 
slowed cell cycle progression in IGF-I-stimulated cells. The absence of a sub-G0 peak 
in cell cycle analysis, and the results of the Annexin-V-FITC assay showed cell death 
was not occurring, neither by apoptosis nor by necrosis. Rather, the researchers found 
that the lycopene interfered with IGF-IR signaling by reducing IGF-I-induced IRS-1 
phosphorylation but not IRS-1 protein levels. Additionally, lycopene reduced the 
capacity of AP-1 to bind with its transcriptional regulatory complex. Even though the 
lycopene appeared to up-regulate the AP-1, the binding capacity was in fact blocked. 
Lycopene had no effect on the expression of the IGF-IR, or on its affinity to bind  
IGF-I. Lycopene increased the number of cell surface-associated IGFBPs by about 
60%. However, due to cross-reactivity of antibodies, the group was unable to identify 
which specific IGFBPs had been increased (Karas et al., 2000). The authors note the 
doses of lycopene used are physiologically achievable, as subjects who eat average-to-
high amounts of tomato-based foods had similar plasma concentrations of lycopene 
(<1 µM) (Gerster, 1997). 
 Resveratrol, at doses less than 50 M, was shown to induce S-phase cell cycle 
arrest followed by apoptotic death in MCF-7 cells (Pozo-Guisado et al., 2002). In 
MDA-MB-231 cells, however, doses of up to 200 M resveratrol had no effect on cell 
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cycle and induced non-apoptotic cell death. The same group went on to investigate the 
role of ER in resveratrol’s effects on cell cycle and apoptosis. The ER was found to 
interact with the p85 regulatory subunit of PI3K in vascular endothelial cells 
(Simoncini et al., 2000) and the same was found to be true of MCF-7 cells (Pozo-
Guisado et al., 2004). In the MCF-7 cells, regardless of the presence or absence of 
estradiol, resveratrol increased ER-associated PI3K activity at a low dose (10 M) 
and then proceeded to inhibit the kinase activity in a dose-dependent manner (50 to 
150 M). The resveratrol inhibited the kinase activity by inducing proteasome-
dependent degradation of the ERα, while levels of p85 were unaffected. In addition, 
any ERα present continued to bind with the p85. Therefore, the resveratrol did not 
inhibit binding of these two proteins. In response to resveratrol treatment, Akt 
phosphorylation followed the same biphasic pattern as the PI3K activity: increased at 
10 µM, and significantly decreased in response to 50 and 100 µM resveratrol. Total 
expression of Akt remained unchanged. The researchers measured the effects of 
resveratrol on the phosphorylation status of GSK-3 as well. Again following the same 
pattern, 10 µM resveratrol increased phosphorylation (and thus inactivation) of GSK-3 
about 2-fold, while doses higher than 50 µM decreased phosphorylation to basal 
levels. To test whether resveratrol affected the nuclear transcriptional activities of 
ERα, the researchers measured mRNA levels of two target genes of ERα: Cat-D and 
pS2. Resveratrol treatment down-regulated the transcription of these two target genes 
in a dose-dependent manner. In summary, resveratrol exerted estrogenic functions at 
low concentrations and anti-estrogenic functions at high concentrations in the non-
nuclear compartment, and acted only as an estrogen antagonist against ERαs nuclear 
transcriptional functions (Pozo-Guisado et al., 2004).    
 The same group went on to investigate the apoptotic pathways involved in 
resveratrol-induced apoptosis of MCF-7 cells (Pozo-Guisado et al., 2005). Resveratrol 
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(10-150 µM) down-regulated Bcl-2, which is transcriptionally regulated by NF-κB 
(Yamamoto and Gaynor, 2004). The resveratrol did in fact modify the expression of 
the p65/p50 heterodimer of NF-κB in the same biphasic pattern seen in the previous 
paper: Low doses of resveratrol (10 and 50 µM) increased expression of the 
heterodimer, while higher doses (100 and 150 µM) virtually completely blocked 
expression. The PI3K inhibitor LY294002 interfered with DNA binding of the 
p65/p50 complex in the presence of 50 µM resveratrol, implicating the PI3K pathway 
in resveratrol’s effects on NF-κB and Bcl-2. Resveratrol decreased the amount of p65 
protein in the nucleus of the cells while total expression within the cell remained the 
same. The researchers found the resveratrol increased I-κB expression in the cytosol, 
which binds and sequesters the p65. Furthermore, high doses of resveratrol inhibited 
calpain’s capacity to degrade I-κB. Use of inhibitors showed this function of 
resveratrol was mediated by both PI3K and ERα, and possibly by the ERα-dependent 
PI3K activity described in the previous paper. The apoptosis induced by resveratrol in 
these MCF-7 cells involved neither caspase-3 nor caspase-8. Rather, the decrease in 
Bcl-2 decreased the mitochondrial membrane potential, causing an increase in ROS 
and thus apoptosis ensued. An increase in NO was also observed, which may cause 
apoptosis or necrosis depending on the redox status of the cell. Since both apoptotic 
and necrotic cell death were observed in these experiments, the authors predict the 
levels of ROS and NO may play a role in determining which type of cell death the 
resveratrol causes in the MCF-7 cells. NF-κB is also responsible for the transcriptional 
regulation of MMP-9 (matrix-metalloproteinase-9), which is induced by IGF-I. 100 
µM resveratrol blocked the IGF-I-induced MMP-9 activity, but did not affect MMP-2 
activity (10 ng/mL IGF-I). Similarly, resveratrol blocked IGF-I-induced cell migration 
(10 ng/mL IGF-I; 150 µM resveratrol, 40% inhibition).  
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 Vyas et al. (2005) investigated the effects of resveratrol on regulation of IGF-II 
in MCF-7 cells. Similar to the studies discussed above, a biphasic pattern was 
observed. At a low concentration of resveratrol (10-6 M), IGF-II mRNA and protein 
expression were increased, as were cell numbers according to BrdU incorporation and 
the MTT assay. A higher dose of resveratrol (10-4 M) showed the opposite effects, 
down-regulating IGF-II mRNA and protein, and inhibiting cell proliferation. IGF-I 
expression was detected neither in the controls nor in the resveratrol-treated MCF-7 
cells. Addition of 17β-estradiol (E2) also induced IGF-II protein expression, while 
tamoxifen or high resveratrol did not. Combination treatments of low resveratrol and 
E2, tamoxifen and E2, low resveratrol and tamoxifen, and high resveratrol and E2 
each down-regulated IGF-II expression compared to the induction by low resveratrol 
or that by E2. Resveratrol appeared to exert mitogenic effects at low concentrations 
and anti-mitogenic effects at high concentrations. Also, the low dose of resveratrol 
was mitogenic in the absence of E2 to an extent similar to the E2 alone. However, in 
the presence of the E2, the resveratrol demonstrated anti-mitogenic effects. Addition 
of IGF-II rescued the cells from the anti-proliferative effects of the high dose of 
resveratrol. Also, blocking IGF-IR function with an antibody inhibited the ability of 
the low dose of resveratrol to stimulate cell proliferation. Together these two pieces of 
evidence implicate the IGF-II/IGF-IR pathway in resveratrol’s mechanisms of action. 
In similar experiments using the ER-negative MCF10 cell line, the researchers 
concluded the ability of resveratrol to stimulate proliferation at the low dose is ER-
dependent, while the inhibitory actions at the higher dose are ER-independent (Vyas et 
al., 2005).  
 Later, the same group demonstrated that in ER(+) MCF-7 (but not ER-) cells, 
the low dose of resveratrol (10-6 M) increased mRNA and protein expression of 
cathepsin D, while the high dose (10-4) decreased the expression (Vyas et al., 2006). 
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Cathepsin D is an aspartyl protease responsible for degradation of the extracellular 
matrix as well as IGFBPs, and is regulated by estrogen and IGF-II (Rochefort et al., 
1989; Conover and De Leon, 1994; Claussen et al., 1997; Vyas et al., 2006). The 
authors recall resveratrol’s inability, at both the low and high dose, to increase IGF-II 
in the presence of E2 or tamoxifen from the prior study, thus noting the potential 
significance of resveratrol in treating breast cancers. In other words, in the presence of 
estrogen or tamoxifen, a sufficiently high dose of resveratrol (i.e. 10-4 M) may inhibit 
ER+ breast cancer cell growth via the dual mechanism of blocking expression of the 
mitogen IGF-II and the protease cathepsin D (Vyas et al., 2006). 
 In 1992, quercetin was found to be an inhibitor of PI3K using cell-free 
biochemical extracts. Matter et al. (1992) isolated PI3K from bovine brain tissue and 
measured effects of quercetin and various analogs on kinase activity. Quercetin was 
the most potent of all compounds tested with an IC50 of 1.3 µg/mL (3.8 µM).The 
analog LY805921, which differed from the structure of quercetin only in that it 
contained an OCH3 group rather than an OH at C7, had an IC50 of 1.7 µg/mL. Two 
other analogs with inhibitory activity had IC50s of 6.2 and 8.4. Four analogs with low 
activity had IC50s > 30 µg/mL, and another 4 had no activity at all. After structure-
activity analysis, the authors found that the substituents of C2 and C3 are critical in 
determining a compound’s ability to inhibit the kinase activity of PI3K. On C3, a 
hydroxyl group (OH) was found on compounds with potent inhibitory activity (IC50 < 
10 µg/mL); a charged functional group such as a carboxylate or amine abolished 
inhibitory activity; a bulky substitution increased the IC50; and compounds with an H 
had poorer activity than those with an OH. Where there was an aromatic ring on C2, 
those compounds with no free hydroxyl groups were poorer inhibitors. An interesting 
example was genistein, which has a phenol on C3 and no aromatic ring on C2 but an 
H. Genistein is known as a potent tyrosine kinase inhibitor and protein kinase 
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inhibitor, yet had no significant activity against PI3K (IC50 > 30 µg/mL). The authors 
found quercetin to be a competitive inhibitor of ATP for the ATP binding site on 
PI3K, with a Ki of 0.88 µM. Quercetin did not compete against PI (phosphatidyl 
inositol) (Matter et al., 1992).  
 Agullo et al. (1997) also investigated the structure-activity relationship of 
various flavonoids and their abilities to inhibit PI3K, tyrosine kinase, and protein 
kinase C (PKC). Out of the flavonoids tested, myricetin, luteolin, quercetin and 
apigenin were the most potent inhibitors of PI3K in a cell-free biochemical assay, with 
IC50 values of 1.8, 8, 10 and 12 µM, respectively. The IC50 value for quercetin was 
higher than that determined by Matter et al. (1992), but Agullo et al. attribute this to 
differences in source and purification protocols of the PI3K, and different assay 
conditions. Comparison among the 14 compounds tested revealed the double bond 
between C2 and C3 of the flavonoid ring, lack of substitutions on hydroxyl groups, 
and 3’ and 4’ hydroxyl groups were the most critical for PI3K inhibitory activity. 
Presence or absence of OH on the 5C of the A ring did not affect PI3K inhibitory 
activity. The authors discuss the differences in specificity among the compounds. For 
example, genistein is specific for inhibition of tyrosine kinases but had no activity 
against PI3K, while quercetin has inhibitory activity against serine/threonine and lipid 
kinases as well as against PI3K (Agullo et al., 1997). 
 Three phytochemicals, genistein, resveratrol and quercetin, were shown to 
inhibit proliferation and cause apoptosis in MCF-7 cells by altering PTEN expression 
(Waite et al., 2005). PTEN is a phosphatase that removes the phosphate group from 
the 3 position of the inositol ring of phosphatidylinositol molecules, thus turning off 
the signal that PI3K activates by phosphorylating that 3 position (Waite and Eng, 
2002). Specifically, quercetin in doses of 0.1 to 1000 nM, increased PTEN protein 
(and to a lesser extent mRNA expression), decreased Akt phosphorylation, and 
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increased p27 expression, in keeping with the known lipid phosphatase activity of 
PTEN. The increase in PTEN expression seen in response to the phytochemical 
treatment was not due to changes in PTEN stability (as there were no changes in 
phosphorylation of key residues that determine PTEN stability: Ser380, Thr382 and 
Thr383) or to changes in degradation (as there were no changes in PTEN association 
with ubiquitin conjugating enzymes UbCH7 and Ubc9). Cyclin D1 expression and 
MAPK phosphorylation, which are downstream targets of PTEN’s protein 
phosphatase activity, were unaffected by phytochemical treatment (Waite et al., 2005).   
 Lin et al. (2007) demonstrated that IGF-I and estrogen enhance one another’s 
cell proliferative activity in MCF-7 cells, through a ROS-dependent pathway which 
results in phosphorylation of IRS-1, ERKs and JNKs. After 3 days of incubation, 10 
nM E2 nearly doubled MCF-7 cell proliferation, and 10 ng/mL IGF-I in addition to the 
E2 increased the cell proliferation even further. IGF-I and E2 also individually 
stimulated colony formation in soft agar, but the effect of the two combined was even 
greater. In E2/IGF-I treated cells, IRS-1, ERKs and JNKs were 
activated/phosphorylated, while p38 was not. E2 alone was able to stimulate the 
ERKs, but the IRS-1 and JNKs were only phosphorylated in the presence of IGF-I. 
IGF-I magnified E2’s induction of c-Jun expression. The E2/IGF-I treatment 
stimulated H2O2 production in the MCF-7 cells, while preincubation with the 
antioxidant N-acetyl-L-cysteine (NAC) suppressed E2/IGF-I’s capacity to induce  
IRS-1, ERK and JNK phosphorylation. The aglycones quercetin and baicalein 
inhibited the E2/IGF-I-induced proliferation, while their respective glycosides, 
quercitrin (quercetin-3-O-rhamnoside), rutin (quercetin-3-O-rutinoside), and baicalin 
(baicalein-7-O-glucuronide), did not. The authors attribute this finding to the 
aglycone’s greater antioxidant capacity compared to their respective glycosides 
(Plumb et al., 1999). In addition, 3-OH flavones also inhibited the actions of E2/IGF-I, 
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while a compound in which the OH was replaced with an OCH3 group could not (Lin 
et al., 2007). The hydroxyl groups of the flavonoids confer antioxidant activity (Cao et 
al., 1997; Babu et al., 2003), and the authors previously showed that hydroxylation of 
the C4’ and C6 of the flavonoid confers apoptosis-inducing ability (Ko et al., 2004).   
 
VI. OBJECTIVES  
The objectives of this research were: 1. To develop a more efficient methylene 
blue assay for accurate and versatile cell counting; 2. To elucidate the mechanisms of 
action by which quercetin-3-β-D-glucoside (Q-3-G) potently inhibited IGF-I-induced 
MCF-7 cell proliferation; and 3. To determine the effects of apple phytochemical 
extracts on cell proliferation and apoptosis in a DMBA-induced rat mammary cancer 
model in vivo, and to determine how apple phytochemical extracts affect the 
expression of cell cycle proteins in vivo. 
 
VII. HYPOTHESIS 
 As discussed in this review, cancer risk is highly influenced by diet. Our lab 
focuses on determining the mechanisms of action by which dietary phytochemicals 
prevent or slow the growth of cancer cells in vitro and in vivo. Our hypothesis is apple 
phytochemical extracts have potent anticancer activity for prevention of breast cancer 
in humans and could modulate multiple signaling pathways. We also hypothesized 
that Q-3-G inhibited IGF-I-induced MCF-7 cell proliferation by interfering with IGF-
IR signaling pathways, mainly the components of the PI3K pathway, which converge 
on cell cycle progression and apoptosis suppression. We also hypothesized that 
feeding whole apple extracts to DMBA-treated Sprague-Dawley rats would modulate 
early stages of mammary cancer promotion and progression by affecting proliferation 
and apoptosis in vivo. 
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CHAPTER 2 
 
A MODIFIED METHYLENE BLUE ASSAY FOR ACCURATE CELL COUNTING 
 
ABSTRACT 
Cell counting is a common technique in cellular and molecular biology 
research applications, such as cell culture maintenance, cell plating, cell growth and 
cell doubling time determinations, as well as cell proliferation and cytotoxicity 
measurements. Many commonly employed cell counting methods exhibit limitations 
that influence resulting accuracy or versatility. For example, the trypan blue method 
typically underestimates cell numbers in culture, and the Lowry protein assay can be 
influenced by cell cycle. An urgent need exists for a method of cell counting that is 
both accurate and versatile. This work intended to explore an adaptation of the 
methylene blue assay to overcome the existing limitations of the procedure, enabling 
application to a broader range of cell densities and various cell culture plates. This 
new methylene blue assay was found to be more efficient, accurate and sensitive. A 
linear relationship (r2>0.99) was established between cell number and absorbance at a 
570 nm wavelength when the new methylene blue assay was applied to three cell lines 
(HepG2, Caco-2, and MCF-7) plated in a broad range of cell densities (0.5 × 104 to 2.5 
× 106) in 4 different types of culture plates (6-, 12-, 24-, and 96-well plates). These 
results demonstrated that the linear relationship between methylene blue absorbance 
and cell number can be maintained at high cell densities. Growth curves were 
determined using both the trypan blue and methylene blue methods. At each time 
point in the HepG2 growth curve, the cell count obtained using the trypan blue assay 
was statistically significantly lower than that obtained using the methylene blue assay 
(p<0.05). The same was true for the Caco-2 growth curve at all time points (p0.05) 
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except the 0 hour. The methylene blue method proposed in this paper may serve as a 
direct, automated counting method for cells grown in any type of culture plate. The 
methylene blue assay has clear advantages over traditional methods for several 
applications, including most assays that require an accurate cell count, such as 
bioavailability and cytotoxicity assays, and more basic experiments such as growth 
curve or doubling time determination for a particular cell line or in response to a 
treatment. The methylene blue assay modified here is a powerful tool for any 
application requiring a versatile, efficient, and accurate method of cell counting, 
especially in the research of natural products, bioactive compounds, phytochemicals, 
functional foods and nutraceuticals.  
 
INTRODUCTION 
Cell counting is a necessary technique in cellular and molecular biology 
research, such as cell culture maintenance, cell plating, cell growth and cell doubling 
time determinations, and cell proliferation and cytotoxicity measurements (Sun and 
Liu, 2006; Wolfe and Liu, 2007; Yoon and Liu, 2007). Accurate cell counts are 
essential in both quantitative and qualitative experiments and interpretation of results 
depends on accurate initial and final cell counts. Consistent cell counting throughout 
an experiment minimizes variation. 
  Currently, the most commonly used method of direct cell counting is trypan 
blue staining followed by microscopic quantification using a hemacytometer. This 
technique involves trypsinizing adherent cells, removing cells from culture, 
centrifugation and re-suspension, staining with trypan blue, and cell counting. Some 
cells may not survive the trypsinization step due to degradation of chromatin by 
trypsin. The loss of any number of cells is a source of underestimated cell numbers, 
making a satisfactory cell count difficult to attain.  The reliability of the trypan blue 
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method depends on a uniform, single cell suspension free of clumps, which would 
certainly interfere with the accuracy of the counting calculations. Cell counting on a 
hemacytometer can be very subjective, with results varying from one researcher to the 
next. There is an urgent need for an objective cell-counting method that will produce 
accurate and consistent cell numbers. An assay which measures cells directly on the 
plate in which they were grown and treated would eliminate these shortcomings. 
 An alternative method that is more objective than the trypan blue cell counting 
method is the Lowry Protein assay (Lowry et al., 1951). In this assay, protein content 
indirectly measures cell numbers. Such a method relies on the generalization that cell 
number and cellular protein are directly proportional. Generally speaking, the more 
cells present, the more protein will be detected. However, total protein content in a cell 
fluctuates over time. For example, cell cycle proteins are synthesized and degraded 
regularly as the cell progresses through the cell cycle (Evans et al., 1983; Glotzer et 
al., 1991; King et al., 1996). External conditions can also influence production of 
proteins in a cell. Protein production decreases dramatically while serum-starved cells 
revert to G0 (Liu et al., 1994; Shirane et al., 1999; Liu et al., 2004; Sun and Liu, 
2006). Therefore, the same number of cells can produce varying levels of protein 
depending on the distribution of cell numbers in each stage of the cell cycle. In 
addition, the protein of collagen-treated plates can interfere with protein-detection 
assays. In such situations protein content in cell culture cannot be directly correlated to 
cell numbers.  
 Lagneau, et al. (1977) introduced an alternative method, the methylene blue 
assay, to measure cytotoxicity. The study measured the cytotoxicity of BCG-treated 
rat macrophages on intestinal cancer cells in vitro. The cells to be measured were 
stained with methylene blue. The stain was eluted from the cells and measured 
spectrophotometrically, yielding a quantitative measure of cytotoxicity.  
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 Finlay et al. (1984) introduced a modified methylene blue staining technique 
for measuring cytotoxicity of growth inhibiting drugs on adherent cell lines using a 
spectrophotometric micro-plate reader. Two human colon adenocarcinoma cell lines, 
HCT-8 and HT-29, were plated at a density of 1  103 cells/well in 96-well plates. 
Two days later, cells were treated with varying concentrations of the growth inhibiting 
drugs doxorubicin, amsacrine derivatives, and nitracrine. After four days the cells 
were stained with methylene blue (5 g/L of 50% (v/v) ethanol:water, 0.1 mL/well) for 
30 minutes, rinsed, and solubilized overnight with 1% Sarkosyl in PBS. Absorbances 
were read on an ELISA microplate reader at a wavelength of 620 nm. The absorbance 
reading is a reflection of the number of surviving cells, which remain attached to the 
plate as cells killed due to the cytotoxicity will detach from the plate. Finlay et al. 
(1984) reported that absorbance correlates with cell numbers and that this methylene 
blue assay is more efficient than the time-consuming processes of trypan blue 
counting or preparing samples for an electronic particle counter. The authors note that 
while some drugs may cause an increase in average cell size as cells accumulate in G2 
phase, this increase does not cause a significant difference in results between the 
methylene blue assay and direct cell counting.  Applications of this technique include 
cytotoxicity assays for various chemicals on adherent cell lines, as well as interactions 
between these cytotoxic agents and other compounds such as hormones, nutrients, and 
DNA repair inhibitors (Finlay et al., 1984). While Finlay et al. demonstrated the 
correlation between methylene blue absorbance and cell number only for cell numbers 
suited for 96-well plates (1 × 103 cells/well), the use of 96-well plates and small cell 
numbers make this assay well-suited for preliminary cytotoxicity screenings. 
Oliver et al. (1989) reported a modification of Lagneau’s original methylene 
blue assay to be used with microwell plates. Cells plated in 96-well plates were first 
fixed with 10% formol saline for 30 minutes. After 30 minutes of staining with 1% 
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(w/v) methylene blue in 0.01 M borate buffer (pH 8.5), wells were rinsed in 0.01 M 
borate buffer and eluted with 1:1 (v/v) ethanol and 0.1 M HCl. Absorbances were read 
at 650 nm on an automated microplate photometer. Oliver et al. found that 
absorbances correlated with cell numbers in the three cell lines assayed (Rat-1, fetal 
rat lung fibroblast; IMR90, human fetal lung; and HFL, human fetal lung fibroblast). 
The authors used this methylene blue assay to observe the influence of growth factors 
on cell proliferation (e.g. PDGF, platelet-derived growth factor), and proposed to use 
the assay for observing in vitro effects of cell growth stimulators or inhibitors. The 
adaptation of a methylene blue assay for use with an automated plate reader has 
contributed a great deal of ease and efficiency to current cytotoxicity and cell 
proliferation assays. The principle drawback, however, is that the assay is limited to 
cell densities ranging from 2 × 103 to 4 × 104 cells per well, depending on the cell line 
(Oliver et al., 1989).  
The proposed cell counting methods discussed above each exhibit limitations 
that influence resulting accuracy or versatility. The trypan blue method underestimates 
cell numbers in culture, the Lowry protein assay can be influenced by cell cycle, and 
current automated methylene blue assays are limited to cultures in 96-well plates. An 
urgent need exists for an accurate and versatile method of cell counting. Our objective 
is to explore an adaptation of the methylene blue assay to overcome the existing 
limitations of the procedure and to enable application to a broader range of cell 
densities and larger cell culture plates. Currently there is no report of such an assay 
that can be applied to 6-, 12-, or 24-well cell culture plates. The methylene blue 
method proposed in this paper may serve as a direct, automated counting method for 
cells grown in any type of culture plate.  
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MATERIALS AND METHODS 
Chemicals.  Methylene blue was purchased from BioQuest (Bedford, MA), 
glutaraldehyde from Sigma Chemical Co. (St. Louis, MO), ethanol from Mallinckrodt 
(Phillipsburg, NJ), and acetic acid from Fisher Scientific (Pittsburgh, PA). Williams’ 
Medium E (WME), Dulbeccos Modified Eagle Medium (DMEM), α-Minimal 
Essential Medium, fetal bovine serum (FBS), Hank’s Balanced Salt Solution (HBSS) 
and Dulbecco’s Phosphate Buffered Saline were purchased from Gibco Life 
Technologies (Grand Island, NY). 
 Cell lines.  The HepG2 human liver cancer cells, Caco-2 human colon cancer 
cells, and MCF-7 human breast cancer cells were obtained from the American Type 
Culture Collection (ATCC, Rockville, MD).  
 Cell Culture.  All cell culture media contained 5% FBS, 10 mM Hepes, 50 
units/mL penicillin, 50 μg/mL streptomycin, and 100 μg/mL gentamicin. HepG2 cells 
were maintained in WME containing an additional 5 μg/mL insulin, 2 μg/mL 
glucagon and 0.05 μg/mL hydrocortisone. Caco-2 cells were maintained in DMEM, 
and MCF-7 cells were grown in α-MEM containing 10% FBS. Cells were maintained 
at 37°C, in a 5% CO2 atmosphere, and passaged before reaching confluence (Liu and 
Sun, 2003).  
Color Formation Stability. HepG2 cells were plated in 12-well plates at a 
density of  7.5 × 105 cells per well. After 4 hours of incubation at 37°C in 5% CO2, the 
media was aspirated and each well was gently rinsed with PBS. Cells were stained and 
fixed by adding 300 μL methylene blue solution (HBSS + 1.25% glutaraldehyde + 
0.6% methylene blue) to each well. After 1 hour of incubation at 37°C in 5% CO2, 
wells were rinsed with distilled water. Plates were drained and briefly air-dried before 
addition of 600 μL elution solution (50% ethanol + 49% PBS + 1% acetic acid) to 
each well for 15 minutes at room temperature. After elution was complete, solutions 
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from each well were transferred to individual microcentrifuge tubes and centrifuged 
for 3 minutes at 12,000 g. The solutions were then transferred in duplicate to a 96-well 
plate (200 μL/well) and read on an ELISA plate reader (Dynex Technologies, 
Chantilly, VA) at a wavelength of 570 nm. Samples were read at 0, 6, 12 and 20 
minutes after centrifugation in order to determine the stability of color formation. 
Methylene Blue (MB) Staining. HepG2 cells were plated in 12-well plates at 
a density of 7.5 x 105 cells per well, three wells per treatment. Cells were fixed and 
stained with methylene blue for durations of 0, 5, 15, 30, 45 and 60 minutes at a 
constant volume of 300 μL/well. After staining and rinsing, each sample was placed at 
4°C until all subsequent samples were collected. Before adding the elution solution, all 
samples were rinsed once more, drained and air-dried, in order to minimize moisture 
variation among the fixed samples. To each well 600 μL of elution solution were 
added, and plates were placed on a shaker at room temperature for 60 minutes. Elution 
solutions were then centrifuged in microcentrifuge tubes for 3 minutes at 12,000 g, 
and transferred in duplicate to a 96-well plate, 200 μL/well. The 96-well plate was 
read on the plate reader at a wavelength of 570 nm.  
 Elution Kinetics.  HepG2 cells were plated in a 12-well plate, at 7.5×105 cells 
in 0.75 mL media per well. Cells were left for 3 hours to attach, then stained and fixed 
with methylene blue for 60 minutes (300 μL/well), rinsed 6 times with distilled water, 
and eluted with 600 μL/well of elution solution for varying durations (0, 5, 15, 30, 45 
and 60 minutes). As the elution solutions were collected from the samples at each time 
point, the solutions were placed in microcentrifuge tubes. After the final sample was 
collected, all samples were micro-centrifuged at 12,000 g for 3 minutes. Samples were 
then transferred to a 96-well plate, 200 μL/well, and 2 wells/sample. The plate was 
read on the plate reader at a wavelength of 570 nm. 
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 Modified Methylene Blue Assay for Cell Counting.  Based on the previously 
described experiments, we have designed a modified methylene blue assay for a broad 
range of cell counting. This method can be directly applied to adherent cells growing 
in any type of culture plate. The modified protocol was as follows: Growth media was 
removed and each well rinsed with PBS. The appropriate volume of methylene blue 
solution (HBSS + 1.25% glutaraldehyde + 0.6% methylene blue) was added to each 
well of the culture plate, according to Table 2.1. After incubation at 37°C for 60 
minutes, the methylene blue solution was removed from the wells, then plates were 
rinsed by gentle submersion in distilled water 6 times. The excess water was allowed 
to drain and the plate was briefly air-dried. The appropriate volume of elution solution 
(50% ethanol + 49% PBS + 1% acetic acid) was added to each well (Table 2.1). After 
15 minutes on a plate rotator at room temperature, the elution solutions were 
centrifuged at 12,000g for 3 minutes. The solutions were transferred to a 96-well plate: 
2 wells per sample, 200 μL into each well. Plates were read using a micro-plate reader 
at 570 nm wavelength. A standard curve was established by plating a range of cell 
densities of particular cell line in the desired culture plate. The equation of the line 
was used to convert absorbance of each sample to cell number.  
 
Table 2.1. Recommended cell numbers and reagent volumes per well for 
methylene blue assay. 
 
Cell Culture Plate 
Cell Number 
Plated Methylene Blue Elution Solution 
  (μL) (μL) 
96-well 0.5 to 5×105 50 100 
24-well 0.5 to 3×105 200 400 
12-well 1 to 10×105 300 600 
 6-well 0.65 to 2.5×106 1000 1000 
 
 Broad Range Standard Curves. Three cell lines, Caco-2, HepG2 and MCF-7, 
were used to demonstrate the application of this modified assay to broad ranges of cell 
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densities (5×103 to 2.5×106) in various cell culture plates (6-, 12-, 24- and 96-well 
plates). In each of the four types of cell culture plates, the three cells lines were plated 
at various densities within the ranges described in Table 2.1. Cells were plated, 
allowed to attach (4 hours for HepG2; 6 hours for Caco-2 and MCF-7), then analyzed 
by the MB assay. Sample solutions were read spectrophotometrically on a plate reader 
at a wavelength of 570 nm. The absorbance of each well was plotted versus initial cell 
density, demonstrating the linear relationship between absorbance at 570 nm and cell 
number. In the 6-well plates, the absorbance of these samples was out of range of the 
plate reader. In these cases, each sample was diluted by an addition of 100 μL of fresh 
elution solution to 100 μL sample solution in each well of the 96-well plate. The 
absorbance of each sample was then corrected for this 1:1 dilution.  
 Trypan Blue (TB) Cell Counting. In order to evaluate the accuracy of trypan 
blue counting, actual counts were plotted versus the predicted cell number. A set of 
Caco-2 cells identical to that of the broad range standard curve described above was 
plated. The cells were left to attach for 6 h (same duration as for methylene blue 
assay), harvested by trypsinization, and 50 μL of cell solution were mixed with 450 μL 
of 0.4% trypan blue solution prepared in 0.85% saline. The cells in 10 μL of this 
suspension were directly counted on a hemacytometer. The average cell count of 4 
fields represents the number of cells per mL of cell solution, and was used to 
determine the total number of cells from each well.  
 Comparison of Cell Growth Curves Determined by Methylene Blue and 
Trypan Blue Counting. On the first day of this 5-day experiment, a standard curve of 
absorbance versus cell number was established. Briefly, Caco-2 (or HepG2) cells were 
plated at densities within the ranges found in Table 2.1. These cell densities were 
plotted against the corresponding absorbance results of the methylene blue assay. The 
equation of the line of the standard curve was then used to convert absorbance of 
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samples to cell number. Cells for the growth curve were plated at a fixed density of 
7.5×105 per well in 12-well plates. Every 24 hours for 5 days, 3 wells were subjected 
to the methylene blue assay, and absorbance was converted to cell number using the 
equation of the line of the standard curve (r2=0.9918). An additional 3 wells were 
counted using trypan blue counting. Cell counts determined by conversion of 
absorbance to cell number via the equation of the line of the standard curve were 
compared to cell counts determined by direct trypan blue counting.      
 Applications in Phytochemical Research:  Antiproliferative Activity. We 
used this modified methylene blue assay to test the anti-proliferative activity of whole 
apple extract. Our lab has previously described the method of extracting soluble free 
phenolics from whole foods (Eberhardt et al., 2000; Dewanto et al., 2002) and has 
used the MTT assay to demonstrate anti-proliferative activity of various fruit and 
vegetable extracts (Chu et al., 2002; Sun et al., 2002; Sun and Liu, 2006). Standard 
Curve. A standard curve of MCF-7 cells was plated under cell culture and media 
conditions as described earlier. Cells were plated in a 96-well plate at densities (in 
triplicate wells) ranging from 0 to 8 × 104 cells per well. Cells were incubated at 37°C 
for 6 hours, at which point the cells were counted by the modified methylene blue 
method. Apple Extract: Anti-Proliferation Dose Response. MCF-7 cells were plated 
under the same conditions, at a cell density of 2.5 × 104 cells per well. Six hours after 
plating, cells were treated with varying doses of apple extract in α-MEM with 10% 
FBS. This medium alone with no apple extract served as the control, since no 
extraction solvent remained in the apple extract. Forty-eight hours after treatment, the 
medium of the experimental cells was replaced with fresh medium containing the 
appropriate dose of apple extract. Cells were stained and assayed by the methylene 
blue method 72 hours after the initial treatment. 
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Statistics. Statistical analysis was done using Minitab Release 12 software 
(Minitab Inc., State College, PA). Values were compared using a paired-t test, with a 
significance level of p < 0.05. 
 
RESULTS 
Optimization of Method.  Color Formation Stability. Variation between 
absorbance readings at 0, 6, 12 and 20 minutes was virtually eliminated (data not 
shown) when the elution solution centrifugation step was added. Absorbance remains 
stable for at least a 30-minute period. 
Methylene Blue Staining Kinetics. The methylene blue stain was introduced to 
the cells and immediately removed for the 0 minute staining data point. The 
absorbance value of the methylene blue eluted from these 0 minute cells was 0.315, or 
19.3% of that measured at 60 minutes staining duration (absorbance of 1.628) (Figure 
2.1). After 5 minutes staining duration the absorbance reached 49.6% that of the 60 
minute time point. The measured absorbance had reached 62.8% by 15 minutes and 
85.4 % by 30 minutes. This curve began to plateau after 45 minutes as staining began 
to reach saturation (97.1%), indicating that 60 minutes was indeed the optimal staining 
duration.  
 Elution Kinetics. Absorbance readings were taken after various durations of 
elution of the methylene blue solution from the cells. After 0 minutes of elution, 
(removing the elution solution immediately after placing it in the well) the mean 
absorbance was 0.677. Elution durations of 5, 15, 30, 45 and 60 minutes yielded 
relatively constant absorbance readings ranging between 2.181 and 2.325 (Figure 2.2). 
From these results, it was determined that 15 minutes was a sufficient elution duration. 
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Figure 2.1.  Methylene Blue Staining Kinetics. The duration of methylene blue 
staining was varied from 0 to 60 minutes. Variation over time among readings of the 
same samples was minimized by centrifugation of samples prior to reading. The curve 
began to plateau after 45 minutes, indicating the point at which staining began to reach 
saturation (mean  SD, n = 3). 
 
Broad Range Standard Curves. Cells were plated in 6-well plates (Figure 
2.3a) at densities between 0.75 and 2.5 × 106 cells per well. The methylene blue 
absorbance of all three cell lines increased linearly with cell numbers producing r2 
values of 0.9978 for HepG2, 0.9922 for Caco-2, and 0.9894 for MCF-7. Cell plated in 
12-well plates (Figure 2.3b), in densities ranging from 1 to 10 × 105 per well, 
demonstrated the same linear correlation between absorbance and cell number as 
exhibited in 6-well plates. The standard curves in these 12-well plates yielded r2 
values of 0.9986, 0.9918, and 0.9987 for HepG2, Caco-2, and MCF-7 cells, 
respectively. Cell densities in 24-well plates (Figure 2.3c) ranged from 0.5 to 3 × 105 
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cells per well and produced standard curves with r2 values of 0.9874, 0.9858, and 
0.9999 for HepG2, Caco-2, and MCF-7 cells, respectively. The 96-well plates (Figure 
2.3d) contained cells in densities between 0.5 and 5 × 104 per well and produced 
standard curves with the r2 values of 0.9938, 0.9914, 0.9940 for HepG2, Caco-2, and 
MCF-7 cells, respectively. The HepG2 cells had the highest methylene blue 
absorbance followed by MCF-7 cells, with Caco-2 cells having the lowest, in all cases 
except the 6-well plates, where the MCF-7 cells had the highest followed by HepG2 
cells.  
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Figure 2.2. Methylene Blue Elution Kinetics. HepG2 cells were fixed and stained 
according to the modified methylene blue assay. Elution times were varied from 0 to 
60 minutes (mean  SD, n = 3). 
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Figure 2.3.  Relationship of cell number to relative absorbance in three cell lines 
(HepG2, Caco-2, and MCF-7) and four different culture plates: 6-well (a), 12-well (b), 
24-well (c) and 96-well (d) (mean  SD, n = 3).   
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Figure 2.3 (Continued) 
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Figure 2.4. Number of Caco-2 cells determined by the trypan blue cell counting 
assay (TB assay) compared to the number of cells initially plated. (a) 6-well 
culture plate. (b) 12-well plate. (c) 24-well plate. An asterisk (*) indicates a 
statistically significant difference (p<0.05) between trypan blue counting results (mean 
+/- SD, n=3) and the corresponding initial plating number. 
 
Trypan Blue Cell Counting. The trypan blue (TB) counts for 6-well plates 
underestimated numbers by 7 to 32%, presumably because the number of cells lost 
from a larger well represents a smaller percentage (Figure 2.4a). In the 6-well plates, 
only the 2 highest cell densities (2×106 and 2.5×106) had TB counts that were 
statistically significantly lower than the initial plating density (p<0.05). The TB counts 
consistently underestimated the initial plating density by between 50 and 75% for 12-  
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and 24-well plates (Figure 2.4b and 2.4c). Trypan blue counts were statistically 
significantly lower than initial plating density (p<0.05) for all cell densities in both the 
24-well and 12-well plates. The cell numbers for 96-well plates were below the lower 
range for TB counting, illustrating one case where the MB assay may be more 
sensitive. 
Comparison of Cell Growth Curves Determined by Methylene Blue and 
Trypan Blue Counting.  A Caco-2 standard curve (not shown) was established over a 
range of 1 × 105 to 10 × 105 cells/well in a 12-well plate. New cells were then plated in 
12-well plates at an initial density of 0.75×105 cells/well. The two growth curves are 
compared in Figure 2.5a. The trypan blue method resulted in significantly lower  
Caco-2 cell counts at every time point except the 0 hour (p<0.05). Beginning at 24 
hours, the difference between the two counting methods began to increase over time. 
At 24, 48, 72, and 96 hours, the TB cell count was 21.5, 21.2, 31.7, and 31.2% lower 
than that of the methylene blue method, respectively.  
 HepG2 cells were plated identically to that of the Caco-2 cells. The linear 
HepG2 standard curve used to convert absorbance to cell number produced an r2 of 
0.9925. The growth curve in Figure 2.5b is a comparison of cell counts obtained using 
the methylene blue assay with those obtained using the trypan blue assay. At each time 
point in the HepG2 growth curve, the cell count obtained using the trypan blue assay 
was statistically significantly lower than that obtained using the methylene blue  assay 
(p<0.05). The initial trypan blue count at 0 hours was 51.1% lower than the methylene 
blue count. At 24, 48, 72 and 96 hours, the trypan blue cell count was 26.4, 33.1, 48.9, 
and 40.2% lower, respectively, than that obtained using the methylene blue method.  
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Figure 2.5. Comparison of cell growth curves determined by the trypan blue 
assay (TB) and the modified methylene blue assay (MB) in both human Caco-2 
colon cancer cells (a) and HepG2 liver cancer cells (b) in vitro. An asterisk (*) 
indicates a trypan blue cell count is statistically significantly different (p<0.05) from 
the corresponding methylene blue count for that time point (mean +/- SD, n=3). 
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Applications in Phytochemical Research:  Antiproliferative Activity. 
Standard Curve. Plotting the cell culture standard curve using the methylene blue 
assay shows absorbance at 570 nm is proportional to cell number plated with an r2 of 
0.9949 (Figure 2.6a). This indicates that the absorbance measured by the methylene 
blue assay directly reflects cell number. The equation of this line can then be used to 
calculate cell numbers of experimental cells from the methylene blue absorbance. For 
example, 9 wells of cells plated at 2.5 × 104 cells per well were assayed by methylene 
blue 6 hours after plating. Using the standard curve to calculate cell number based on 
absorbance generated a mean cell number of 2.504 × 104 per well.   
 Apple Extract: Anti-Proliferation Dose Response. An application of the 
methylene blue direct cell counting assay is illustrated in Figure 2.6. Cell number of 
each treated group can be accurately calculated through the standard curve (Figure 
2.6a) using absorbance. From Figure 2.6b one can see MCF-7 cell proliferation was 
significantly inhibited at 25 mg/mL (6.1 × 104) as compared to control (7.6× 104, 
p<0.05). At a dose of 40 mg apple extract per mL, cell number was 3.5 × 104, (p < 
0.01). Alternatively, cell proliferation data can be presented as percent of control as 
illustrated in Figure 2.6c. This eliminates the need for the standard curve while 
producing the same results. Compared to control, treatment with apple extract 
significantly inhibits cell proliferation at doses of 25 mg/mL (81% of control, p < 
0.05) to 40 mg/mL (48.6% of control, p < 0.01). Similar results are obtained whether 
the data is presented as cell number or percent of control, suggesting this methylene 
blue assay can be used either way.  
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Figure 2.6. Applications in phytochemical research: Antiproliferative activity. (a) 
Cell Number Standard Curve. MCF-7 cells were plated at varying densities, allowed 
to attach for 6 hours, then stained with methylene blue. The equation of the line (y = 
0.0947x + 0.0407, r2 = 0.09949) was used to convert the absorbance at 570 nm of 
experimental cells to cell number. (b) Results Presented as Cell Number. MCF-7 cells 
were plated in a 96-well plate at a density of 2.5 × 104 cells per well, allowed to attach 
for 6 hours, then treated with varying doses of apple extract for 72 hours. Absorbance 
was determined by the modified methylene blue assay, then converted to cell number 
using the standard curve equation of the line (a). Apple extract significantly reduced 
cell number in a dose-dependent manner between 25 and 40 mg/mL (*: p < 0.05; #: p 
< 0.01). (c) Results Presented as Percent of Control. Absorbance data from (b) was 
presented as a percent of the control, rather than converting to cell number. In this 
way, it is also clear that apple extract significantly reduced cell number in a dose-
dependent manner between 25 and 40 mg/mL (*: p < 0.05; #: p < 0.01). 
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DISCUSSION 
Various trials were carried out in order to optimize the methylene blue assay 
for accuracy, efficiency and convenience. Previously, absorbance readings of the 
elution solution would vary over time and eventually stabilize after about 20 minutes, 
indicating possible interference by suspended particles or proteins in the elution 
solution. An extra step of centrifuging the samples after elution virtually eliminated 
variation among the same readings over time.  
 The methylene blue staining kinetics curve (Figure 2.1) began to plateau after 
45 minutes, indicating staining began to reach saturation around that point. The mean 
absorbance of samples appeared relatively constant between 5 and 60 minutes elution 
time (Figure 2.2). It is possible, then, that a shortened elution time, i.e. 15 or 30 
minutes, would be no less effective than the 60 minutes prescribed by the current 
protocol. Our results demonstrated one hour was the optimal duration for methylene 
blue staining, while the elution step can be reduced to 15 minutes. Even with the 
added step of centrifugation, this modified assay is more time-efficient than the 
original procedure. The modified methylene blue assay is a quick and accurate cell 
counting method, especially useful when multiple samples must be counted 
simultaneously.  
A linear relationship can be established between cell number and absorbance 
with an r2 > 0.99 (Figure 2.3). This new methylene blue assay was applied to three cell 
lines (HepG2, Caco-2, and MCF-7) plated in a broad range of cell densities (5 × 104 to 
2.5 × 106) in 4 different types of culture plates (Table 2.1). These results demonstrated 
that the linear relationship between methylene blue absorbance and cell number can be 
maintained at high cell densities. The significance of the modifications discussed in 
this paper is that an automated methylene blue assay can now be applied directly to 
cells grown and treated in any size culture plate.  
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 Applications of this method include most assays which require an accurate cell 
count, such as bioavailability and cytotoxicity assays, and more basic experiments 
such as growth curve or doubling time determination for a particular cell line or in 
response to a treatment (Liu et al., 2004; He and Liu, 2007; Yoon and Liu, 2007). One 
limitation of the method is that the cells stained with methylene blue are necessarily 
destroyed. The applications of the method, then, are limited to those in which 
determining a cell count is the end-point. Otherwise, an identical set of cells must be 
plated in parallel for the experiment.  
 The methylene blue assay has the advantage over the Lowry protein assay of 
being independent of the varying protein content of cells. Therefore, it is especially 
useful in situations where protein content cannot be used to reflect cell number, for 
example, experiments which run through the duration of the cell cycle (e.g. growth 
curves). Additionally, the method may be useful where conditions or treatments that 
may variably inhibit protein synthesis such as reverting cells to G0 (Sun and Liu, 
2006). In these cases, protein content may vary and would not reflect the actual 
number of cells in the culture. Under certain conditions, then, it may not be possible to 
correlate protein content with cell number, especially across treatments which may 
affect protein levels. Other limitations of the protein assay include lack of 
differentiation between viable and dead cells, and interference of the protein on 
collagen-treated plates. The methylene blue assay offers the advantage of fixing and 
staining the cells in the very wells in which they were grown and treated. In the TB 
assay, cells are destroyed by trypsinization and lost by transfer steps, a distinct 
limitation that the methylene blue assay overcomes. 
 The MTT assay (Liu and Sun, 2003) and a subsequent variation, the MTS 
assay (Mossmann, 1983; Liu et al., 2002), are two common cytotoxicity assays, both 
of which are based on the assumption that enzyme activity is indicative of cell 
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number. Enzyme levels in cells, however, fluctuate over time or under different 
conditions. For instance, mitochondrial dehydrogenase activity, measured by the MTT 
assay, is cell-type specific (Laville et al., 2004).  
 The DNA thymidine assay can be used to convert the measure of thymidine 
incorporated by the cells into a cell number. The process of thymidine uptake, 
however, occurs only during DNA synthesis, the S phase of the cell cycle. This assay, 
therefore, is more suited to measuring DNA synthesis than actual cell numbers. 
Another limitation of this assay is the use of the radioactive isotope 3H. For reasons 
such as occupational exposure and waste disposal, a non-radioactive alternative would 
certainly be desirable (Yang et al., 1996; Laville et al., 2004).  
 A more recent method which claims to have several advantages over DNA 3H 
thymidine uptake or the MTS assay is an acid phosphatase assay, in which cytosolic 
acid phosphatase activity is used as a measure of cell proliferation (Laville et al., 
2004). One limitation noted by the authors is the variability of cytosolic acid 
phosphatase expression between cell types, and across conditions which may influence 
expression. An assay that directly reflects cell number (such as the MB assay), rather 
than possible biological indicators of cell number, would have a clear advantage. This 
methylene blue assay will be very useful for standardizing any biological marker by 
cell number. 
 Methylene blue becomes very useful in cases where it is difficult or impossible 
to obtain a cell count by traditional methods. In particular, cell numbers in a 96-well 
plate are so low that it is difficult or even impossible to trypsinize and harvest the cells 
for trypan blue counting or protein extraction. Methylene blue eliminates the need for 
removing the cells from the wells, and has been shown to provide an accurate cell 
count where trypan blue counting, for example, is unsatisfactory (Figures 2.3 and 2.4).    
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The cell proliferation assay illustrated in Figure 2.6 is an example of a useful 
food chemistry application of this method. The standard curve r2 of 0.9949 
demonstrates that absorbance is directly proportional to cell number. The data in 
Figure 2.6a and b clearly show that apple extract inhibited proliferation of MCF-7 
cells after 72 hours of treatment by showing the change in actual cell numbers. This 
cell based assay has many useful applications in phytochemical research, and can be 
used to test the effects of a variety of whole food extracts or phytochemicals on any 
cell line.  
 The modifications made to current methylene blue assays are simple yet 
valuable. We have demonstrated that methylene blue standard curves of optical 
density versus cell number produce r2 values >0.99 (Figure 2.3). Such standard curves 
can be used to convert methylene blue absorbance of samples in any culture plate to an 
accurate cell number. Compared to traditional trypan blue cell counting on a 
hemacytometer, the results from the methylene blue assay are more accurate and more 
reliable (Figure 2.4). The methylene blue assay has clear advantages over traditional 
methods for several applications, including cell counting (eg. growth curves, Figure 
2.5) and cytotoxicity assays. This method of direct cell counting is reliable and 
inexpensive, enabling its wide use in the research areas of natural products, bioactive 
compounds, phytochemicals, functional foods and nutraceuticals. The methylene blue 
assay modified here is a powerful tool for any application requiring a versatile, 
efficient, and accurate method of cell counting.  
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CHAPTER 3 
 
QUERCETIN-3-β-D-GLUCOSIDE INHIBITS IGF-I-MEDIATED MCF-7 CELL 
SURVIVAL BY BLOCKING CELL CYCLE PROGRESSION AND INDUCING 
APOPTOSIS VIA DOWN-REGULATION OF AKT ACTIVATION 
 
ABSTRACT 
 In the United States, breast cancer is the most frequently occurring cancer 
among women, accounting for an estimated 26% of new diagnoses in 2008, and is the 
second-leading cause of cancer deaths among women, accounting for 15% of cancer 
deaths estimated in 2008. An estimated 30% of cancer risk may be attributed to diet. 
Epidemiological evidence supports the association between fruit and vegetable 
consumption and reduced risk of developing cancer. In particular, apple consumption 
has been correlated with reduced breast cancer risk as well as more favorable 
prognostic factors. Our lab has previously shown that whole apple extracts inhibited 
human breast cancer cell proliferation in vitro and mammary cancer in vivo. IGF-I 
Receptor signaling may be as critical as Estrogen Receptor signaling in breast cancer. 
The objective of this study was to determine whether whole apple extracts and purified 
phytochemicals from apples interfered with IGF-I-mediated signal transduction 
pathways in MCF-7 human breast cancer cells. Quercetin-3-β-D-Glucoside (Q-3-G) 
proved to be surprisingly effective, inhibiting IGF-I-induced MCF-7 cell proliferation 
more potently than FBS-stimulated proliferation, as well as more potently than 
quercetin inhibited cell growth. Q-3-G blocked cell cycle progression and induced 
apoptosis by interfering with the PI3K pathway; namely, down-regulation of Akt 
phosphorylation and Cyclin D1 expression. The results of this study help to explain 
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the mechanisms by which apple consumption may reduce breast cancer risk. 
Additionally, such studies of purified compounds contribute to the understanding of 
cancer cell behavior and may inform future endeavors in chemotherapeutic drug 
design. 
 
INTRODUCTION 
  In the United States, breast cancer is the most frequently occurring cancer 
among women, accounting for an estimated 26% of new diagnoses in 2008, and is the 
second-leading cause of cancer deaths among women, accounting for 15% of cancer 
deaths estimated in 2008 (estimates exclude basal and squamous cell skin cancers and 
in situ carcinoma except bladder) (American Cancer Society, 2008). The American 
Cancer Society predicts ~185,000 new cases and more than 40,000 deaths due to 
breast cancer in 2008. While advances in treatment are being made, cancer is still 
considered a preventable disease. Therefore, research in the area of breast cancer 
prevention is necessary and valuable.  
An estimated 30% of cancer risk may be attributed to diet (Willett, 1995; Peto, 
2001). Epidemiology studies have consistently demonstrated the correlation between 
diets high in fruits, vegetables, and whole grains, and reduced risk of developing 
cancer (Block et al., 1992). Apples, in particular, have been associated with decreased 
breast cancer risk. A multi-center case-control study in Italy found that, controlling for 
total fruit consumption, patients who consumed > one apple per day had an odds ratio 
of breast cancer incidence of 0.82 compared to those who ate fewer than one apple per 
day (Gallus et al., 2005). Our lab has shown that apples fed to Sprague-Dawley rats in 
doses equivalent to human consumption of 1, 3 or 6 apples per day significantly 
reduced tumor incidence, size and burden and delayed onset of DMBA-induced 
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mammary tumors in a dose-dependent manner (Liu et al., 2005). Our lab has also 
shown that whole apple extracts inhibit MCF-7 cell cancer growth in vitro (Yoon and 
Liu, 2007; Sun and Liu, 2008; Felice et al., 2009). 
 IGF-I (Insulin-like Growth Factor-I) is a hormone which acts as a mediator 
between growth hormone (GH) and growth during fetal and early childhood 
development (Holly et al., 1999). IGF-I also has the potential to support neoplastic 
growth. Circulating levels of IGF-I, controlling for the IGFBP3 binding protein, have 
been shown to correlate more significantly with hormone responsive breast cancer 
than circulating levels of estrogen, controlling for SHBG (sex hormone binding 
globulin) (Holly et al., 1999).  In premenopausal women, IGF-I/IGFBP3 levels 
correlate with high mammographic breast density (Byrne et al., 2000), which in turn is 
known to correlate with increased breast cancer risk (Hankinson et al., 1998). While 
targeting the ER in estrogen-responsive breast cancers has been largely successful, 
targeting the IGF-I Receptor (IGF-IR) offers as much if not more potential to prevent 
and treat breast cancer.   
The IGF-IR signals through two major pathways: the PI3K/Akt pathway, and 
the Mek/Erk MAPK pathway (Werner and LeRoith, 2000). In MCF-7 cells, the     
IGF-IR exerts its mitogenic effects through the PI3K/Akt pathway (Dufourny et al., 
1997), which was the focus of this study. Binding of IGF-I to the IGF-IR stimulates 
autophosphorylation of the receptor which then phosphorylates Insulin Receptor 
Substrate-1 (IRS-1; Izumi et al., 1987; Shemer et al., 1987). Phosphorylation of IRS-1 
creates a docking site suitable for Src-homology-domain-containing signaling proteins 
such as the p85 subunit of PI3K. Through phosphorylation of precursor molecules in 
the lipid membrane, PI3K is responsible for the generation of phosphatidylinositol-3, 
4, 5-triphosphate (PIP3), which recruits other molecules such as PDK-1 and Akt. 
PDK-1 is then able to phosphorylate and activate Akt, which is responsible for 
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activating a myriad of downstream signaling pathways (Lawlor and Alessi, 2001; 
Cantley, 2002). As a result of IGF-IR signaling, Akt drives cell cycle progression by 
promoting transcription of Cyclin D1 as well as preventing Cyclin D1 degradation by 
inhibiting GSK-3 (Lawlor and Alessi, 2001). Akt suppresses apoptosis by 
phosphorylating and thus inhibiting the pro-apoptotic mitochondrial protein Bad 
(Downward, 1999), and phosphorylating and inactivating Caspase-9 (Cardone et al., 
1998).  
The objective of this study was to determine the effects of two phytochemicals 
found in apples, quercetin and quercetin-3-β-D-glucoside (Q-3-G), on IGF-I-
stimulated MCF-7 cell growth in vitro. We found that Q-3-G very potently and 
specifically inhibited MCF-7-cell growth by altering cell cycle distribution and 
inducing mass apoptosis via down-regulation of Akt phosphorylation. 
  
MATERIALS AND METHODS  
Reagents. α-Minimal Essential Medium (α-MEM), phenol-red free α-MEM, 
fetal bovine serum (FBS), Hank’s Balanced Salt Solution (HBSS) and Dulbecco’s 
Phosphate Buffered Saline (PBS) were purchased from Gibco Life Technologies 
(Grand Island, NY). Methylene blue was purchased from BioQuest (Bedford, MA), 
ethanol from Mallinckrodt (Phillipsburg, NJ), and acetic acid from Fisher Scientific 
(Pittsburgh, PA). Quercetin, quercetin-3-β-D-glucoside (Q-3-G), glutaraldehyde, 
transferrin, bovine serum albumin (BSA), propidium iodide (PI), Triton X-100, 
acridine orange (AO) and ethidium bromide (EB) were purchased from Sigma-Aldrich 
(St. Louis, MO). Recombinant human IGF-I was purchased from R&D Systems 
(Minneapolis, MN).     
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Antibodies. The primary antibodies (anti-IGF-I-Receptor β, anti-Phospho-
IGF-I-Receptor β [Tyr1135/1136], anti-Akt, anti-Phospho-Akt [Ser473], anti-Cyclin D1, 
anti-CDK-4, anti-PCNA, anti-Bcl-2, anti-p27, anti-Caspase-9 and anti-PARP) and the 
secondary antibodies (anti-Mouse IgG, anti-Rabbit IgG, and anti-Biotin) were 
purchased from Cell Signaling Technology (Danvers, MA). Anti-β-actin and anti-p21 
were purchased from Sigma (St. Louis, MO). 
 Cell Culture. MCF-7 cells were obtained from the American Type Culture 
Collection (ATCC, Rockville, MD). For culture maintenance and experiments 
requiring FBS, α-MEM containing 10 mM Hepes, 50 units/mL penicillin, 50 μg/mL 
streptomycin, 100 μg/mL gentamicin, and 10% FBS was used (referred to as FBS). 
Cells were kept in a humidified incubator at 37°C with 5% CO2 and were passaged 
every 5 days (Liu and Sun, 2003). For starvation purposes and for all experiments 
using IGF-I, phenol-red free, serum-free α-MEM, containing 0.2 mg/mL bovine serum 
albumin (BSA), 10 µg/mL transferrin, 10 mM Hepes, 50 units/mL penicillin, 50 
μg/mL streptomycin, and 100 μg/mL gentamicin, was used (referred to as Serum Free 
Medium, or SFM) (Dufourny et al., 1997).   
 Apple Extraction. Whole apple extracts were prepared using the method 
previously described by our laboratory (Sun et al., 2002). Briefly, whole apples of the 
Red Delicious variety were cleaned, dried, and cored. Apples were homogenized in 
ice-cold 80% acetone for 5 minutes in a chilled Waring blender followed by 3 minutes 
in a Polytron homogenizer. After vacuum filtration through a no. 2 Whatman filter 
paper on a Buchner funnel, the filtrate was evaporated at 45°C to reduce the volume 
by at least 90%. Filtrate was brought up to volume with dH2O and stored at -40°C 
until use.  
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 Cytotoxicity. MCF-7 cells were plated at a density of 4x104 cells per well and 
incubated to attach to the plates. Cells were then serum-starved for 12 hours and 
treated for 24 hours with varying doses of phytochemicals (quercetin or Q-3-G) in 
either α-MEM with 10% FBS or in serum-free and phenol red-free α-MEM with 100 
ng/mL IGF-I. All Q-3-G treatments contained 1% methanol (MeOH), while all 
quercetin treatments contained 0.5% dimethyl sulfoxide (DMSO). Cell numbers were 
determined by the methylene blue assay as described previously (Felice et al., 2009). 
Briefly, medium was gently removed from the cells and each well was rinsed once 
with 100 µL PBS, and 50 µL methylene blue staining solution (HBSS + 1.25% 
glutaraldehyde + 0.6% methylene blue) were added to each well. The plates were 
returned to the 37°C incubator for 1 hour. After removal of the methylene blue, the 
plates were carefully rinsed 3 times in dH2O. 100 µL of elution solution (50% ethanol 
+ 49% PBS + 1% acetic acid) were added to each well and incubated for 15 minutes at 
room temperature with gentle agitation. Absorbance was read on an automated plate 
reader (Dynex Technologies, Chantilly, VA) at a wavelength of 570 nm. Doses which 
contained > 90% cell viability compared to the respective control (FBS or IGF-I plus 
solvent) were considered non-cytotoxic. Values are presented as percent of control, 
mean ± S.D., at least in triplicates.  
Cell proliferation. To determine effects on cell proliferation, MCF-7 cells 
were plated in 96-well plates at a density of 2.5 × 104 cells per well, incubated for 24 
hours, serum-starved for 12 hours, and treated for 72 hours. Medium containing the 
appropriate treatments was refreshed after the first 48 hours of treatment. Cells were 
treated with various combinations of FBS or IGF-I with whole apple extracts 
(contained no solvent), 2-α-hydroxy-ursolic acid (0.1% DMSO), Q-3-G (1% MeOH) 
or quercetin (0.5% DMSO), in doses shown in Figures 3.1 and 3.2. Cell numbers were 
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determined using the methylene blue assay described above, and are presented as 
percent of the control, mean ± S.D., at least in triplicates. 
 Cellular Antioxidant Activity (CAA) Assay. The CAA Assay, developed in 
our lab (Wolfe and Liu, 2007), measures antioxidant activity of pure phytochemicals 
in a cell culture model. Briefly, cells are treated with a combination of the 
phytochemical being tested and dichlorofluorescin diacetate (DCFH-DA), the 
substrate. Once inside the cell, the non-polar DCFH-DA is deacetylated to the more 
polar dichlorofluoroscin (DCFH). Peroxyl radicals generated from 2,2’-azobis(2-
amidinopropane) dihydrochloride (ABAP) lead to the oxidation of DCFH to form a 
polar fluorescent compound, dichlorofluorescein (DCF). The effects of 
phytochemicals that quench the peroxyl radicals and prevent the oxidation of the 
DCFH to DCF are measured as a decreased fluorescence. MCF-7 cells were plated in 
96-well plates and incubated for 24 hours. After medium was removed, cells were 
washed with PBS and treated in triplicate wells for 1 h with α-MEM containing 25 µM 
DCFH-DA in addition to varying doses of either quercetin or Q-3-G. 600 µM ABAP 
in HBSS was added to each well, and plates were read on a Fluoroskan Ascent FL 
plate-reader (ThermoLabsystems, Franklin, MA) at 5 minute increments for a duration 
of 1 hour (emission at 538 nm and excitation at 485 nm). Results were quantified as 
described previously (Wolfe and Liu, 2007; Wolfe et al., 2008) and are presented as 
an EC50 for cellular antioxidant activity. 
 Flow Cytometry. The flow cytometry analysis was conducted using the 
method described previously (Sun and Liu, 2008).  Briefly, MCF-7 cells were plated 
in 6-well plates at a density of 5 × 105 cells per well and incubated for 12 hours, after 
which the cells were serum-starved in SFM for 12 hours. Cells were treated in SFM 
containing 100 ng/mL IGF-I, 0.15% MeOH, and varying doses of Q-3-G as shown in 
124 
 
Figure 3.3. Samples were harvested at 24 and 48 hours, stained in a detergent 
hypotonic propidium iodide solution (0.1% sodium citrate, 0.05 mg/mL propidium 
iodide, 0.1% v:v Triton-X 100), and stored on ice in the dark at 4°C (Yen et al., 1998; 
Sun and Liu, 2008). Samples were filtered through a 40 micron nylon mesh and run on 
a BD Biosciences LSRII flow cytometer (San Jose, CA), with collection of the PI 
emission in a 576/26 band pass filter. Cell cycle and sub-G0 data were analyzed with 
BD FACSDiva software (Sun and Liu, 2008). Results are presented as percent of 
events in the parent population, where the parent population for the cell cycle analysis 
was the total number of singlet intact nuclei in the sample and the parent population 
for the sub-G0 peak analysis was the total number of singlet events in the sample; 
mean ± S.D, n = 3 except in the 24 hour SFM control where n = 2. 
 Western blotting. The Western blotting protocol was described previously 
(Liu et al., 1997)  Briefly, MCF-7 cells were plated in 6-well plates at a density of 5 × 
105 cells per well, incubated for 24 hours, serum-starved for 12 hours, and treated with 
SFM, IGF-I, or IGF-I with Q-3-G for the times indicated in the figure legends. All 
treatments and controls contained 0.2% MeOH. Cells were harvested by scraping in 
ice-cold PBS, centrifuged, and re-suspended in RIPA lysis buffer (containing 50 mM 
Tris, pH 7.4; 1% Igepal; 150 mM sodium chloride; 1mM EDTA) with protease 
inhibitors (1 µg/mL aprotinin; 1 µg/mL leupeptin; 1 µg/mL pepstatin; 1 mM 
phenylmethylsulfonyl fluoride [PMSF]; 1 mM sodium orthovanadate; 1 mM sodium 
fluoride). Total protein concentration was determined using Sigma Total Protein Kit 
(Sigma-Aldrich) and a Dynex Microplate Reader (Dynex Technologies, Chantilly, 
VA). Samples were boiled with Laemmli 2× sample buffer for 5 minutes, separated on 
12% SDS-polyacrylamide gels and transferred to Immobilon-p membranes (Milipore, 
Billerica, MA) as described previously (Liu et al., 1997). Membranes were blotted 
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with the appropriate primary antibody (anti-phospho-IGF-I Receptor, anti-Akt, anti-
phosho-Akt, anti-Cyclin D1, anti-CDK-4, anti-PCNA, anti-PARP, anti-Caspase-9, or 
anti-p21) followed by incubation with the appropriate secondary antibody (anti-mouse 
or anti-rabbit IgG HRP-conjugate). The LumiGLO chemiluminescent reagent and 
hydrogen peroxide reagent (Cell Signaling Technology, Danvers, MA) were applied 
before exposing membranes to Kodak Biomax MR Film (Kodak, Rochester, NY) film. 
The phospho-IGF-IR membranes were stripped of the antibodies (30 minutes on 
shaker at 50°C in stripping buffer containing 0.76% Tris base, 2% sodium dodecyl 
sulfate [SDS] and 0.7% β-mercaptoethanol, pH 6.8) and re-probed for total IGF-IR 
expression. The Cyclin D1 membranes were stripped and re-probed for Bcl-2 
expression. The p21 membranes were stripped and re-probed for p27 expression. 
Protein expression was determined by calculating the optical density of the bands 
using Labworks software (UVP Laboratories, Upland, CA) and expression was 
presented as percent of IGF-I control, mean ± S.D, n = 3 except for Akt and p-Akt 
where  n = 6.  
 Acridine Orange/Ethidium Bromide (AO/EB) Staining. The AO/EB 
staining of cells was measured using a modified method (Cotter and Martin, 1996). 
MCF-7 cells were serum-starved for 12 hours and treated with 100 ng/mL IGF-I and 
varying doses of Q-3-G for 24 hours. All treatments and controls contained 0.2% 
MeOH. To harvest the cells, culture medium was first removed and saved. Cells were 
removed by trypsinization and were recombined with the medium from the well. 
Samples were then centrifuged and cells were re-suspended in a solution of 100 
µg/mL acridine orange and 100 µg/mL ethidium bromide in 0.9% saline for 2 minutes. 
Sample tubes were protected from light, kept on ice, and coded to ensure blinded 
counting. After 2 minutes, 10 µL of sample were placed on a slide for counting under 
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fluorescence microscopy using a 488 nm illumination/520 nm emission filter. Cells 
were scored for apoptosis as follows. Live non-apoptotic cells were green, with green 
nuclei and a normal distribution of chromatin. Early apoptotic cells had condensed 
chromatin in the form of a crescent shape or as bright beads. The bright nucleus may 
be green or yellow. Late apoptotic cells had bright orange nucleus, condensed orange 
chromatin, and reduced cell size. Necrotic cells had orange nuclei with a normal 
distribution of chromatin, and dead cells were a uniform dark, flat red (Cotter and 
Martin, 1996; Renvoize et al., 1998; Ribble et al., 2005). Cells were scored and 
reported as number of cells in each category per 200 cells counted. Results presented 
are the average of 3 experiments, mean ± S.D.    
 Statistics. Statistical analysis was conducted using Minitab Release 15 
statistical software (Minitab Inc., State College, PA). For cell proliferation data, values 
were compared to the control using the student’s t-test. For cell cycle analysis, a chi-
square test was used to determine whether differences existed, followed by an 
ANOVA/Fisher’s LSD for pair-wise comparisons. Western blots and AO/EB staining 
were also analyzed using ANOVA/Fisher’s LSD. Statistical significance was set at P 
< 0.05 for all analyses. 
 
RESULTS 
Effects of whole apple extracts and pure phytochemicals on IGF-I-induced 
MCF-7 cell proliferation. Whole apple extracts inhibited both FBS- and IGF-I-
stimulated cell proliferation in a dose-dependent manner (Figure 3.1a). However, the 
apple extracts were more potent on the IGF-I-treated cells at all doses except for the 
highest dose of 40 mg/mL, where the proliferation of both the FBS- and IGF-I-
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stimulated cells was inhibited by ~50%. Non-cytotoxic doses of 20, 30 and 40 mg/mL 
whole apple extract reduced FBS-stimulated growth to 85.0 ± 4.5, 68.1 ± 5.1, and 51.2 
± 2.9 % of the FBS control, respectively, while the same doses reduced IGF-I-
stimulated growth to 61.7 ± 5.0, 49.4 ± 2.5, and 53.3 ± 3.9 % of the IGF-I control.     
2-α-hydroxy-Ursolic Acid (OHUA) inhibited both FBS- and IGF-I-stimulated MCF-7 
cell proliferation to a similar extent, indicating the same mechanism of action in both 
systems (Figure 3.1b). Doses of 14, 16, 18 and 20 µM OHUA reduced FBS-induced 
MCF-7 cell proliferation to 79.3 ± 3.4, 64.3 ± 6.2, 40.6 ± 1.5 and 32.4 ± 1.7% of the 
FBS control, respectively. Doses of 12.5, 15, 17.5 and 20 µM OHUA reduced IGF-I-
induced MCF-7 cell proliferation to 88.1 ± 2.7, 76.3 ± 1.6, 62.8 ± 3.3 and                
49.1 ± 5.3 % of the IGF-I control, respectively. Quercetin-3-β-D-glucoside (Q-3-G) 
inhibited IGF-I-stimulated cells much more dramatically than FBS-stimulated cells 
(Figure 3.1c). In FBS-stimulated cells, Q-3-G only significantly inhibited proliferation 
at doses of 18 and 20 µM, reducing proliferation to 81.7 ± 3.4 and 73.3 ± 5.8 % of the 
FBS control, respectively. However, Q-3-G significantly inhibited IGF-I-induced 
proliferation at doses as low as 6 µM (47.9 ± 2.9 % of IGF-I control). 8 µM Q-3-G 
reduced proliferation to 37.0 ± 6.5 % of IGF-I control, and 10 µM to 25.5 ± 1.4%. 
Reduced proliferation began to plateau between 12 and 20 µM at around 20% of the 
IGF-I control. All doses used were non-cytotoxic. 
IGF-I induced MCF-7 cell proliferation. IGF-I stimulated MCF-7 cell 
proliferation in a time- and dose-dependent manner (Figure 3.3a and b). After 72 hours 
treatment, α-MEM containing 10% FBS increased cell proliferation to 229.0 ± 22.4% 
of the cell number at hour zero. 10 ng/mL IGF-I induced cell proliferation to nearly 
the same extent as the FBS, increasing cell proliferation to 195.3 ± 21.2% of the cell 
number at hour zero. The SFM control cell numbers slowly decreased over time to 
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84.0 ± 3.4% of the zero hour cell numbers. Since 100 ng/mL IGF-I stimulated cell 
proliferation to nearly the same extent as 10% FBS, this dose was used throughout the 
remaining experiments.  
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Figure 3.1. Effects of whole apple extracts and pure phytochemicals on MCF-7 
cell proliferation induced by FBS or by IGF-I. MCF-7 cells were serum-starved for 
12 hours, then treated for 72 hours with varying doses of whole apple extracts or pure 
phytochemical, in α-MEM with 10% FBS or in serum-free α-MEM with 10 ng/mL 
IGF-I. Cell proliferation was measured using the methylene blue assay. (a) Whole 
apple extracts. Apple extracts inhibited both FBS- and IGF-I-stimulated cell 
proliferation in a dose-dependent manner. However, the apple was more potent against 
the IGF-I-treated cells. (b) 2-α-hydroxy-Ursolic Acid (OHUA). OHUA inhibited both 
FBS- and IGF-I-stimulated MCF-7 cell proliferation to a similar extent, indicating the 
same mechanism of action in both systems. (c) Quercetin-3-β-D-glucoside (Q-3-G). 
Q-3-G inhibited IGF-I-stimulated cells much more dramatically than FBS-stimulated 
cells, indicating a mechanism of action involving the IGF-I receptor signaling 
pathways. (Results are presented as percent of respective controls: mean ± SD; n = 3; 
*P < 0.05.) 
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Figure 3.2. Cytotoxicity of Quercetin and Q-3-G. MCF-7 cells were serum-starved 
for 12 hours and incubated for 24 hours with varying doses of the specified 
phytochemical in α-MEM containing 10% FBS or 100 ng/mL IGF-I. The methylene 
blue assay was applied, and viable, attached cells remaining in the wells are presented 
as percent of the corresponding control. Doses which contained cells in numbers         
> 90% of the control were considered non-cytotoxic (indicated by red line). (a) In both 
FBS- and IGF-I-treated cells, quercetin was determined to be non-cytotoxic in doses  
< 20 µM. (b) Quercetin-3-β-D-glucoside (Q-3-G) was determined to be non-cytotoxic 
in doses up to and including 100 µM in both FBS- and IGF-I-treated cells. (Results are 
presented as percent of respective controls: mean ± SD; n = 3.)  
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Figure 3.3. Cell Proliferation. MCF-7 cells were serum-starved for 12 hours, then 
treated with various combinations of IGF-I, FBS, quercetin and Q-3-G. Cell numbers 
were determined by the methylene blue assay. (a) MCF-7 cells were treated for 24, 48 
and 72 hours with α-MEM containing either 10% FBS, 100 ng/mL IGF-I, or serum-
free α-MEM (SFM). After 72 hours, 100 ng/mL IGF-I stimulated MCF-7 cell growth 
to nearly the same extent as did 10% FBS. (b) After 72 hours, IGF-I stimulated   
MCF-7 cell growth in a dose-dependent manner. (c) MCF-7 cells were treated for 72 
hours with varying doses of quercetin in α-MEM containing either 10% FBS or 100 
ng/mL IGF-I. Quercetin inhibited IGF-I-mediated cell proliferation to a greater extent 
than FBS-mediated proliferation. (d) After 72 hours, Q-3-G inhibited IGF-I-stimulated 
cell proliferation much more dramatically than FBS-stimulated proliferation, and also 
much more potently than did quercetin. 
Effects of Quercetin and Q-3-G on FBS- and IGF-I-stimulated MCF-7 cell 
proliferation. Non-cytotoxic doses of quercetin (up to 20 µmol/L, Figure 3.2a) 
inhibited IGF-I-stimulated cell proliferation more potently than FBS-stimulated 
growth (Figure 3.3c). Quercetin (20 µmol/L) significantly reduced FBS-stimulated 
cell proliferation to 64.1 ± 9.6% of the FBS control, and significantly reduced IGF-I-
stimulated cell proliferation to 43.1 ± 2.6% of IGF-I control. Q-3-G inhibited IGF-I-
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stimulated MCF-7 cell proliferation much more potently than FBS-stimulated 
proliferation (Figure 3.3d).  Non-cytotoxic doses of Q-3-G (Figure 3.2b) reduced FBS-
stimulated cell proliferation to 58.3 ± 4.7% of FBS control at 20 µmol/L and plateaued 
at ~30% of control at 30 µmol/L (30.4 ± 1.3% at 30 µmol/L and 29.6 ± 2.2% at 40 
µmol/L). Q-3-G reduced IGF-I-stimulated proliferation to 84.6 ± 9.5% of the IGF-I 
control at only 3 µmol/L, 23.8 ± 1.4% at 5 µmol/L, 24.8 ± 2.9% at 10 µmol/L, and 
plateaued at ~20% beginning at 15 µmol/L (18.1 ± 1.0%) through 40 µmol/L        
(21.6 ± 1.5%); (P < 0.05, n = 3). 
Q-3-G has weaker cellular antioxidant activity than Quercetin. MCF-7 
cells were treated with either quercetin (0, 2, 4, 6, 8, 10 or 12 µM) or Q-3-G (0, 25, 50, 
75, 100, 125, or 150 µM) and their cellular antioxidant activities were measured using 
the CAA assay (Table 3.1 and Figure 3.4). The EC50 for quercetin was determined to 
be 6.28 ± 0.25 µM (Figure 3.4a), while the EC50 for Q-3-G was 106.63 ±13.26 µM 
(Figure 3.4b). 
Table 3.1. Anti-Proliferative and Anti-Oxidant Activities of Quercetin and Q-3-G 
in MCF-7 Cells. Anti-proliferative Activity. As seen in Figure 3.1 (c,d), Q-3-G 
inhibited proliferation of IGF-I-stimulated MCF-7 cells much more dramatically than 
FBS-stimulated cells. Q-3-G was also much more potent than quercetin was against 
both IGF-I- and FBS-stimulated cells. Cellular Antioxidant Activity (CAA) Assay. 
MCF-7 cells were treated with phytochemical and the substrate DCFH-DA, followed 
by the oxidant ABAP. Oxidation of the substrate by ABAP-generated peroxyl radicals 
was measured by a fluorescence plate reader.  Quercetin exhibited potent cellular 
antioxidant activity with an EC50 of 6.28 µM. Quercetin-3-Glucoside had weak 
cellular antioxidant activity, with an EC50 of 106.63 µM. The doses of Q-3-G used in 
all other experiments in this study (up to 20 µM) have virtually no antioxidant 
capacity in MCF-7 cells as determined by the CAA assay.  
EC50 (µM) Anti-Proliferative Activity Anti-Oxidant Activity 
 FBS IGF-I CAA Assay 
Quercetin 29.4 17.3 6.3 
Q-3-G 24.4 3.6 106.6 
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Q-3-G blocked IGF-I-mediated cell cycle progression. After 24 hours treatment, 
90.1 ± 0.6% of the cells of SFM control samples were in G0/G1 phase of the cell cycle 
(Figure 3.5a). Stimulation with 100 ng/mL IGF-I for 24 hours reduced this to 78.2 ± 
0.2%. Addition of the Q-3-G concomitantly with the IGF-I increased the percentage of 
G0/G1 cells, in a dose-dependent manner, to a level comparable to that of SFM (87.2 
± 0.8% at 15 µmol/L Q-3-G.) A similar pattern was observed with the S-phase cells in 
the population (Figure 3.5b). 5.3 ± 0.7% of the cells of SFM control were in S phase 
after 24 hours. Stimulation of IGF-I increased this to 12.4 ± 0.5%. Addition of the    
Q-3-G then reduced the number of S phase cells to 6.0 ± 0.2% at 15 µmol/L, similar to 
the SFM control. Again, the same trend was observed in the G2/M phase cells (Figure 
3.5c). 3.4 ± 0.1% of the cells of SFM control samples were in G2/M phase. This 
increased to 8.2 ± 0.7% upon IGF-I stimulation, and decreased to 5.3 ± 0.4% upon 
addition of 15 µmol/L Q-3-G. Similar patterns occurred after 48 hours of treatment. 
91.0 ± 0.8% of the cells of SFM control were in G0/G1 phase, 82.0 ± 1.8% of the  
IGF-I-treated cells were G0/G1, and in samples treated with 15 µM Q-3-G in addition 
to the 100 ng/mL IGF-I, 88.5 ± 0.2% of the population was in G0/G1 phase (Figure 
3.5d). 2.9 ± 0.3% of the SFM control cells were in S phase, 9.0 ± 0.9% of the IGF-I-
stimulated cells were in S phase, and cells treated with IGF-I and 5, 10 and 15 µM    
Q-3-G had 4.4 ± 0.2, 4.4 ± 0.6 and 4.2 ± 0.2% of their populations in S phase, 
respectively (Figure 3.5e). Similarly, after 48 hours, 4.8 ± 0.7% of the population were 
G2/M phase cells, which increased to 7.8 ± 0.8% after IGF-I stimulation and 
decreased to 4.4 ± 0.8 and 4.2 ± 0.1% after treatment with 10 and 15 µM Q-3-G, 
respectively (Figure 3.5f).  
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Figure 3.4. Cellular Antioxidant Activity (CAA) Assay. MCF-7 cells were treated 
with phytochemical and the substrate DCFH-DA, followed by the oxidant ABAP. 
Oxidation of the substrate by ABAP-generated peroxyl radicals was measured by a 
fluorescence plate reader. Quercetin exhibited potent cellular antioxidant activity with 
an EC50 of 6.28 µM (a). Quercetin-3-Glucoside had weak cellular antioxidant activity, 
with an EC50 of 106.63 µM (b). The doses of Q-3-G used in all other experiments in 
this study (up to 20 µM) have virtually no antioxidant capacity in MCF-7 cells as 
determined by the CAA assay. 
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Q-3-G affected the expression and activation of key cell signaling proteins.  
Effects on IGF-I Receptor expression and activation. After 12 hours treatment, 
IGF-IR expression under SFM treatment was 67.6 ± 9.9% of the IGF-I control. 
Treatment with Q-3-G in doses of 5, 10, 15 and 20 µmol/L increased IGF-IR 
expression to 132.2 ± 19.1, 127.6 ± 19.8, 130.1 ± 15.6, and 119.2 ± 22.1% of the   
IGF-I control, respectively (Figure 3.6a). The effect of Q-3-G on IGF-IR 
phosphorylation followed nearly the same trend as that seen in receptor expression 
(Figure 3.6b), except for the complete absence of IGF-IR phosphorylation in the SFM 
control, as expected. (IGF-IR phosphorylation, after treatment with 5, 10, 15 and 20 
µM Q-3-G in addition to the 100 ng/mL IGF-I, increased to 133.0 ± 14.2, 123.6 ± 5.8, 
121.3 ± 9.9 and 115.5 ± 20.8% of the IGF-I control.) A similar pattern was seen after 
24 hours of treatment. IGF-IR expression in the SFM control was 78.0 ± 11.7% of the 
IGF-I control, and treatment with 5, 10, 15 and 20 µM Q-3-G increased expression to 
118.0 ± 11.8, 124.7 ± 4.2, 120.9 ± 5.7, 101.9 ± 12.4% of the IGF-I control, 
respectively (Figure 3.6c). The IGF-IR phosphorylation followed the same pattern: no 
phosphorylation in the SFM control, and the 4 doses of Q-3-G increased 
phosphorylation to 122.1 ± 4.4, 121.6 ± 3.6, 128.9 ± 17.7, and 108.0 ± 26.8% of the 
IGF-I control (Figure 3.6c). Therefore, any effects seen on the IGF-IR by Q-3-G 
appeared to be due to changes in receptor expression rather than phosphorylation.  
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Figure 3.5. Effect of Q-3-G on cell cycle distribution of IGF-I-stimulated MCF-7 
cells. MCF-7 cells were serum-starved for 12 hours, then treated for 24 or 48 hours 
with varying doses of Q-3-G in SFM containing 100 ng/mL IGF-I. Cells were then 
lysed and stained in a hypotonic propidium iodide staining solution. Nuclei 
suspensions were passed through a flow cytometer, and cell cycle distribution of the 
samples was recorded. G0/G1 phase cells. After 24 hours of treatment (a), 90.1% of 
the SFM control parent population (parent population being the singlet nuclei 
measured in the sample) was in G0/G1 phase of the cell cycle. Stimulation with the 
IGF-I reduced this to 78.2%. Addition of the Q-3-G along with the IGF-I increased the 
percentage of G0/G1 cells, in a dose-dependent manner, to a level comparable to that 
of SFM (>87% at doses of 3 through 15 µM). Similar results were seen after 48 hours 
of treatment (d). S phase cells. After 24 hours of treatment (b), 5.3% of the parent 
population of the SFM control cells were in S phase. Stimulation of IGF-I increased 
this to 12.4%. Addition of the Q-3-G then reduced the number of S phase cells to 
levels similar to the SFM control (5.2% at 10 µM; 6.0% at 15 µM). After 48 hours (e), 
2.9% of the SFM control cells were in S phase, 9.0% of the IGF-I-stimulated cells 
were in S phase, and cells treated with IGF-I and 5, 10 and 15 µM Q-3-G had 4.4, 4.4 
and 4.2% of their populations in S phase, respectively. G2/M phase cells. Again, the 
same trend was observed in the G2/M phase cells. After 24 hours (c), 3.4% of the 
SFM control samples were in G2/M phase. This increased to 8.2% upon IGF-I 
stimulation, and decreased to 5% upon addition of Q-3-G (5.0% at 10 µM and 5.3% at 
15 µM). Similarly, after 48 hours (f), 4.8% of the population were G2/M phase cells, 
which increased to 7.8% after IGF-I stimulation and decreased to 4.4 and 4.2% after 
treatment with 10 and 15 µM Q-3-G, respectively. (Bars with no letters in common are 
statistically significantly different, P < 0.05.) 
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Figure 3.6. Effects of Q-3-G on IGF-I Receptor expression and phosphorylation. 
MCF-7 cells were plated at a density of 5×105 cells per well, allowed to attach for 24 
hours, and serum-starved for 12 hours. Cells were treated with Q-3-G and IGF-I 
simultaneously for 12 or 24 hours. After 12 hours, treatment with Q-3-G appeared to 
increase IGF-IR expression compared to the IGF-I control (a). The effect of Q-3-G on 
IGF-IR phosphorylation (b) followed the same trend as that in (a). After 24 hours 
treatment, Q-3-G in doses of 5 and 10 µM appeared to increase IGF-IR expression 
compared to the IGF-I control, while expression decreased with 15 and 20 µM Q-3-G 
back to a level similar to that of the IGF-I control (c). The effect of Q-3-G on IGF-IR 
phosphorylation (d) followed the same trend as that in (c). Therefore, any effects seen 
on the receptor by Q-3-G appear to be due to changes in expression of the receptor 
rather than phosphorylation. (Mean ± SD, n=3. Bars with no letters in common are 
statistically significantly different, P < 0.05.) 
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Effects on Akt expression and activation. Neither IGF-I nor Q-3-G affected 
expression of Akt (Figure 3.7a). However, IGF-I induced Akt phosphorylation (Figure 
3.7b) over the SFM control, as expected (Akt phosphorylation in the SFM control was 
72.1 ± 16.6% of the IGF-I control). Addition of Q-3-G reduced Akt phosphorylation 
in a clear dose-dependent manner. Doses of 5, 10, 15 and 20 µM Q-3-G reduced Akt 
phosphorylation to 90.7 ± 15.5, 80.0 ± 13.4, 75.1 ± 16.3, and 63.8 ± 8.9% of the IGF-I 
control, respectively (mean ± S.D., n=6).  
Cyclin D1.  After 24 hours of treatment with 100 ng/mL IGF-I, Cyclin D1 
expression was clearly up-regulated compared to the SFM control (Figure 3.8). 
Addition of 5, 10, 15 and 20 µM Q-3-G down-regulated IGF-I-induced Cyclin D1 
expression to 37.3 ± 12.7, 31.9 ± 14.5, 17.8 ± 9.7, and 23.4 ± 8.0% of the IGF-I 
control, respectively. Q-3-G reversed the effects of IGF-I on Cyclin D1 expression 
(mean ± S.D., n = 3).  
CDK-4. IGF-I treatment upregulated CDK-4 expression (Figure 3.9) when 
compared to the SFM control (77.4 ± 11.3% of the IGF-I control). Addition of 5, 10, 
15 and 20 µM Q-3-G reduced CDK-4 expression to 58.3 ± 5.6, 53.7 ± 4.5,              
51.5 ± 10.4, and 63.5 ± 22.7% of the IGF-I control, respectively. Q-3-G reversed the 
effects of IGF-I on CDK-4 expression (mean ± S.D., n = 3).  
p21, p27 and PCNA. The expression of p21, p27 and PCNA were not 
significantly altered by treatment with IGF-I alone or in combination with various 
doses of Q-3-G. p21 showed a slight increasing trend upon treatment with IGF-I, and 
IGF-I with Q-3-G, yet no treatment was significantly different from any other (Figure 
3.10a). p27 expression was nearly the same between the SFM and IGF-I controls, and 
addition of Q-3-G appeared to cause a decreasing trend, although not significantly 
(Figure 3.10b). Treatment with IGF-I slightly increased PCNA expression over the 
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SFM control, and addition of Q-3-G decreased the expression, although none of the 
changes was significant (Figure 3.10c). 
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Figure 3.7. Effects of Q-3-G on Akt expression and phosphorylation. (a) Akt 
expression. Neither IGF-I nor Q-3-G affected expression of Akt. (b) Akt 
Phosphorylation. IGF-I induced Akt phosphorylation over the SFM control, as 
expected. Addition of Q-3-G to the IGF-I reduced Akt phosphorylation in a clear 
dose-dependent manner. Doses of 5, 10, 15 and 20 µM Q-3-G reduced Akt 
phosphorylation to 90.7 ± 15.5%, 80.0 ± 13.4%, 75.1 ± 16.3%, and 63.8 ± 8.9% of the 
IGF-I control, respectively. (Mean ± SD, n=6. Bars with no letters in common are 
statistically significantly different, P < 0.05.) 
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Figure 3.8. Effect of Q-3-G on Cyclin D1 expression. MCF-7 cells were plated at a 
density of 5×105 cells per well and incubated for 24 hours. Cells were then serum-
starved for 12 hours. After 24 hours of treatment with 100 ng/mL IGF-I, Cyclin D1 
expression was clearly up-regulated compared to the SFM control. After addition of 
varying doses of Q-3-G,  5, 10, 15 and 20 µM Q-3-G down-regulated Cyclin D1 
expression to 37.3 ± 12.7%, 31.9 ± 14.5%, 17.8 ± 9.7%, and 23.4 ± 8.0% of the IGF-I 
control, respectively. Q-3-G reversed the effects of IGF-I on Cyclin D1 expression.  
(Mean ± SD, n = 3. Bars with no letters in common are statistically significantly 
different, P < 0.05.) 
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Figure 3.9. Effect of Q-3-G on CDK-4 Expression. MCF-7 cells were plated and 
serum-starved as in Fig. 3.7. Cells were then treated for 24 hours with 100 ng/mL 
IGF-I and varying doses of Q-3-G. IGF-I treatment upregulated CDK-4 expression 
compared to the negative control. Addition of 5, 10, 15 and 20 µM Q-3-G reduced 
CDK-4 expression to 58.3 ± 5.6%, 53.7 ± 4.5%, 51.5 ± 10.4%, and 63.5 ± 22.7% of 
the IGF-I control, respectively. Q-3-G reversed the effects of IGF-I on CDK-4 
expression. (Mean ± SD, n = 3. Bars with no letters in common are statistically 
significantly different,  P < 0.05.)  
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Figure 3.10. Effect of Q-3-G on expression of p21, p27 and PCNA. MCF-7 cells 
were plated at a density of 5×105 cells per well, allowed to attach for 24 hours, and 
serum-starved for 12 hours. Cells were treated with Q-3-G and IGF-I simultaneously 
for 24 hours. After 24 hours of treatment, Q-3-G appeared to slightly increase p21 
expression (a) and slightly decrease p27 expression (b), although not significantly. 
Both IGF-I and Q-3-G had little effect on PCNA expression (c). (Mean ± SD, n=3. 
Bars with no letters in common are statistically significantly different, P < 0.05. β-
actin shown applies to p21 membrane which was stripped and re-probed for p27. 
PCNA was detected on the same membrane as CDK-4, Fig. 3.8.) 
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Q-3-G reversed IGF-I-mediated apoptosis suppression.  
Flow Cytometry. As expected, addition of IGF-I to the SFM suppressed 
apoptosis in MCF-7 cells. This was evident in the pattern of sub-G0 fragments seen in 
the flow cytometric analysis. After 24 hours (Figure 3.11a), 6.4 ± 1.1% of the singlet 
events counted from the SFM control sample were sub-G0 fragments. 100 ng/mL  
IGF-I reduced this to 3.4 ± 0.4%. Addition of Q-3-G reversed the effects of IGF-I, 
returning the level of sub-G0 fragments to that similar to the SFM control (5.7 ± 0.5% 
at 10 µM and 4.6 ± 0.5% at 15 µM). Similar results were seen after 48 hrs (Figure 
3.11b), only to a much greater extent. In the SFM control sample, 9.5 ± 2.1% of the 
events were sub-G0 fragments, while 4.8 ± 0.6% of the IGF-I control events were sub-
G0 fragments. With 15 µM Q-3-G, 44.9 ± 1.1% of the sample population were sub-G0 
fragments, indicating mass cell death through apoptosis.   
Acridine Orange/Ethidium Bromide (AO/EB) Staining. Figure 3.12a shows 
AO/EB stained MCF-7 cells. Cells with uniform green appearance were scored as 
healthy, with bright condensed yellow or orange nuclei as apoptotic, and dark red as 
dead. All groups were treated with 100 ng/mL IGF-I. Addition of Q-3-G to the IGF-I-
treated cells increased the proportion of apoptotic cells in a dose-dependent manner   
(0 µM: 3.3 ± 0.6 apoptotic cells per 200 cells; 5 µM: 5.2 ± 2.8; 10 µM: 11.9 ± 4.7; 15 
µM: 10.6 ± 1.3; 20 µM: 14.7 ± 5.5, Figure 3.12b). The proportion of dead cells was 
not significantly different among groups (Figure 3.12c).  
Caspase-9 cleavage.  Figure 3.13 represents expression of the cleavage 
fragment of Caspase-9, as a percent of the IGF-I control. There was no significant 
difference between the SFM and IGF-I controls (SFM: 93.0 ± 27.9% of the IGF-I 
control). However, the administration of Q-3-G in addition to the IGF-I increased 
Caspase-9 cleavage to 221.8 ± 65.5, 234.2 ± 57.8, 248.1 ± 131.8, and 221.3 ± 62.4% 
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of the IGF-I control in doses of 5, 10, 15 and 20 µM, respectively. Although the 
variation was large, all Q-3-G treatment groups were statistically significantly 
different from the IGF-I control (mean ± S.D., n=3, p<0.05).  
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Figure 3.11. Effect of Q-3-G on Sub-G0 peak. After 24 hours treatment (a), flow 
cytometric analysis demonstrated that addition of 100 ng/mL IGF-I reduced the 
proportion of sub-G0 fragments compared to the SFM control from 6.4% to 3.4% of 
the parent population (singlet events measured in the sample), indicating the IGF-I 
suppressed cell death in the MCF-7 cells. Addition of Q-3-G reversed the effects of 
IGF-I, returning the level of sub-G0 fragments to that similar to the SFM control 
(4.6% after treatment with 15 µM Q-3-G). Similar results were seen after 48 hrs (b), 
only to a much greater extent. 9.5% of the SFM control and 4.8% of the IGF-I control 
were sub-G0 fragments. With 15 µM Q-3-G, more than 44.9% of the parent 
population were sub-G0 fragments. (Mean ± SD, n = 3. Bars with no letters in 
common are statistically significantly different, P <  0.05.) 
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Figure 3.12. Acridine Orange/Ethidium Bromide (AO/EB) Staining of MCF-7 
cells treated with Q-3-G. MCF-7 cells were serum-starved for 12 hours, then treated 
for 24 hrs with varying doses of Q-3-G. (All treatments contained 100 ng/mL IGF-I.) 
Cells were harvested by scraping followed by centrifugation, then resuspended in 
AO/EB solution on ice in the dark. After 2 minutes, 10 µL of sample were placed on a 
slide for counting under fluorescence microscopy using a 488 nm illumination/520 nm 
emission filter. Cells with uniform green appearance were scored as healthy, cells with 
bright condensed yellow or orange nuclei as apoptotic, and dark red cells as dead (a). 
Addition of Q-3-G to the IGF-I increased the proportion of apoptotic cells in a dose-
dependent manner (b), while the background number of dead cells did not differ 
significantly among treatments (c). (Mean ± SD, n = 3. Bars with no letters in 
common are statistically significantly different, P < 0.05.) 
 
PARP Cleavage. Figure 3.12 shows the effects of Q-3-G on PARP cleavage in 
MCF-7 cells. The upper band represents the intact PARP protein, the expression of 
which was statistically the same between the SFM and IGF-I controls, and which 
decreased upon treatment with Q-3-G (Figure 3.14a).  The expression of the PARP 
cleavage fragment, which indicates apoptosis, is presented as percent of the expression  
a 
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Figure 3.13. Effect of Q-3-G on Caspase-9 Cleavage. The figure represents 
expression of the cleavage fragment of Caspase-9 (lower band), as a percent of the 
IGF-I control (the upper band is the intact Caspase-9 protein). No significant 
difference existed between the SFM and IGF-I controls. However, the administration 
of Q-3-G in addition to the IGF-I increased Caspase-9 cleavage to 221.8 ± 65.5%, 
234.2 ± 57.8%, 248.1 ± 131.8%, and 221.3 ± 62.4% of the IGF-I control in doses of 5, 
10, 15 and 20 µM, respectively. (Mean ± SD, n=3. Bars with no letters in common are 
statistically significantly different, P < 0.05.) 
of the intact PARP protein in the IGF-I control treatment (Figure 3.14b). Upon 
addition of Q-3-G, the corresponding increase of the 89 kDa fragment of PARP in a 
dose-dependent manner indicated that PARP cleavage and therefore apoptosis had 
occurred. Note the complete absense of the 89 kDa fragment in the positive control, 
where IGF-I suppressed PARP cleavage. Addition of only 5 µM Q-3-G reversed this 
effect, returning the level of cleavage fragment to 21.4 ± 45% of the IGF-I intact 
control, a level similar to that of the SFM control (19.2 ± 4.5%). Doses of 10, 15 and 
20 µM Q-3-G induced PARP cleavage to 25.1 ± 17.2, 34.9 ± 16.9, and 33.3 ± 11.5% 
of the intact IGF-I control, respectively  (mean ± S.D., n = 3). 
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Figure 3.14. Effect of Q-3-G on PARP Cleavage. After 24 hours treatment, 5, 10, 15 
and 20 µM Q-3-G decreased expression of intact PARP (upper band) to 63.91 ± 
7.15%, 44.40 ± 20.55%, 51.78 ± 8.07%, and 55.47 ± 8.02% of the intact PARP 
expression in the IGF-I control, respectively (a). Upon addition of Q-3-G, the 
corresponding increase of the 89 kDa fragment of PARP (lower band) in a dose-
dependent manner indicated that apoptosis and therefore PARP cleavage had occurred 
(b). Note the complete absense of the 89 kDa fragment in the IGF-I control, where 
IGF-I suppressed PARP cleavage. Addition of only 5 µM Q-3-G reversed this effect, 
returning the level of cleavage fragment to 21.4 ± 4.5% of the intact PARP expression 
in the IGF-I control, a level similar to that of the SFM control (19.2 ± 4.5%). Doses of 
10, 15 and 20 µM Q-3-G induced PARP cleavage to 25.1 ± 17.2%, 34.9 ± 16.9%, and 
33.3 ± 11.5% of the intact IGF-I control, respectively. (Mean ± SD, n = 3. Bars with 
no letters in common are statistically significantly different, P < 0.05.) 
Bcl-2. Doses of 5, 10, 15 and 20 µM Q-3-G increased Bcl-2 expression relative 
to the IGF-I control (Figure 3.15). However, none of these differences was statistically 
significant (mean ± S.D., n=3).  
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Figure 3.15. Effect of Q-3-G on Bcl-2 Expression. Membranes from Cycin D1 
(Figure 3.6) were reprobed for Bcl-2 expression. 5, 10, 15 and 20 µM Q-3-G increased 
Bcl-2 expression relative to the IGF-I control. However, none of these differences was 
statistically significant. (Mean ± SD, n=3. Bars with no letters in common are 
statistically significantly different, P < 0.05.)  
 
DISCUSSION 
Insulin-like Growth Factor I (IGF-I) is a growth factor produced by the liver 
for endocrine functions and by many other tissues for autocrine and paracrine 
functions (Yakar et al., 1999). IGF-I acts through binding to the IGF-IR. The IGF-IR 
is 70% homologous to the insulin receptor, but has independent roles in cell 
proliferation and survival, differentiation, and neoplastic growth (Baserga et al., 
2003). As such, the IGF-IR has become an attractive target for cancer research. 
Nutrition, the IGF-I system, and cancer risk are all closely intertwined. The 
three major factors influencing endocrine IGF-I production in the liver are growth 
hormone (Bichell et al., 1992), insulin (Kaytor et al., 2001; Kaytor et al., 2001b) and 
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nutritional status (caloric and protein intakes) (Clemmons et al., 1981; Thissen et al., 
1994). Caloric restriction studies in a p53-deficient mouse bladder cancer model, 
which reduced cancer incidence, were also shown to reduce IGF-I levels (Dunn et al., 
1997). Adding IGF-I back to the circulation of the mice reversed the effect on cancer 
incidence. Higher levels of GH are associated with higher cancer risk (Maison et al., 
1998).  
 The results of this study have shown that Q-3-G reverses the mitogenic and 
anti-apoptotic effects of IGF-I in MCF-7 cells in vitro. Q-3-G inhibited MCF-7 cell 
proliferation more potently than quercetin, and Q-3-G inhibited IGF-I-stimulated cell 
proliferation much more potently than FBS-stimulated proliferation (Figure 3.3). Most 
of the remaining markers that were investigated showed the same pattern of IGF-I-
mediated stimulation or down-regulation of a response compared to the SFM control 
cells, followed by reversal of that signal upon addition of the Q-3-G. Taken together, 
these data indicated that Q-3-G was clearly targeting IGF-IR signaling.  
 According to the cell cycle analysis (Figure 3.5), IGF-I stimulated cell 
proliferation by promoting cell cycle progression as expected. After 24 hours, IGF-I-
treated cells had a smaller proportion of the population in G0/G1 phase, and a greater 
proportion in S and G2/M phases, compared to the SFM control (Figure 3.5a-c). 
Treatment with Q-3-G along with the IGF-I reversed this effect, returning the cell 
cycle distribution to that similar to the SFM control. The corresponding sub-G0 
fragment data (Figure 3.11a) show that in these 24 hour samples, 6.4% of the events 
were sub-G0 fragments in the SFM control, 3.4% were sub-G0 in the IGF-I control, 
and 4.6% were sub-G0 after treatment with 15 µM Q-3-G in addition to the             
100 ng/mL IGF-I. Therefore, ~95% of the events in the samples were intact nuclei. Of 
these populations of intact nuclei, IGF-I decreased the percentage of G0/G1 cells from 
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90.1% in the SFM control to 78.2% in the IGF-I control, indicating progression past 
the G1/S checkpoint. 15 µM of Q-3-G reversed the effects of IGF-I, increasing the 
proportion of cells in the G0/G1 phase to 87.2%.  After 48 hours treatment, though the 
proportions were different, the patterns looked the same. 9.5% of the singlet events in 
the SFM control and 4.8% in the IGF-I control were sub-G0 fragments (Figure 3.11b). 
Treatment with 15 µM Q-3-G dramatically increased this to 44.9%. Of the remaining 
singlet nuclei in the samples, 91.0% and 82.0% of the SFM and IGF-I controls, 
respectively, were in G0/G1 phase (Figure 3.5d). Addition of 15 µM Q-3-G to the 
IGF-I increased this to 88.5%, showing the same reversal of the effects of IGF-I seen 
after 24 hours. Since the sub-G0 peak in the 48 hour samples of doses 3 through        
15 µM Q-3-G approached the origin of the histogram, the proportion of sub-G0 
fragments may in fact be an underestimate. Therefore, the sub-G0 peak may be used 
only as an indication that cell death is occurring in the samples in a time- and dose-
dependent manner, but cannot be used as an absolute quantification of apoptosis. 
 Additional apoptosis markers showed patterns similar to the flow cytometry 
results. IGF-I suppressed apoptosis compared to SFM control as demonstrated by 
PARP cleavage (an early event; Figure 3.14), AO/EB staining (showing early and late 
apoptotic cells; Figure 3.12), and the sub-G0 peak (a late event, Figure 3.11) as 
mentioned above. Treatment with Q-3-G concomitantly with the IGF-I reversed these 
effects. Therefore, Q-3-G has blocked both of the IGF-IR’s main cell survival 
mechanisms: driving cell cycle progression and suppressing apoptosis.  
 The one apoptosis marker which did not respond significantly to treatment was 
Bcl-2 (Figure 3.15). Expression of Bcl-2 in the IGF-I control was slightly lower than 
the SFM control, while Q-3-G appeared to increase expression over both the SFM and 
IGF-I controls. Since Bcl-2 is a pro-survival protein (Adams and Cory, 1998), this 
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pattern is inconsistent with results of other apoptotic markers in this study, where     
Q-3-G induced apoptosis. On the other hand, Bcl-2 is known to have cell cycle-
modulatory functions that involve sections of the Bcl-2 protein which are unrelated to 
its anti-apoptotic functions. In response to inadequate growth conditions, Bcl-2 
prompts entry into quiescence and delays return to the cell cycle (Adams and Cory, 
1998, and sources therein). This function is consistent with the results shown here: 
after 24 hours treatment, Q-3-G induces G1 cell cycle arrest and a corresponding up-
regulation of Bcl-2. Nevertheless, the differences in Bcl-2 expression were not 
statistically significant between any of the treatment groups and therefore this cannot 
be regarded as a major mechanism of action of the Q-3-G. The lack of significance 
may be due to the large variation between gels, and/or to sub-optimal western blotting 
or imaging conditions for this particular protein. Further investigation would be 
needed to address these uncertainties.  
 IGF-I Receptor expression in MCF-7 cells increased with Q-3-G treatment. In 
the absence of IGF-I, IGF-IR phosphorylation was completely absent, verifying the 
model.  After 12 and 24 hours of treatment, the pattern of IGF-IR phosphorylation 
mirrored that of the receptor expression, indicating that any effect of treatment on the 
receptor was on expression and not on phosphorylation (Figure 3.6). Therefore, any 
down-stream effects seen, such as the down-regulation of Akt phosphorylation (Figure 
3.7b) and Cyclin D1 expression (Figure 3.8), were clearly not due to an inhibition of 
IGF-IR activation. Increased expression of IGF-IR has been seen in cancer cell lines 
and tumors, and is associated with aggressive tumor phenotypes in some types of 
cancer such as synovial sarcoma (Xie et al., 1999) and lung carcinoma (Long et al., 
1998). In breast tumors, however, while IGF-IR expression was elevated compared to 
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normal tissue, this up-regulation was associated with a more favorable prognosis 
(Papa et al., 1993).  
 The ratio of IGF-IR to IRS-1 expression is an important factor determining 
whether the receptor activates mitogenic or differentiation pathways. A high IGF-IR to 
IRS-1 ratio favors differentiation, which is a cancer-protective effect (Valentinis and 
Baserga, 2001). In a rat prostate cancer cell line, quercetin altered this ratio by 
reducing IRS-1 as well as inhibiting the IGF-I-induced up-regulation of the receptor 
(Wang et al., 2003). Genistein has been shown to affect differentiation markers in 
MCF-7 (Constantinou et al., 1998). After 12 and 24 hours of treatment, Q-3-G in 
addition to IGF-I treatment caused a clear up-regulation of IGF-IR in this study. This 
may help to drive the cells toward differentiation. At least for the doses and treatment 
times employed in this study, the increased IGF-IR expression occurred concomitantly 
with significantly reduced Akt activation. Therefore it is believed the increased      
IGF-IR expression may be functioning much like that induced by the quercetin 
mentioned above in the rat prostate cancer cells, which promoted cellular 
differentiation rather than mitogenesis. Future studies may investigate the effects of  
Q-3-G on the IRS-1 expression in MCF-7 cells, as well as the IGF-IR-mediated 
differentiation pathways in MCF-7 cells.  
 In this study, Akt phosphorylation was clearly induced by IGF-I treatment, and 
abrogated upon addition of Q-3-G to the IGF-I (Figure 3.7b). Across all treatments, 
total Akt expression did not change. As the Q-3-G did not inhibit IGF-IR 
phosphorylation, the point of action is presumably downstream of the receptor and 
upstream of Akt.  The most likely target is PI3K, as quercetin aglycone has been 
demonstrated to be a PI3K inhibitor (Matter et al., 1992; Agullo et al., 1997). Akt 
phosphorylation at the Ser473 residue was investigated in this study. In order to be fully 
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activated, Akt must be phosphorylated on two key residues: Ser473 and Thr308. Thr308, 
which occurs in the activation loop of the protein, is phosphorylated by PDK-1 (Alessi 
et al., 1996). mTOR phosphorylates Ser473 in the carboxy terminus (Sarbassov et al., 
2005). Phosphorylation of both of these residues is required for full Akt activation, 
both are stimulated by IGF-I treatment, and phosphorylation of one is not dependent 
on the phosphorylation state of the other (Alessi et al., 1996). The pattern of the bands 
on the Western Blots show one visible band in the SFM control, and two visible bands 
at all other treatments, presumably from an electrophoretic mobility shift. Since the 
upper band, presumably the Akt with a higher level of phosphorylation, is the band 
that diminishes upon Q-3-G treatment, the authors speculate phosphorylation of a 
residue other than Ser473 was being diminished. In this study, Cyclin D1 was clearly 
up-regulated by IGF-I and clearly down-regulated by concomitant treatment with     
Q-3-G and IGF-I (Figure 3.8). Since Akt phosphorylation was significantly down-
regulated by the Q-3-G treatment in this study, it is possible that Cyclin D1 expression 
was down-regulated by interference with both of Akt’s actions: driving Cyclin D1 
transcription, and suppressing Cyclin D1 degradation.  
 As summarized by Clark et al. (2005), p21 was originally known as a Cyclin-
dependent Kinase Inhibitor (CKI) and could induce cell cycle arrest when triggered by 
p53 in an ERK- and p38-dependent fashion. In MCF-7 cells treated with IGF-I, 
however, p21 aided in cell proliferation induced by the IGF-I in an ERK-dependent 
manner. Additionally, the roles of IGF-I in Cyclin D1 up-regulation and Rb 
phosphorylation were determined to be PI3K-dependent and ERK-independent in 
MCF-7 cells and these functions did not depend on p21. In a study by Clark et al. 
investigating the role of IGF-I in DNA repair, in acute assays (1 through 6 hours) the 
IGF-I-induced expression of p21 was dependent on both PI3K and ERK pathways. 
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Chronic (24 and 48 hours) induction of p21 expression by IGF-I was found to be 
partially dependent on PI3K activity and was associated with increased DNA 
synthesis. The authors conclude that in MCF-7 cells suffering DNA damage as a result 
of bleomycin treatment, IGF-I induced p21, which aided in cell cycle arrest (Clark et 
al., 2005). In the current study, although not statistically significant, the pattern of p21 
expression (Figure 3.10a) is consistent with what is known regarding the functions of 
p21 in response to IGF-I and the pathways involved. All samples treated with IGF-I 
showed p21 expression somewhat higher than the SFM control. However, this 
induction was not affected by addition of Q-3-G. IGF-I may have induced p21 
expression via an ERK-dependent pathway to induce cell proliferation. Q-3-G then 
inhibited cell cycle and apoptosis via a PI3K pathway, thus inhibiting proliferation 
without altering p21 expression. 
 IGF-I down-regulates p27 by increasing the levels of Skp2, a ubiquitin ligase 
for p27, thereby stimulating ubiquitination and subsequent proteosome degradation of 
p27. This process is believed to involve the PI3K pathway (Yuhong et al., 2003). The 
results of the current study show a slight decrease in p27 expression after treatment 
with IGF-I compared to the SFM control (Figure 3.10b). Unexpectedly, addition of   
Q-3-G to the IGF-I treatment further down-regulated p27 expression. While a trend is 
visible, the lack of statistical significance and large variation render these data 
inconclusive.  
 Proliferating cell nuclear antigen (PCNA), often used as a marker of cell 
proliferation, is a DNA clamp which serves to increase the processivity of DNA 
polymerase during DNA replication and repair and is under the transcriptional control 
of E2F transcription factors (Krishna et al., 1994; Kelman and O'Donnell, 1995; 
Tommasi and Pfeifer, 1999; Ahn et al., 2002; Maga and Hubescher, 2003). As such, 
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one would expect to see an increase in PCNA expression upon addition of IGF-I to the 
serum-starved MCF-7 cells in this study, and a decrease in expression upon addition 
of the Q-3-G, when reduced cell proliferation and cell cycle arrest are evident. This 
pattern is seen (Figure 3.10c) although the differences between treatment groups are 
slight and non-significant. This could be attributed to the timing of the experiment. 
Both the Cyclin D1 and PCNA expression were measured after 24 hours of treatment. 
However, since PCNA is controlled by E2F transcription factors, and Cyclin 
D1/CDK-4 regulate E2F activity by phosphorylating Rb, PCNA expression may occur 
slightly later. Perhaps after a longer treatment period larger differences in PCNA 
expression may become apparent.  
 The antioxidant properties of phytochemicals have gained much attention in 
recent years, since oxidative stress has been linked with chronic diseases such as 
cancer, and reactive oxygen species (ROS) can function as signaling molecules within 
cells. Lin et al. (2007) demonstrated that IGF-I and estrogen enhance one another’s 
cell proliferative activity in MCF-7 cells, through a ROS-dependent pathway which 
results in phosphorylation of IRS-1, ERKs and JNKs. The aglycones quercetin and 
baicalein inhibited this effect, while their respective glycosides, quercitrin (quercetin-
3-O-rhamnoside), rutin (quercetin-3-O-rutinoside), and baicalin (baicalein-7-O-
glucuronide), did not. Plumb et al. (1999) found that quercetin aglycone had more 
potent antioxidant activity than two glycosides (quercetin 3-O-glucuronide and 
quercetin 3-O-rutinoside) using the Trolox equivalent antioxidant capacity (TEAC) 
assay. The cellular antioxidant activity (CAA) assay results seen in the current study 
are consistent: quercetin had potent antioxidant activity in MCF-7 cells with an EC50 
of 6.28 ± 0.25 µM, while Q-3-G was a much weaker antioxidant activity with an EC50 
of 106.63 ± 13.26 µM (Figure 3.4 and Table 3.1). The doses of Q-3-G used for the 
remainder of experiments in this study ranged from 1 to 20 µM. In the CAA assay,   
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20 µM of Q-3-G showed little to no antioxidant activity. Therefore, we conclude that 
the effects of Q-3-G on IGF-I-induced proliferation and signal transduction seen in 
this study cannot be attributed to quenching of ROS. 
 ERα functions via genomic events in the nucleus, and via signal transduction 
events in the plasma membrane (Mawson, et al. 2005). The ER and IGF-IR pathways 
collaborate to promote cell cycle progression in various ways. In the nucleus, estrogen 
has been shown to increase the transcription of IGF-I, IGF-IR, and IRS-1. IGF-I-
treated ER+ MCF-7 cells demonstrated increased ER transcriptional activity. Estrogen 
increases expression of c-myc, which blocks p21, while insulin increases expression of 
Cyclin E. Estrogen, insulin, and IGF-I also promote expression of Cyclin D1. 
Together these events lead to enhanced progression through the G1-S transition. At the 
plasma membrane, estrogen-bound ER may bind and activate the IGF-IR or bind the 
p85 subunit of PI3K and Src, directly activating the PI3K and p21/ras/MAPK 
pathways (Mawson, et al. 2005). 
 ER can be activated by phosphorylation induced by estrogen or other growth 
factors such as EGF and IGF-I (Kato et al., 1995; Bunone et al., 1996; Fagan and Yee 
2008). Activation function domain-1 (AF-1) of the ER is regulated by growth factors, 
while AF-2 is activated by estrogen. IGF-I can induce ER activation in two ways:  
phosphorylation of Ser118 of the AF-1 by MAPK, and phosphorylation of Ser167 of  
AF-1 by Akt (Ignar-Trowbridge et al., 1993; El-Tanani and Green, 1997).  
 In both normal and cancerous breast tissue, IGF-I and estrogen both work to 
potentiate one another’s transcriptional activity (Fagan and Yee, 2008). In the absence 
of estrogen, treatment with IGF-I increased transcriptional activity of the ER in   
MCF-7L cells (Lee et al., 1997). IGFBP-1 inhibited ER activation by both IGF-I and 
157 
 
by estrogen (Figueroa et al., 1993). The implication is that IGF-I is necessary for the 
ER to reach its full activation potential stimulated by estrogen (Fagan and Yee, 2008). 
 Cascio et al. (2007) provide further evidence of the crosstalk between IGF-I 
and ER signaling in MCF-7 cells. While IGF-I (50 nM) can stimulate nuclear 
localization of the ER, it is less efficient than E2 (10 nM). After 1 and 4 hrs of 
treatment, IGF-I stimulated transcription of Cyclin D1 mRNA more efficiently than 
E2 or both in combination. IGF-I recruited ER to the Cyclin D1 AP-1 sequence to 
fully activate transcription of Cyclin D1, although IGF-I alone recruited less ER than 
E2 had recruited. However, even in the absence of the ER (knockdown by RNA 
interference), IGF-I was able to stimulate some Cyclin D1 transcription (Cascio et al., 
2007).  
 In the current study, it is quite possible the IGF-I treatment stimulated nuclear 
translocation of ER and recruitment of ER and its co-regulators to the AP-1 site to 
promote Cyclin D1 transcription. However, since all treatments are devoid of E2, then 
these actions of ER cannot be expected to reach full potential. As mentioned earlier, 
IGF-I can activate ER via phosphorylation of Ser167 of the AF-1 site by Akt. 
Treatment with Q-3-G clearly down-regulated phosphorylated Akt. Therefore, a 
subsequent reduction in phosphorylation of ER at Ser167 would be expected. The 
crosstalk that occurs between IGF-IR and ER signaling must always be kept in mind. 
IGF-I-stimulated growth is inhibited by anti-estrogens, and estrogen-stimulated 
growth is inhibited by anti-IGF-I treatments (Wakeling et al., 1989; Freiss et al, 1990). 
IGF-I signaling may contribute to resistance against anti-estrogen treatments in breast 
cancers. Therefore, a compound that targets IGF-IR signaling in breast cancer may be 
especially valuable.  
 Q-3-G was much more potent than the quercetin aglycone in inhibiting IGF-I-
mediated MCF-7 cell proliferation. This may be attributed to greater bioavailability of 
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the glycoside compared to quercetin aglycone (Hollman and Katan, 1998). The 
following studies investigated the influence of IGF-I on cellular glucose transporters, 
which play a significant role in the absorption of quercetin glycosides (Lostao et al., 
1994; Gee et al., 1998; Kellett, 2001). 
 Neonatal rats, ages 8-12 days, were fed rat milk substitute (RMS) which 
contained no growth factors, or RMS supplemented with IGF-I or IGF-II in 
concentrations which approximated those found in rat milk. Control rats were 
naturally dam-fed (Lane et al., 2002). While serum glucose levels in the RMS-fed rat 
pups were lower than dam-fed pups, addition of IGF-I or IGF-II returned blood 
glucose to normal levels. The same pattern was seen in SGLT1 mRNA expression in 
the mid-jejunum: RMS-fed pups had lower mRNA levels than dam-fed, while mRNA 
levels in pups supplemented with IGF-I or IGF-II were similar to the dam-fed 
controls. Histological localization of the SGLT1 transporter corroborated the mRNA 
results: no positive cells were visible in samples from the RMS group, while the IGF-I 
and IGF-II supplemented groups showed similar staining to the dam-fed group. 
Expression of GLUT2 mRNA in the mid-jejunum of RMS-fed pups was also lower 
than the dam-fed controls. Levels in IGF-I-supplemented pups were not statistically 
significantly different from the RMS group, while levels in the IGF-II-supplemented 
pups were not statistically significantly different from the dam-fed controls (Lane et 
al., 2002).  
 The jejunal uptake of glucose in neonatal piglets fed an IGF-I-supplemented 
RMS was reported (Alexander and Carey, 1999 and 2001). The researchers found the 
IGF-I increased glucose uptake, via PI3K activation, but saw no change in SGLT1 
expression. Lane et al. speculate this may be because Alexander and Carey used 
piglets ages 1-5 days, a time when SGLT1 expression may be below detection limits 
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of Western Blotting, as the expression of SGLT1 and GLUT2 increase during the 
suckling period of the neonates. Also, Alexander and Carey used a porcine RMS 
containing oxytetracycline which inhibits mitochondrial protein synthesis, and 
neomycin which may affect protein synthesis and processing. Inclusion of these 
antibiotics may also explain the lack of difference in SGLT1 expression seen in this 
model (Lane et al., 2002). Lane concludes the difference in glucose uptake in the 
piglet model due to IGF-I supplementation may have been the result of SGLT1 
translocation, rather than changes in expression (Lane et al., 2002).In their own rat 
pup model, Lane et al. summarize that IGF-I and IGF-II play a role in the developing 
jejunum’s ability to absorb glucose from the intestinal lumen.      
 In light of the known functions of IGF-I in fetal and early childhood growth, 
and the fact that insulin stimulates IGF-I production, it makes sense that IGF-I would 
be involved in glucose transport into the cell, particularly in the small intestine. Intake 
of food triggers insulin which stimulates IGF-I production. IGF-I may stimulate 
growth and other metabolic functions by up-regulating expression of glucose 
transporters so that cells may absorb the available glucose.  
In MCF-7 cells, SGLT1 is expressed in very low levels, if expressed at all. For 
example, in a study investigating the tyrosine kinase-independent functions of EGFR 
in cancer cell survival, SGLT1 mRNA was detected by RT-PCR, but the 
corresponding protein was not detectable by western blotting (Weihua et al., 2008). 
However, another group found a novel glucose transporter, GLUT12, to be expressed 
in MCF-7 cells (Rogers et al., 2002). GLUT12 is normally only expressed in skeletal 
muscle, heart, and fat, all insulin-sensitive tissues. In MCF-7 cells grown without 
insulin, the GLUT12 was localized to the perinuclear area, and continuous growth in 
insulin showed GLUT12 expression in the membrane. However, they were not able to 
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show an acute re-localization response to insulin (Rogers et al., 2002). Later the same 
group found GLUT12 to be expressed in breast cancer tumors but not in the 
corresponding healthy mammary tissues from the same patients (Rogers et al., 2003).  
 Similarly, another group found the GLUT-1 transporter to be expressed in all 
12 primary breast tumors and all 8 lymph node metastases tested (Brown and Wahl, 
1993). In normal mammary tissue from the same patient, the GLUT-1 expression was 
lower than that seen in the respective tumor. They suggested this may partly explain 
the selectivity of 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) for tumor cells, which is 
used as a marker for increased glucose metabolism enabling visualization of tumors by 
positron emission tomography (PET) imaging. In 2008, Ong et al. (2008) 
demonstrated that higher expression of GLUT-1 and hexokinase  II, a glycolytic 
enzyme, correlated with the uptake of FDG in 5 human cancer cell lines (AGS, A431, 
A549, Colo 320 HSR, and HepG2). Fibroblast control cells had lower expression of 
GLUT-1 and hexokinase II than did the cancer cell lines (Ong et al., 2008). In general, 
tumor cells are known to have higher glucose demand (Weber, 1977) and higher 
expression of glucose transporters (Smith, 1999) than normal cells. 
 Whether SGLT1, GLUT 12, or another transporter, the possibility exists in our 
model that IGF-I treatment may cause up-regulation or translocation of one or more 
glucose transporters in the MCF-7 cells, thereby allowing a route of increased 
absorption of Q-3-G into the cells. This connection may explain why the Q-3-G was 
so much more dramatically effective in the IGF-I-treated cells than the FBS-treated 
cells, and why Q-3-G was so much more effective than the quercetin aglycone, which 
may only enter the cells through passive diffusion. This hypothesis warrants further 
study, as mechanisms which improve delivery of an anti-cancer agent to a cancer cell 
are valuable. Walgren et al. (2000) warns caution in such lines of thinking regarding 
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drug design: though a glucose moiety may facilitate transport of a chemical into a cell, 
it also facilitates efflux out of the cell via the multidrug resistance protein-2 (MRP-2). 
MCF-7 cells do not express MRP-1 (Zhang and Morris, 2003), MRP-2 (Smitherman et 
al., 2004), or P-glycoprotein (Fairchild et al., 1990; Zhang and Morris, 2003). The 
absence of all three of these efflux transporters may contribute to the efficacy of       
Q-3-G in the current study. 
 This study shows Q-3-G to be a very potent, very effective inhibitor of IGF-I 
signaling in MCF-7 cells in vitro. Future studies will add insight into the mechanisms 
of action. Such studies may include an assessment of: the IGF-IR to IRS-1 ratio to 
determine whether the increased receptor expression may drive cells into a 
differentiation pathway; IRS-1 expression and phosphorylation; PI3K expression, 
activation, and kinase activity; Akt phosphorylation at other key residues; and effects 
on AP-1 and GSK-3 in Cyclin D1 transcription and degradation. The dramatic potency 
of Q-3-G compared to quercetin is intriguing. Thus, future studies should include 
assessment of the effects of IGF-I on expression and localization of glucose 
transporters, and mechanisms of absorption, metabolism, and efflux of Q-3-G in 
MCF-7 cells as well as other normal and cancerous mammary cell lines. The IGF-I 
system is a critical component of breast cancer signaling, and the connections between 
diet and cancer are clear. The results of this study help to explain the mechanisms by 
which apple consumption may reduce breast cancer risk. Additionally, such studies of 
purified compounds contribute to the understanding of cancer cell behavior and may 
inform future endeavors in chemotherapeutic drug design. 
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CHAPTER 4 
 
FRESH APPLES INHIBIT CELL PROLIFERATION AND INDUCE APOPTOSIS  
IN MAMMARY TISSUES OF RATS IN VIVO 
 
ABSTRACT 
Apple extracts had potent antioxidant activity and antiproliferative activity 
against cancer cells in vitro and in vivo. The objectives of this study were to determine 
the effects of apple phytocemical extracts on cell proliferation and apoptosis in 
mammary tissues of rats in vivo, and to determine how apple phytochemical extracts 
affect the expression of cell cycle proteins in vivo. Rats were given whole apple 
extracts (0, 3.3, 10.0 or 20.0 g/kg body weight) by gavage starting 2 weeks after 
DMBA administration and continuing for 7 weeks. In the apple-treated groups, the 
expression of proliferating cell nuclear antigen (PCNA), BrdU-labeled cells, Cyclin 
D1 and Bcl-2 decreased, and Bax expression and nuclear fragmentation increased, 
suggesting that the dietary intervention effectively protected against chemically-
induced mammary carcinogenesis in this model. These results demonstrate the potent 
capacity of fresh apples to suppress cell proliferation and induce apoptosis in DMBA-
treated mammary tissues in rats. 
 
INTRODUCTION 
Cancer is a serious public health problem worldwide. It results from a 
multistage, multi-mechanism carcinogenesis process that involves mutagenic, cell 
death and epigenetic mechanisms with three distinguishable but closely allied stages: 
initiation, promotion, and progression (Moolgavkar, 1978). In 2008 the American 
Cancer Society estimated a total of 1,437,180 new cancer cases and 565,650 deaths 
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from cancers in the United States (Jemal et al., 2008). Although diagnosis and 
treatment are the major strategies of controlling cancer, cancer prevention is receiving 
greater attention. Over the past decades, a promising new approach, called 
“chemoprevention,” which targets the carcinogenic process at the cellular and 
molecular levels, has been studied. Chemoprevention is the attempt to halt or reverse 
the development and progression of precancerous cells through use of noncytotoxic 
nutrients, bioactive compounds, and/or pharmacological agents during the time period 
between tumor initiation and malignancy (Griffin, 1980). Research has demonstrated 
that cancer is a largely avoidable disease. It is estimated that more than two-thirds of 
cancer may be prevented through lifestyle modification (Doll and Peto, 1981; Oliveria 
et al., 1997; Willett, 2002). Nearly one-third of these cancer occurrences can be 
attributed to the American diet alone with its typically high-fat, low-fiber content (Doll 
and Peto, 1981; Willett, 2002). Fruit and vegetable consumption has been consistently 
shown to reduce the risk of many cancers (Block et al., 1992; Liu et al., 2005; Liu et 
al., 2009). It has been suggested that the phytochemicals in fruits and vegetables are 
the primary contributors to the prevention of cancers (Liu, 2003; Liu, 2004). 
 Apples and apple juice are a very significant part of the diet and are one of the 
best sources of antioxidant phytochemical compounds in the Western world (Boyer 
and Liu, 2004; Wolfe et al, 2008). Epidemiological and laboratory studies have shown 
that consumption of apples and apple juice is associated with a reduced risk of cancer 
(Deneo-Pellegrini et al., 1996; Gallus et al., 2005; Liu et al., 2005; Michels et al., 
2006; Veeriah et al., 2008;). In previous studies, apple extracts have been shown to 
have potent antioxidant and antiproliferative activity against colon, liver and breast 
cancer cells in vitro in a dose-dependent manner (Eberhardt et al., 2000; Sun et al., 
2002; Wolfe et al., 2003; Yoon and Liu, 2007; Maldonado-Celis et al., 2008; Sun and 
Liu, 2008). While apple extracts inhibited proliferation of estrogen-receptor negative 
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MDA-MB-231 cells more potently than estrogen-receptor positive MCF-7 cells, the 
extracts effectively down-regulated Cyclin D1 and CDK-4 expression, decreased Rb 
phosphorylation, caused G1 cell cycle arrest, and consequently inhibited proliferation 
in both cell lines (Sun and Liu, 2008). In a previous study, we reported apple extracts 
had activity inhibiting NF-κB activation in human breast cancer MCF-7 cells (Yoon 
and Liu, 2007). Recently, we reported that apple extracts inhibited the initiation of 
mammary carcinogenesis in a DMBA-induced model in rats (Liu et al., 2005; Liu et 
al., 2009). However, the mechanism(s) of apple phytochemicals in the prevention of 
cancer is still unclear. Thus, the objectives of the present study were to determine the 
effects of apple phytochemical extracts on cell proliferation and apoptosis in 
mammary tissues of rats in vivo, and to determine how apple phytochemical extracts 
affect the expression of cell cycle proteins in vivo.  
 
MATERIALS AND METHODS 
Reagents. Acetone, wax, ethanol, and formalin (36%) were purchased        
from Fisher Scientific (Pittsburgh, PA). Hematoxylin, eosin, proteinase K, and               
7, 12-dimethylbenz (a)anthracene (DMBA) were obtained from Sigma Chemical Co. 
(St. Louis, MO). All other chemicals used in the study were of analytical grade. 
 Apple Extraction. Apples of the Red Delicious variety were purchased from 
Cornell Orchards (Cornell University, Ithaca, NY). Fresh apples were cleaned and 
dried before extraction. Apples were extracted using the method reported previously in 
our laboratory (Liu et al., 2002; Sun et al., 2002; Liu et al., 2009). Briefly, 100 g fresh 
weight of the edible part of apples was weighed and homogenized with chilled 80% 
acetone (1:2, w/v) using a chilled Warning blender for 5 min. The sample was then 
further homogenized using a Polytron homogenizer for an additional 3 min. The 
homogenates were filtered through Whatman #1 filter paper on a Buchner funnel 
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under vacuum. The filtrate was evaporated at 45 °C until approximately 90 % of the 
filtrate had been evaporated. The apple extracts were standardized to contain 175.4 ± 
18.8 mg total phenolics per 100 g apples (Sun et al., 2002). The standardized apple 
extracts were frozen and stored at -40 C until use in the feeding study.  
 Animal Care and Treatment. Pathogen-free weanling female Sprague-
Dawley rats, 35 days of age, were purchased from Harlan Company (Indianapolis, 
IN). The rats adapted immediately to the Prolab 5P76 Isopro RMH 3000 diet and were 
housed in a room for 2 weeks with a 12 h light / 12 h dark cycle prior to the initiation 
of the experiment. The rats were randomly assigned to five groups (n=12 per group). 
Four groups of rats (50 days old) were given 10 mg of DMBA dissolved in 1 mL of 
corn oil by gavage; the fifth group (the negative control group) which received no 
DMBA was given 1 mL of corn oil. Rats were administered the control extracts or 
whole apple extracts by gavage, starting 2 weeks after DMBA administration and 
continuing for the 7 weeks until the end of the experiment. The apple treatments were 
3.3 (low), 10.0 (middle) and 20.0 (high) g fresh apples/kg body weight, which were 
equivalent to human consumption of 1, 3, and 6 apples per day, respectively. Animals 
were weighed weekly.  
 All animals were sacrificed under anesthesia at the end of the 9th week after 
DMBA administration and arterial blood samples were collected from each rat. At 
least 2 h prior to killing, rats were injected with 5-bromo-2’-deoxyuridine (BrdU) at a 
dose of 50 mg/kg body weight, intraperitoneally for the mammary BrdU-labeling 
index. All mammary glands were removed, fixed in 70 % alcohol, and subsequently 
dehydrated and embedded in wax. The tissue wax was cut into 3 μm sections, fixed on 
slides and processed for immunohistochemistry analysis.  
 BrdU Incorporation Assay. Cells in mammary gland tissues undergoing DNA 
synthesis were labeled with BrdU and analyzed using a ZYMED BrdU Staining Kit 
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(Invitrogen, South San Francisco, CA). Specimens were dewaxed and immersed in 
PBS (phosphate-buffered saline) containing 3.0 % hydrogen peroxide for 10 min at 
room temperature. The sections were washed twice in distilled water for 5 min (each) 
at room temperature and then washed three times with PBS. The trypsin solution was 
applied directly onto the specimens, which were incubated for 10 min. After the 
sections had been washed three times with PBS, they were submerged in denaturing 
solution for 30 min, washed three times with PBS, and incubated in Blocking Solution 
for 10 min. A sufficient amount of Biotinylated Mouse Anti-BrdU solution was 
applied directly onto the specimens, which were incubated for 1 h at 37 °C in a 
humidified chamber. After the sections had been washed three times with PBS, an 
amount of peroxidase-anti-mouse IgG2a solution sufficient to cover the specimens was 
added and sections were incubated for 10 min at room temperature. The chromogenic 
reaction was developed with 3, 3’-diaminobenzidine (DAB) for 3 min, and all sections 
were counterstained with hematoxylin. A minimum of 4,000 cells in each tissue 
sample were randomly selected for the BrdU incorporation assay, and positive cells 
were counted. 
 Immunohistochemical Staining of PCNA, Cyclin D1, Bcl-2, and Bax. The 
sections of mammary gland tissues were deparaffinized in xylene and rehydrated 
through graded alcohol. The sections were incubated for 10 min at 95 - 100 C in 10 
mmol/L sodium citrate buffer (pH 6.0). Endogenous peroxidases in the mammary 
gland cells were inactivated by immersing the sections in 0.3% hydrogen peroxide for 
10 min, and the sections were then incubated for 10 min with 10 % normal goat serum 
to block non-specific binding. The sections were subsequently incubated at 4 C 
overnight with one of four antibodies: 1) anti-PCNA antibody (monoclonal mouse, 
PC10, IgG, 1:50 dilution, Calbiochem, Lab, Inc., Temecula, CA); 2) anti-cyclin D1 
antibody (monoclonal mouse, DCS-6, IgG, 1:25 dilution, Calbiochem, Lab, Inc., 
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Temecula, CA); 3) anti-Bcl-2 antibody (rabbit polyclonal, N-9, IgG, 1:15 dilution, 
Santa Cruz Biotechnology, Delaware, CA); or 4) anti-Bax antibody (polyclonal rabbit, 
AB-1, IgG,1:20 dilution, Calbiochem, Lab, Inc., Temecula, CA). The sections were 
then incubated with biotinylated anti-mouse IgG or anti-rabbit IgG (ZYMED, Lab, 
Inc., Carlsbad, CA) for 30 min, followed by peroxidase-conjugated streptavidin 
(ZYMED, Lab, Inc) for 30 min. The chromogenic reaction was developed with DAB 
for 3 min, and all sections were counterstained with hematoxylin. The same protocol 
was applied to the controls with the omission of the primary antibody. Microscopic 
images were measured at a magnification of 400×. Two thousand cells were counted in 
five visual fields in one of 4 glands from each rat, and an average of the cells 
positively stained for specific protein expression (mean ± S.D.) in mammary gland 
tissues randomly chosen from 8 rats in each group were analyzed. 
 Immunohistochemical Staining by TUNEL Assay. Cell apoptosis was 
determined using the ApopTag@Plus Peroxidase In Situ Apoptosis Detection Kit 
(Serologicals Corporation, Norcross, GA) based on the terminal deoxynucleotidyl-
transferase mediated dUTP nick end labeling (TUNEL) assay (Liu et al., 2009). 
Briefly, the slices of rat mammary gland tissues were deparaffinized in xylene and 
rehydrated through graded alcohol, then washed in PBS, treated with proteinase K (20 
μg/ml) for 15 min at room temperature, quenched in 3.0 % hydrogen peroxide in PBS 
for 5 min, washed 2 times in PBS, incubated in equilibration buffer at least 10 
seconds, and labeled with TdT reaction mix in a humidified box for 1 h at 37 °C. The 
slices were washed in stop/wash buffer for 10 min and then washed 3 times in PBS. 
The slides were then incubated for 30 min in a solution of anti-Digoxigenin 
Conjugate, and colorized with DAB. All sections were counterstained with 0.5 % 
(w:v) methyl green. Controls consisted of omission of the TdT reaction mix. 
Microscopic images were measured at a magnification of 400×. Four thousand cells 
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were counted in five visual fields randomly in the section, and mammary gland tissues 
randomly chosen from 8 rats in each group were examined to determine the number of 
apoptotic cells (mean ± S.D.).  
 Statistical Analysis. Data were expressed as mean ± S.D. Levene’s test for 
equality of variances followed by the t-test for equality of means were used to analyze 
body weight. The expression of PCNA, TUNEL, Cyclin D1, Bcl-2, Bax, and BrdU 
labeling in mammary gland tissues were analyzed using the Student’s t-test, Welch’s t-
test or ANOVA. Data analyses were generated and plots were constructed using SPSS 
for Windows version 16.0 (SPSS Inc., Chicago, IL) and SigmaPlot version 11 for 
Windows (Systat Software Inc., San Jose, CA). Statistical significance was set at 
P<0.05, and all P values were unadjusted for multiple comparisons. 
 
RESULTS 
Effect of Apple Extracts on Body Weight. Body weights of animals in each 
group were monitored weekly and are presented in Figure 4.1. Throughout the 
duration of the experiment, the body weights of the low, middle and high apple groups 
were not statistically different from one another. Similarly, the body weights of the 
positive and negative control groups did not differ from each other throughout the 
experiment. At the end of week 9, both the negative (217 ± 11 g) and the positive (226 
± 11 g) control groups weighed more than the high apple group (208 ± 17 g) (P<0.05). 
The positive control group outweighed the middle apple group (214 ± 9 g) as well. 
Body weights were within a normal range, suggesting no toxicity in the animals fed 
apple extracts as reported previously (Liu et al., 2009). 
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Figure 4.1. Effects of varying doses of apple extracts on body weight of rats. The 
female Sprague-Dawley rats were fed 3.3 (low), 10.0 (middle), or 20.0 (high) g fresh 
apples/kg body weight starting 2 weeks after DMBA administration and continuing for 
7 weeks until the end of the experiment. Control -: the negative control group; Control 
+: the positive control group. 
 
Immunohistochemistry for BrdU Labeling in Mammary Gland Tissue. 
Cell proliferation in mammary gland tissues, as measured by nuclear BrdU 
incorporation, was significantly lower in the apple treatment groups than in the 
positive control group in a dose dependent manner (P<0.05) (Figure 4.2). A low rate 
of BrdU incorporation was observed in the negative control group (1.1 ± 0.8, per 
4,000 cells). A high rate of BrdU incorporation was observed in the positive control 
group (22.6 ± 15.8, per 4,000 cells). The inhibitory rates of BrdU incorporation in 
mammary gland tissues were 24.6, 58.2 (P<0.05), and 89.3 % (P<0.01) in the low, 
middle, and high dose groups, respectively, compared to the positive control group.  
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Figure 4.2. Effects of varying doses of fresh apple extracts on BrdU labeling in rat 
mammary gland cells in vivo. High power view (400×) of the cells of BrdU labeling: 
(A) negative control group (Control -) (n=10); (B) positive control group (Control +) 
(n=10); (C) low dose (n=9): (D) middle dose (n=10); and (E) high dose (n=10). The 
BrdU labeled cells were visualized with DAB; positive cells are reddish-brown in 
color. Bars with no letters in common are significantly different (P<0.05). 
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Effects of Apple Extracts on the Cell Cycle and Related Proteins in 
Mammary Gland Tissue. As shown in Figure 4.3, the expression of proliferating cell 
nuclear antigen (PCNA) was the lowest in the negative control group. With DMBA 
treatment, the expression of PCNA was dramatically increased when compared to the 
negative control (P<0.05).  PCNA expression in the apple-treated groups was 
significantly lower than that in the positive control group (P<0.05) (Figure 4.3). 
Compared with the positive control group, the inhibitory rates of PCNA expression 
were 44.0, 66.8, and 72.8 % in the low, middle, and high dose groups, respectively, 
demonstrating a clear dose response.  
Cyclin D1 is one of the key markers in the G1 to S phase transition of the cell 
cycle. Cyclin D1 expression was detected among the mammary gland tissues in the 
control and apple-treated groups by immunohistochemistry. As shown in Figure 4.4, a 
low expression of Cyclin D1 in mammary gland tissues from the negative control 
group was observed. Cyclin D1 expression significantly decreased in the apple-treated 
groups compared to the positive control group (30.7± 12.3, per 4,000 cells; P<0.05) 
(Figure 4.4). A dose response was also observed. The inhibitory rates of Cyclin D1 
expression were 22.1, 58.5, and 73.5 % in the low, middle, and high doses of apple 
extracts, respectively, in comparison with the positive control group.  
 Apoptosis Induction and Expression of Related Proteins in Mammary 
Gland Tissue. Apoptosis was detected in mammary gland tissues using the TUNEL 
assay. As shown in Figure 4.5, a low rate of apoptosis was observed in the mammary 
gland tissues from the negative control group (4.9± 2.3, per 4,000 cells). Occurrences 
of apoptosis in mammary gland cells in the apple treatments were significantly higher 
than those in the control groups (P<0.01). Apoptosis expression was increased by 6.1, 
12.9 and 14.6 times in the low, middle, and high dose groups, respectively, compared 
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to the positive control group (2.9± 1.3, per 4,000 cells). Apoptosis was induced by 
apple extracts in a dose-dependent manner.  
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Figure 4.3. Effects of varying doses of fresh apple extracts on PCNA expression in 
rat mammary gland tissues in vivo. High power view (400×) of the PCNA 
expression: (A) negative control group (Control -) (n=8); (B) positive control group 
(Control +) (n=8); (C) low dose (n=8); (D) middle dose (n=8); and (E) high dose 
(n=8). The expression of PCNA was visualized with DAB; positive cells are reddish-
brown in color. Bars with no letters in common are significantly different (P<0.05). 
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Figure 4.4. Effects of varying doses of fresh apple extracts on expression of Cyclin 
D1 in rat mammary gland tissues in vivo. High power view (400×) of Cyclin D1 
expression: (A) negative control group (Control -) (n=8); (B) positive control group 
(Control +) (n=8); (C) low dose (n=8); (D) middle dose (n=8); and (E) high dose 
(n=8). The expression of Cyclin D1 was visualized with DAB; positive cells are 
reddish-brown in color. Bars with no letter in commons are significantly different 
(P<0.05). 
 
185 
 
 
Control - Control + Low Middle High
A
po
pt
ot
ic
 C
el
ls
 (1
/4
,0
00
 c
el
ls)
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
a
b
ab
cd
c
 
Figure 4.5. TUNEL Assay: Effects of varying doses of fresh apple extracts on 
induction of apoptosis in rat mammary gland tissues in vivo. High power view 
(400×) of apoptosis expression: (A) negative control group (Control -) (n=8);  (B) 
positive control group (Control +) (n=8); (C) low dose (n=8); (D) middle dose (n=8); 
and (E) high dose (n=8). The apoptotic cells were visualized with DAB; positive cells 
are reddish-brown in color. Bars with no letters in common are significantly different 
(P<0.05).   
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The expression of Bcl-2 and Bax was examined in mammary gland tissues 
among the control and apple-treated groups by immunohistochemistry. Both Bcl-2 and 
Bax expression in the mammary gland tissues were observed in the negative control 
group. Bcl-2 expression in the apple treated groups was significantly lower than that in 
the positive control group in a dose dependent manner (P<0.05) (Figure 4.6). The 
inhibitory rates of Bcl-2 expression were 29.3, 48.6, and 55.6% in the low, middle, and 
high dose groups, respectively, in comparison with the positive control group (45.3 ± 
19.8, per 2,000 cells). Bax expression in the positive control group (7.0 ± 2.7, per 
2,000 cells) was significantly lower than that in the apple-treated groups (P<0.05) 
(Figure 4.7). Bax expression in the negative control group was 8.5 ± 5.6, per 2,000 
cells. The expression of Bax in the lowest dose group (15.9 ± 6.1, per 2,000 cells) was 
2.3 times greater than that in the positive control group.  A dose response relationship 
was observed among the apple-treated groups as compared to the positive control 
group.  
 
DISCUSSION 
Epidemiological studies, including case-control and cohort studies, have 
consistently shown that regular consumption of fruits and vegetables is associated with 
a reduced risk of developing cancer and other chronic diseases (Block et al., 1992). In 
a large cohort study of 34,467 women in the Nurses' Health Study (NHS) who had 
undergone colonoscopy or sigmoidoscopy, it was found that consumption of fruit was 
inversely related to the risk of distal adenomas of the colon or rectum after controlling 
for potential confounding factors (Michels et al., 2006). A case-control study in 
Uruguay has shown that apple consumption was associated with significant reduction 
in colorectal cancer risk for men and women (Deneo-Pellegrini et al., 1996). Other   
case-control studies conducted in Italy have shown that there is a consistent inverse  
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Figure 4.6. Effects of varying doses of fresh apple extracts on Bcl-2 expression in 
rat mammary gland tissues in vivo. High power view (400×) of Bcl-2 expression in 
the following groups: (A) negative control group (Control -) (n=8); (B) positive 
control group (Control +) (n=8); (C) low dose (n=8); (D) middle dose (n=8); and (E) 
high dose (n=8). The cell plasma was visualized with DAB; positive cells are reddish-
brown in color. Bars with no letters in common are significantly different (P<0.05).    
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Figure 4.7. Effects of varying doses of fresh apple extracts on Bax expression in 
rat mammary gland tissues in vivo. High power view (400×) of Bax expression in 
the following groups: (A) negative control group (Control -) (n=8); (B) positive 
control group (Control +) (n=8); (C) low dose (n=8); (D) middle dose (n=8); and (E) 
high dose (n=8). The cell plasma was visualized with DAB; positive cells are reddish-
brown in color. Bars with no letters in common are significantly different (P<0.05). 
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association between apples and risk of various cancers. The studies included cases of 
various types of cancer: 598 of the oral cavity and pharynx, 304 of the esophagus, 460 
of the larynx, 1,953 of the colorectum, 2,569 of the breast, 1,031 of the ovary and 
1,294 of the prostate (Gallus et al., 2005). A case-control study in Brazil found regular 
apple consumption to be associated with reduced breast cancer risk (OR = 0.30) after 
adjustment for family income level, since income was also found to have both a strong 
association with breast cancer and an influence on diet (Di Pietro et al., 2007). 
 In previous studies of selected common fruits and vegetables, apple has been 
shown to possess potent antioxidant and anti-proliferative activity against cancer cells 
(Chu et al., 2002; Sun et al., 2002). Median effective doses (EC50) were 42.5 ± 2.6 
mg/mL and 49.4 ± 1.6 mg/mL in human colon cancer Caco-2 cells and liver cancer 
HepG2 cells treated with different levels of whole apple extracts (Liu and Sun, 2003).  
 Slattery (2001) discusses the strengths and limitations that the various types of 
epidemiology studies (clinical, case-control, and cohort) have in determining the 
association between diet and cancer. She underscores the importance of timing and 
duration of exposure, considering that certain foods such as fruits and vegetables may 
exert protective effects at a specific stage in the disease process. In that light, animal 
and cell studies become extremely valuable in helping to uncover the mechanisms by 
which whole foods or individual phytochemicals can prevent or slow the growth of 
cancer. That information, in turn, is crucial for effective and careful design of dietary 
intervention studies.  
 In our previous study, apple extracts inhibited mammary carcinogenesis in a 
DMBA-induced rat mammary cancer model during a 24-week study (Liu et al., 2005; 
Liu et al., 2009). A dose-response relationship was observed. Apple extracts not only 
inhibited cell proliferation in mammary tumor tissues, but also induced apoptosis in 
the mammary tumor tissues from this rat model. The inhibition of cell proliferation in 
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mammary tumor cells was attributed to down-regulation of PCNA, Cyclin D1 and 
Bcl-2 and up-regulation of Bax and nuclear fragments (Liu et al., 2009).  
 Several major groups of polyphenolic compounds occur in apples: flavan-3-
ols, flavonols, dihydrochalcones, anthocyanins, and phenolic acids (hydroxybenzoic 
acid and hydroxycinnamic acids) (Tsao et al., 2003). The major flavan-3-ols, or 
catechins, present in apples are catechin and epicatechin (stereoisomers), procyanidin 
B1 (dimer of epicatechin and catechin) and procyanidin B2 (dimer of two epicatechin 
molecules). A study by Gosse et al. (2005) reported that apple procyanidins in drinking 
water prevented colon carcinogenesis in male Wistar rats induced by azoxymethane 
(AOM). Gosse et al. (2006) also reported that apple procyanidins had 
chemopreventive properties in an in vitro model of colon cancer, affecting intracellular 
signaling pathways and triggering apoptosis in a human adenocarcinoma-derived 
metastatic cell line (SW620). 
 The second major group of polyphenols in apples is the flavonols, such as 
quercetin, kaempferol and myricetin. However, quercetin and its glycosides, occurring 
nearly exclusively in the peel, are by far the most abundant of the flavonoids and can 
contribute up to 18% of total phenolics in the apple (Tsao et al., 2003). In our lab, 29 
compounds were isolated from red delicious apple peels, including triterpenoids, 
flavonoids, organic acids, and plant sterols (He and Liu, 2008). Quercetin-3-O-β-D-
glucopyranoside was one of major flavonoids in the peel, followed by quercetin-3-O-
β-D-galactopyranoside. Trace amounts of quercetin were detected along with             
(-)-catechin, (-)-epicatechin, and quercetin-3-O-α-L-arabinofuranoside. Quercetin 
exhibited anti-proliferative activity against MCF-7 cells in vitro with an EC50 of 137.5 
± 2.6 µM, while the quercetin-3-O-β-D-glucopyranoside was even more potent with 
an EC50 of 23.9 ± 3.9 µM. 
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 The anti-cancer properties of quercetin have been extensively studied in vitro. 
For example, quercetin induced a G1 cell cycle arrest and apoptosis in MDA-MB-453 
mammary carcinoma cells via down-regulation of Bcl-2 expression and up-regulation 
of Bax expression and cleavage of caspase-3 and PARP (Choi et al., 2008). In MDA-
MB-468 human breast cancer cells, quercetin reduced proliferation and blocked cell 
cycle progression by inhibiting the expression of a mutant p53, the form highly 
expressed in that cell line, at the translational level (Avila et al., 1994). Her-2/neu, a 
receptor tyrosine kinase (RTK) that functions through dimerizing with other RTKs, is 
an important player in breast cancer signaling (Hynes and Lane, 2005; Olayioye et al., 
2000). Quercetin caused down-regulation of the Her-2/neu receptor, along with a 
corresponding decrease in phosphorylation of PI3K and Akt, in human breast 
carcinoma SK-Br3 cells which over-express Her-2/neu (Jeong et al., 2008). A similar 
down-regulation of the Her-2/neu receptor by quercetin in MCF-7 cells, and in a    
Her-2/neu over-expressing ovarian cancer cell line SK-Ov3 was observed. Quercetin 
has been shown to interfere with signaling pathways involved in migration and 
metastasis. Matrix metalloproteinases are responsible for dissolving the extracellular 
matrix, allowing tumor cells to migrate and invade distant sites (Duffy et al., 2000). 
TPA (12-O-tetradecanoylphorbol-13-acetate) induces MMP-9 through a protein kinase 
C (PKC)δ/extracellular signal-regulated kinase (ERK)/AP-1 pathway. In MCF-7 cells, 
quercetin blocked this induction by reducing activation of PKCδ and ERK, and 
reducing AP-1 activity (Lin et al., 2008). As a result, MMP-9 expression, and cell 
migration and invasion were reduced.  
 In this study, female Sprague-Dawley rats were fed 3.3 (low), 10.0 (middle), or 
20.0 (high) g fresh apples/kg body weight per day starting 2 weeks after DMBA 
administration and continuing for 7 weeks until the end of the experiment. Body 
weights in the low, middle and high apple groups were all statistically the same, yet 
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the markers of proliferation and apoptosis were clearly different in a dose-dependent 
manner. In addition, the body weights of the negative and positive control groups were 
statistically the same throughout the experiment, and yet the markers were 
dramatically different. By the end of the experiment (week 9), the positive control 
group weighed more than high and middle apple groups and had the expected 
corresponding higher proliferation and lower apoptosis markers than the high and 
middle apple groups. On the other hand, by week 9, the negative control group 
weighed more than the high apple group but had proliferation markers that were 
somewhat lower than, yet statistically the same as, the high apple group. There was no 
consistent pattern within this experiment to indicate that body weights influenced the 
proliferation and apoptosis of mammary cells in these animals.  
 Cell proliferation in the mammary gland tissues was determined using the 
BrdU-labeling assay and PCNA expression as the proliferative markers. Apple extracts 
significantly inhibited the expression of PCNA and BrdU incorporation in mammary 
gland tissues compared to the positive control group in a dose-dependent manner 
(P<0.05) (Figures 4.2 and 4.3). This indicates that apple extracts could inhibit cell 
proliferation and DNA synthesis in the mammary gland tissues of DMBA-treated rats. 
BrdU, a thymidine analogue incorporated into DNA, can be quantified through 
fluorescent or chromophoric quenching of dyes which bind to DNA or through 
antibodies to BrdU (Gratzner, 1982). The BrdU incorporation into cells as a 
proliferative marker is an early and sensitive index for in vivo studies. A number of 
therapeutic agents have been observed to reduce BrdU-labeling in mammary tumor 
cells in a DMBA-induced mammary model (Ip et al., 1994; Kitagawa and Noguchi, 
1994; Whitsett et al., 2006; Liu et al., 2009). PCNA is a nuclear protein which 
functions as an auxiliary protein for DNA polymerase δ and is an absolute requirement 
for DNA synthesis. PCNA, a key protein in DNA replication and DNA damage repair, 
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is a stable cell-cycle regulated nuclear protein that is expressed during the cell cycle 
and whose rate of synthesis is correlated directly with the proliferative rate of cells 
(Bravo et al., 1987). The higher specificity of PCNA for the S-phase might be thought 
to be advantageous over other proliferation markers as it should label those cells that 
have passed the important G1/S boundary of the cell cycle. PCNA has been shown to 
be more sensitive in detecting proliferating cells in some tumors (Fairman, 1990; Hall 
and Levinson, 1990; McCormick and Hall, 1992). In this study, very low levels of 
PCNA expression and BrdU-labeled cells were observed in the negative control group, 
and both were highly expressed in the DMBA-treated (positive control) group. This 
indicates that PCNA expression and BrdU-labeled cells are sensitive markers of cell 
proliferation of mammary gland tissues. The apple extracts reduced both markers in a 
dose-dependent manner indicating the extracts may inhibit cell proliferation in the 
mammary tissues of DMBA-treated rats.  
 In the present study, our findings showed that apple extracts not only affected 
the expression of a major protein (Cyclin D1) in mammary gland tissues, but also 
induced apoptosis and the expression of related proteins. The results showed that apple 
extracts significantly inhibited Cyclin D1 expression and significantly increased 
apoptosis compared to the positive control group. Cell proliferation of mammary 
cancer cells is tightly mediated through cell cycle control (Sanchez and Dynlacht, 
1996). The deregulation of the cell cycle has been reported to be correlated with the 
induction of apoptosis (Eastman and Rigas, 1999). The cyclin-dependent kinases 
(CDKs) are key cell cycle regulators, and their activities are modulated by binding to 
cyclins (Helin, 1998). Binding of Cyclin D to CDK4 and CDK6 leads to the 
phosphorylation of the retinoblastoma (Rb) protein. Phosphorylation of Rb prevents it 
from repressing the E2F family of transcription factors and leads to the transcription of 
several genes required for the G1-to-S phase transition, thereby promoting cellular 
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proliferation (Sherr, 1995). Cyclin D1 is over-expressed in 35-50% of breast cancers 
(Ishii et al., 2006). Over-expression of Cyclin D1 has also been linked to the 
development of endocrine resistance in breast cancer cells (Hui et al., 2002). A 
number of therapeutic agents have been observed to induce Cyclin D1 degradation in 
vitro (Langenfeld et al., 1997; Huang et al., 2005). These studies indicate that the 
induction of Cyclin D1 degradation might offer a useful avenue for therapeutic 
intervention (Yu et al., 2001). In our previous study, apple extracts inhibited Cyclin D1 
expression in mammary tumor tissue in a 24-week study (Liu et al., 2009).  
Significantly decreased Cyclin D1 expression was also found in the mammary gland 
tissues in the apple-treated groups of the current study. This indicates that apple extract 
not only affects the cell cycle during initiation, but it also affects proliferation of cells 
post-initiation in the DMBA-induced mammary carcinogenesis rat model. 
 In contrast to non-specific cellular necrosis, apoptosis is characterized by a 
specific pattern of DNA degradation that exposes 3’-OH ends. As a result, apoptotic 
cells within tissue sections can be identified by the terminal deoxynucleotidyl 
transferase (TdT)-mediated deoxyuridine nick end labeling (TUNEL) of exposed     
3’-OH ends with non-isotopically digoxigenin-labelled dUTP (Huerta et al., 2007; 
Gavrieli et al., 1992). The TUNEL assay is widely used and accepted as a tool for 
indicating apoptosis. Bcl-2 family proteins are mainly involved in the cell-intrinsic 
apoptotic pathway by activation of pro-apoptotic Bcl-2 family members, which induce 
the permeabilization of the outer mitochondrial membrane (OMM), resulting in the 
release of cytochrome-c (Cyt-c) and other inter-membrane space proteins (Roussi et 
al., 2007). Functionally, the Bcl-2-related proteins either inhibit or promote apoptosis, 
and interactions among these proteins determine whether a cell lives or dies. Bcl-2 is 
an anti-apoptotic protein and Bax a pro-apoptotic protein. In our study, apple extracts 
induced apoptosis in mammary gland tissues from the apple-treated groups. In 
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addition, apple extracts significantly decreased Bcl-2 expression and increased Bax 
expression in the apple-treated groups in a dose dependent manner. Thus, we can 
partly explain the mechanism by which apple extracts induce apoptosis: via regulation 
of the Bcl-2 pathway by down-regulation of Bcl-2 expression and up-regulation of 
Bax expression in mammary gland tissue. 
 In conclusion, our data demonstrated that whole apple extracts potently 
inhibited proliferation and induced apoptosis in mammary tissues of DMBA-treated 
Sprague-Dawley rats. These results suggest that a dietary intervention effectively 
protected against chemically-induced mammary carcinogenesis in this model. The 
inhibition of cell proliferation and induction of apoptosis in mammary cancer may be 
regulated through the down-regulation of Cyclin D1 and Bcl-2 expression as well as 
up-regulation of Bax expression. Thus, these findings strongly support the view that 
consumption of whole apples is an effective way to achieve cancer protection as well 
as support our previous hypothesis that health benefits of fruits and vegetables are due 
to the additive and/or synergistic effects of phytochemicals (Liu, 2004). Nevertheless, 
the exact mechanism(s) of how apples prevent mammary cancer warrants further 
study. 
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